Immunomodulators

Macrocyclic compounds are developed to inhibit PD-1/PD-L1 and PD-L1/CD80 interactions, addressing immune evasion and exhaustion, thereby enhancing immune responses and treatment efficacy for cancer and infectious diseases.

JP2024540950AInactive Publication Date: 2024-11-06BRISTOL MYERS SQUIBB CO
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024523704
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-10-20
Filing Date
2022-10-19
Publication Date
2024-11-06
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current treatments for diseases such as cancer and infectious diseases are limited by the inhibitory interactions between PD-1 and PD-L1, which lead to immune evasion and exhaustion, reducing the effectiveness of immune responses.

Method used

Development of macrocyclic compounds that inhibit the interactions between PD-1/PD-L1 and PD-L1/CD80, enhancing immune responses and restoring T-cell function.

Benefits of technology

The macrocyclic compounds effectively inhibit PD-1/PD-L1 and PD-L1/CD80 interactions, stimulating immune responses and enhancing treatment efficacy against cancer and infectious diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024540950000001
    Figure 2024540950000001
  • Figure 2024540950000002
    Figure 2024540950000002
  • Figure 2024540950000003
    Figure 2024540950000003
Patent Text Reader

Abstract

The present disclosure provides novel macrocyclic peptides that inhibit PD-1 / PD-L1 and PD-L1 / CD80 protein / protein interactions and are therefore useful in ameliorating various diseases, including cancer and infectious diseases.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] (CROSS REFERENCE TO RELATED APPLICATIONS) This application claims priority to U.S. Provisional Application No. 63 / 257,862, filed October 20, 2021, which is incorporated by reference in its entirety.

[0002] (Technical field) The present disclosure provides macrocyclic compounds capable of binding to and inhibiting PD-L1, as well as PD-1 and CD80, which exhibit immunomodulatory effects in vitro, making them therapeutic tools in the treatment of a variety of diseases, including cancer and infectious diseases. [Background technology]

[0003] The programmed cell death 1 (PD-1) protein is an inhibitory member of the CD28 receptor family, which also includes CD28, CTLA-4, ICOS, and BTLA. PD-1 is expressed on activated B cells, T cells, and myeloid cells.

[0004] The PD-1 protein is a 55 kDa type I transmembrane protein that belongs to the Ig gene superfamily. PD-1 contains a membrane-proximal immunoreceptor tyrosine inhibitory motif (ITIM) and a membrane-distal immunoreceptor tyrosine switch motif. PD-1 is structurally similar to CTLA-4, but lacks the MYPPY motif that is important for binding to CD80 and CD86 (B7-2). Two ligands for PD-1 have been identified: PD-L1 (B7-H1) and PD-L2 (b7-DC). It has been reported that activation of PD-1-expressing T cells is downregulated by interaction with cells expressing PD-L1 or PD-L2. Both PD-L1 and PD-L2 are members of the B7 protein family that bind PD-1, but not other members of the CD28 family. PD-L1 ligands are prevalent in a variety of human cancers. Interaction between PD-1 and PD-L1 results in a reduction in tumor-infiltrating lymphocytes, reduced T-cell receptor-mediated proliferation, and immune evasion of cancer cells. Blockade of the local interaction between PD-1 and PD-L1 can reverse immune suppression, and is even more effective when the interaction between PD-1 and PD-L2 is also blocked.

[0005] PD-L1 has also been shown to interact with CD80. The PD-L1 / CD80 interaction on expressing immune cells has been shown to be an inhibitory interaction. Blocking this interaction has been shown to abolish this inhibitory interaction.

[0006] When T cells expressing PD-1 come into contact with cells expressing its ligand, their functional activity in response to antigenic stimulation (such as proliferation, cytokine secretion, and cytotoxicity) is reduced. In the healing of infections or tumors, or in the establishment of self-tolerance, PD-1 / PD-L1 or PD-L2 interactions downregulate immune responses. Chronic antigenic stimulation, for example caused by tumor disease or chronic infection, increases the expression level of PD-1 on T cells, resulting in dysfunctional activity against chronic antigens. This is called "T cell exhaustion," and B cells also show suppression and "exhaustion" of PD-1 / PD ligands.

[0007] Blockade of PD-1 / PD-L1 ligation using antibodies against PD-L1 is known to restore and enhance T cell activation in many systems. Patients with advanced cancers can benefit from treatment with monoclonal antibodies against PD-L1. Preclinical animal models of tumors and chronic infections have shown that blocking the PD-1 / PD-L1 pathway with monoclonal antibodies can enhance immune responses, leading to tumor rejection and suppression of infection. Antitumor immunotherapy by blocking PD-1 / PD-L1 can enhance therapeutic immune responses against many histologically distinct tumors.

[0008] Inhibition of PD-1 / PD-L1 interactions was also found to enhance T cell activity in chronic infection systems. Blockade of PD-L1 improved viral clearance and restored immunity in mice infected with chronic lymphocytic choriomeningitis virus. Humanized mice infected with HIV-1 show enhanced protection against viremia and viral exhaustion of CD4+ T cells. Blockade of PD-1 / PD-L1 with monoclonal antibodies against PD-L1 can restore antigen-specific functionality to T cells from HIV patients in vitro.

[0009] Blockade of the PD-L1 / CD80 interaction is also known to stimulate immunity, and the immune stimulation caused by blockade of the PD-L1 / CD80 interaction is known to be enhanced by further combining blockade of the PD-1 / PD-L1 or PD-1 / PD-L2 interaction.

[0010] Alterations in immune cell phenotype have been hypothesized to be important factors in septic shock. These include increased levels of PD-1 and PD-L1. Cells from septic shock patients with increased levels of PD-1 and PD-L1 show increased apoptosis of T cells. Antibodies against PD-L1 can reduce the level of immune cell apoptosis. Furthermore, PD-1-deficient mice are more resistant to septic shock symptoms than wild-type mice. Studies have revealed that blocking PD-L1 interactions with antibodies can suppress inappropriate immune responses and ameliorate disease symptoms.

[0011] Blockade of the PD-1 / PD-L1 pathway has been shown to amplify immune responses to chronic antigens as well as enhance responses to vaccines, including therapeutic vaccines against chronic infections.

[0012] The PD-1 pathway is a key inhibitory molecule in T cell exhaustion resulting from chronic antigen stimulation during chronic infection and tumor disease. Blockade of PD-1 / PD-L1 interaction by targeting the PD-L1 protein is known to restore antigen-specific T cell immune function in vitro and in vivo, including enhancing responses to vaccination in tumor or chronic infection conditions. Therefore, agents that block the interaction of PD-L1 with either PD-1 or CD80 are desirable. Summary of the Invention

[0013] The present disclosure provides macrocyclic compounds that inhibit PD-1 / PD-L1 and CD80 / PD-L1 proteins / proteins and are useful for ameliorating various diseases, including cancer and infectious diseases.

[0014] In a first embodiment, the present disclosure provides a compound of formula (I): [ka] [In the formula, A is, [ka] is selected from, where [ka] is the moiety that binds to the carbonyl group, [ka] represents a moiety attached to a nitrogen atom; n is 0 or 1; m is 1 or 2; u is 0 or 1; w is 0, 1, or 2; R x is selected from hydrogen, amino, hydroxy, and methyl; R 14 and R 15 is independently selected from hydrogen and methyl; R 16a is selected from hydrogen and C1-C6 alkyl; R 16 is -(C(R 17a )2)2-XR 30 , -(C(R 17a R 17 )) 0-2 -X'-R 30 , -(C(R 17a R 17 ) 1-2 C(O)NR 16a ) m' -X'-R 30 , -C(R 17a )2C(O)N(R 16a )C(R 17a )2-X'-R 31 , -(C(R 17a R 17 )) 1-2 C(O)N(R16a )C(R 17a )2-X'-R 31 , -C(R 17a )2[C(O)N(R 16a )C(R 17a )2] w' -XR 31 , -C(R 17a R 17 ) 1-2 [C(O)N(R 16a )C(R 17a R 17 ) 1-2 ] w' -X'-R 31 , -(C(R 17a )(R 17 )C(O)NR 16a ) n' -H, and -(C(R 17a )(R 17 )C(O)NR 16a ) m' -C(R 17a )(R 17 )-CO2H; Here, the spacer PEG q' R 16 (q' is the number of -(CH2CH2O)- units in the spacer PEG); w' is 2 or 3; n' is 1 to 6; m' is 0 to 5; q' is 1 to 20; X is a chain of 1 to 172 atoms, the atoms being selected from nitrogen, carbon and oxygen, and the chain may contain 1, 2, 3, or 4 groups selected from -NHC(O)-, -NHC(O)NH-, and -C(O)NH-, as incorporated herein; the chain may contain -CO2H, -C(O)NH2, -CH2C(O)NH2, and -(CH2) 1-2 optionally substituted with 1 to 6 groups independently selected from COH; X' is a chain of 1 to 172 atoms, the atoms being selected from carbon and oxygen, the chain may include 1, 2, 3, or 4 groups selected from -NHC(O)-, -NHC(O)NH-, and -C(O)NH-, as incorporated herein; the chain may include -CO2H, -C(O)NH2, and -(CH2) 1-2 optionally substituted with 1 to 6 groups independently selected from COH, with the proviso that X' is other than unsubstituted PEG; X is a chain of 1 to 172 atoms, the atoms being selected from nitrogen, carbon and oxygen, the chain optionally containing 1, 2, 3, or 4 groups selected from -NHC(O)-, -NHC(O)NH-, and -C(O)NH-, as incorporated herein; the chain optionally being substituted with 1 to 6 groups independently selected from -CO2H, -C(O)NH2, -CH2C(O)NH2, and -(CH2)CO2H; X' is a chain of 1 to 172 atoms, the atoms being selected from carbon and oxygen, which chain may contain 1, 2, 3, or 4 groups selected from -NHC(O)-, -NHC(O)NH-, and -C(O)NH-, as incorporated herein; the chain may be optionally substituted with 1 to 6 groups independently selected from -CO2H, -C(O)NH2, and -CH2CO2H, with the proviso that X' is other than unsubstituted PEG; R 30 is selected from -YB-COOH, -YB-SO3H, -YBS(O)OH and -YBP(O)(OH); R 31 is selected from -YB-COOH, -YB-SO3H, -YBS(O)OH and -YBP(O)(OH); Each R 17a is independently selected from hydrogen, C1-C6 alkyl, -CH2OH, -CH2CO2H, -(CH2)2CO2H; Each R 17 are independently hydrogen, -CH3, (CH2) z N3, -(CH2) z NH2, -XR 31 , -(CH2) zCO2H, -CH2OH, CH2C≡CH, and -(CH2) z -Triazolyl-XR 35 is selected from; where z is 1 to 6; R 35 is selected from -YB-COOH, -YB-SO3H, -YBS(O)OH and -YBP(O)(OH); B is a 5-6 membered aryl or heteroaryl group, said heteroaryl group containing 1-3 heteroatoms selected from -O-, -S-, and -N-; Y is a bond, O, S, or S(O) 1-2 Selected from; R a , R e , R j , and R k are each independently selected from hydrogen and methyl; R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , and R 13 are independently selected from the side chains of natural amino acids and the side chains of unnatural amino acids, or form a ring with the adjacent corresponding R groups described below; R b is methyl, or R b and R 2 together with the atoms to which they are attached form a ring selected from azetidine, pyrrolidine, morpholine, piperidine, piperazine, and tetrahydrothiazole; wherein each ring is optionally substituted with 1 to 4 groups independently selected from amino, cyano, methyl, halogen, and hydroxy; R d is hydrogen or methyl, or R d and R 4together with the atoms to which they are attached form a ring selected from azetidine, pyrrolidine, morpholine, piperidine, piperazine, and tetrahydrothiazole; wherein each ring is optionally substituted with 1 to 4 groups independently selected from amino, cyano, methyl, halogen, hydroxy, and phenyl; R g is hydrogen or methyl, or R g and R 7 together with the atoms to which they are attached form a ring selected from azetidine, pyrrolidine, morpholine, piperidine, piperazine, and tetrahydrothiazole; wherein each ring is optionally substituted with 1 to 4 groups independently selected from amino, benzyl optionally substituted with halogen, benzyloxy, cyano, cyclohexyl, methyl, halogen, hydroxy, isoquinolinyloxy optionally substituted with methoxy groups, quinolinyloxy optionally substituted with halogen, and tetrazolyl; said pyrrolidine and piperidine rings are optionally fused to a cyclohexyl, phenyl, or indole group; and R l is methyl, or R l and R 12 together with the atoms to which they are attached form a ring selected from azetidine and pyrrolidine; wherein each ring is optionally substituted with 1 to 4 groups independently selected from amino, cyano, methyl, halogen, and hydroxy. or a pharma- ceutically acceptable salt thereof.

[0015] In a first aspect of the first embodiment, the present disclosure provides a compound comprising: [ka] or a pharma- ceutically acceptable salt thereof.

[0016] In a second aspect of the first embodiment, m is 1; w is 0; and R 14 , R 15 , and R16a are hydrogen.

[0017] In a third aspect of the first embodiment, R 16 But -(C(R 17a )2)2-XR 30 , -(C(R 17a R 17 )) 0-2 -X'-R 30 and -(C(R 17a R 17 ) 1-2 C(O)NR 16a ) m' -X'-R 30 is selected from.

[0018] In a fourth aspect of the first embodiment, Each R 17a is selected from hydrogen, -CO2H, and -CH2CO2H; X is a chain of 8 to 46 atoms, the atoms being selected from carbon and oxygen, which chain may include 1, 2, or 3 -NHC(O)-, C(O)NH groups incorporated herein; the chain may be optionally substituted with 1 or 2 groups independently selected from -COH, -C(O)NH, -CHC(O)NH, and -CHCOH; and R 30 teeth, [ka] Selected from; Y is selected from a bond, O or S.

[0019] In a fifth aspect of the first embodiment, the present disclosure provides a compound represented by formula (I): A, [ka] and; m is 1; w is 0; R 14 , R 15 , and R 16aare each hydrogen; and R 16 But -C(R 17a )2C(O)N(R 16a )C(R 17a )2-X'-R 31 and -(C(R 17a R 17 )) 1-2 C(O)N(R 16a )C(R 17a )2-X'-R 31 Select from or a pharma- ceutically acceptable salt thereof.

[0020] In a sixth aspect of the first embodiment, Each R 17a is selected from hydrogen, -CO2H, and -CH2CO2H; X' is a chain of 8 to 48 atoms, the atoms being selected from carbon and oxygen, which chain may contain 1, 2, or 3 -NHC(O)- or -C(O)NH- groups as incorporated herein; the chain may be optionally substituted with 1 or 2 groups independently selected from -COH, -C(O)NH, -CHC(O)NH, and -CHCOH, with the proviso that X' is other than unsubstituted PEG; and R 30 teeth, [ka] Selected from; Y is selected from a bond, O or S.

[0021] In a seventh aspect of the first embodiment, the present disclosure provides a compound represented by formula (I): A, [ka] and; m is 1; w is 0; R 14 , R 15 , and R 16a are each hydrogen; and R 16 But -C(R 17a )2[C(O)N(R 16a )C(R 17a )2] w' -XR 31 and -C(R 17a R 17 ) 1-2 [C(O)N(R 16a )C(R 17a R 17 ) 1-2 ] w' -X'-R 31 Select from or a pharma- ceutically acceptable salt thereof.

[0022] In an eighth aspect of the first embodiment, Each R 17a is selected from hydrogen, -CO2H, and -CH2CO2H; X is a chain of 8 to 48 atoms, the atoms being selected from carbon and oxygen, which chain may contain 1, 2, or 3 -NHC(O)- or -C(O)NH- groups as incorporated herein; the chain may be optionally substituted with 1 or 2 groups independently selected from -COH, -C(O)NH, -CHC(O)NH, and -CHCOH; and R 31 teeth, [ka] Selected from; Y is selected from a bond, O or S.

[0023] In a ninth aspect of the first embodiment, the present disclosure provides a compound represented by formula (I): A, [ka] and; m is 1; w is 0; R 14 , R 15 , and R 16aare each hydrogen; and R 16 But -(C(R 17a )(R 17 )C(O)NR 16a ) n' -H] or a pharma- ceutically acceptable salt thereof.

[0024] In a tenth aspect of the first embodiment, Each R 17a is hydrogen; and Each R 17 is hydrogen, -CH3, (CH2) z N3, -(CH2) z NH2, -XR 31 , -(CH2) z CO2H, -CH2OH, CH2C≡CH, and -(CH2) z -Triazolyl-XR 35 , where at least one R 17 is other than hydrogen, -CH3, or -CH2OH; z is 1 to 4; R 31 teeth, [ka] Selected from; Y is selected from a bond, O, or S; X is a chain of 7 to 155 atoms, the atoms being selected from carbon and oxygen, which chain may contain 1, 2, or 3 -NHC(O)-, or -C(O)NH- groups as incorporated herein; the chain may be optionally substituted with 1 or 2 groups independently selected from -COH, -C(O)NH, -CHC(O)NH, and -CHCOH; and R 35 teeth, [ka] Selected from; Y is selected from a bond, O or S.

[0025] In an eleventh aspect of the first embodiment, the present disclosure provides a compound represented by formula (I): A, [ka] and; m is 1; w is 0; R 14 , R 15 , and R 16a are each hydrogen; and R 16 But -(CR 17a )(R 17 )C(O)NR 16a ) m' -C(R 17a )(R 17 )-COH] or a pharma- ceutically acceptable salt thereof.

[0026] In a twelfth aspect of the first embodiment, m' is 1 to 3; Each R 17a is hydrogen; Each R 17 is hydrogen, -CH3, (CH2) z N3, -(CH2) z NH2, -XR 31 , -(CH2) z CO2H, -CH2OH, CH2C≡CH, -(CH2) z -Triazolyl-XR 35 Selected from; z is 1 to 4; R 31 teeth, [ka] Selected from; Y is selected from a bond, O, or S; X is a chain of 20 to 60 atoms, the atoms being selected from carbon and oxygen, which chain may contain 1, 2, or 3 -NHC(O)-, -C(O)NH- groups as incorporated herein; the chain may be optionally substituted with 1 or 2 groups independently selected from -COH, -C(O)NH, -CHC(O)NH, and -CHCOH; and R 35 teeth, [ka] Selected from; Y is selected from a bond, O or S.

[0027] In a thirteenth aspect of the first embodiment, the present disclosure provides a compound represented by formula (I): R 1 is phenylC1-C3 alkyl, where the phenyl portion may be optionally substituted with hydroxyl, halogen, or methoxy; R 2 is C1-C7 alkyl, or R 2 and R b form a piperidine ring together with the atoms to which they are attached; R 3 But NR x R y (C1-C7 alkyl), NR u R v carbonyl C1-C3 alkyl, or carboxy C1-C3 alkyl; R 4 and R d form a pyrrolidine ring together with the atoms to which they are attached; R 5 is hydroxy C1-C3 alkyl, imidazolyl C1-C3 alkyl, or NR x R y (C1-C7 alkyl); R 6 is carboxy C1-C3 alkyl, NR u R v Carbonyl C1-C3 alkyl, NR x R y(C1-C7 alkyl), or C1-C7 alkyl; R 7 and R g together with the atoms to which they are attached form a pyrrolidine ring which may be optionally substituted with hydroxy; R 8 and R 10 is indolyl C1-C3 alkyl optionally substituted with benzothienyl or carboxy C1-C3 alkyl; R 9 is hydroxy C1-C3 alkyl, amino C1-C4 alkyl, or C1-C7 alkyl; R 11 is C1-C3 alkoxyC1-C3 alkyl or C1-C7 alkyl; R 12 is C1-C7 alkyl or hydroxy C1-C3 alkyl; and R 13 is C1-C7 alkyl, carboxyC1-C3 alkyl, or -(CH2)3NHC(NH)NH2] or a pharma- ceutically acceptable salt thereof.

[0028] In a fourteenth aspect of the first embodiment, the present disclosure provides a compound represented by formula (I): A, [ka] and; m is 1; w is 0; R 14 and R 15 are hydrogen; R 16a is hydrogen or methyl; R d is methyl or R d and R 4together with the atoms to which they are attached form a ring selected from azetidine, pyrrolidine, morpholine, piperidine, piperazine, and tetrahydrothiazole; wherein each ring is optionally substituted with one or two groups independently selected from amino, cyano, methyl, halogen, hydroxy, and phenyl; R g is methyl or R g and R 7 together with the atoms to which they are attached form a ring selected from azetidine, pyrrolidine, morpholine, piperidine, piperazine, and tetrahydrothiazole; wherein each ring is optionally substituted with one or two groups independently selected from amino, benzyl optionally substituted with halogen, benzyloxy, cyano, cyclohexyl, methyl, halogen, hydroxy, isoquinolinyloxy optionally substituted with methoxy groups, quinolinyloxy optionally substituted with halogen, and tetrazolyl; said pyrrolidine and piperidine rings are optionally fused to a cyclohexyl, phenyl, or indole group; and R l is methyl or R l and R 12 together with the atoms to which they are attached form a ring selected from azetidine, pyrrolidine, morpholine, piperidine, piperazine, and tetrahydrothiazole; wherein each ring is optionally substituted with one or two groups independently selected from amino, cyano, methyl, halogen, and hydroxy. or a pharma- ceutically acceptable salt thereof.

[0029] In a second embodiment, the present disclosure provides a compound of formula (II): [ka] [In the formula, A is, [ka] is selected from, where n is 0 or 1; R 14 and R 15 is independently selected from hydrogen and methyl; R 16a is selected from hydrogen and C1-C6 alkyl; R 16 is -(C(R 17a )2)2-XR 30 , -(C(R 17a R 17 )) 0-2 -X'-R 30 , -(C(R 17a R 17 ) 1-2 C(O)NR 16a ) m' -X'-R 30 , -C(R 17a )2C(O)N(R 16a )C(R 17a )2-X'-R 31 , -(C(R 17a R 17 )) 1-2 C(O)N(R 16a )C(R 17a )2-X'-R 31 , -C(R 17a )2[C(O)N(R 16a )C(R 17a )2] w' -XR 31 , -C(R 17a R 17 ) 1-2 [C(O)N(R 16a )C(R 17a R 17 ) 1-2 ] w' X'-R 31 , -(C(R 17a )(R 17 )C(O)NR 16a ) n' -H, and -(C(R 17a )(R 17 )C(O)NR 16a ) m' -C(R 17a )(R 17 )-CO2H; Here, the spacer PEG q'R 16 (q' is the number of -(CH2CH2O)- units in the spacer PEG); w' is 2 or 3; n' is 1 to 6; m' is 0 to 5; q' is 1 to 20; X is a chain of 1 to 172 atoms, the atoms being selected from carbon and oxygen, the chain optionally containing 1, 2, 3, or 4 groups selected from -NHC(O)-, -NHC(O)NH-, and -C(O)NH, as incorporated herein; the chain optionally being substituted with 1 to 6 groups independently selected from -COH, -C(O)NH, -CHC(O)NH, and -CHCOH; X' is a chain of 1 to 172 atoms, the atoms being selected from carbon and oxygen, which chain may contain 1, 2, 3, or 4 groups selected from -NHC(O)-, -NHC(O)NH-, and -C(O)NH, as incorporated herein; the chain may be optionally substituted with 1 to 6 groups independently selected from -CO2H, -C(O)NH2, and -CH2CO2H, with the proviso that X' is other than unsubstituted PEG; R 30 teeth, [ka] Selected from; R 31 teeth, [ka] Selected from; Each R 17a is independently selected from hydrogen, C1-C6 alkyl, -CH2OH, -CH2CO2H, -(CH2)2CO2H; Each R 17 are independently hydrogen, -CH3, (CH2) z N3, -(CH2) z NH2, -XR 31 , -(CH2) zCO2H, -CH2OH, CH2C≡CH, and -(CH2) z -Triazolyl-XR 35 is selected from; where z is 1 to 6; and R 35 teeth, [ka] Selected from; Y is a bond, O, S, or S(O) 1-2 Selected from; R a , R f , R j , R k , R l , and R m is hydrogen; R b and R c is methyl; R g is selected from hydrogen and methyl; R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , and R 12 are independently selected from the side chains of natural amino acids and the side chains of unnatural amino acids, or form a ring with the adjacent corresponding R groups described below; R d is selected from hydrogen and methyl, or R d and R 4 together with the atoms to which they are attached form a ring selected from azetidine, pyrrolidine, morpholine, piperidine, piperazine, and tetrahydrothiazole; wherein each ring is optionally substituted with 1 to 4 groups independently selected from amino, cyano, methyl, halogen, halomethyl, and hydroxy; R e is selected from hydrogen and methyl, or Re and R 5 together with the atoms to which they are attached form a ring selected from azetidine, pyrrolidine, morpholine, piperidine, piperazine, and tetrahydrothiazole; wherein each ring is optionally substituted with 1 to 4 groups independently selected from amino, cyano, methyl, halogen, halomethyl, and hydroxy; R h is selected from hydrogen and methyl, or R h and R 8 together with the atoms to which they are attached form a ring selected from azetidine, pyrrolidine, morpholine, piperidine, piperazine, and tetrahydrothiazole; wherein each ring is optionally substituted with 1 to 4 groups independently selected from amino, cyano, methyl, halogen, halomethyl, and hydroxy; and R i is selected from hydrogen and methyl, or R i and R 9 together with the atoms to which they are attached form a ring selected from azetidine, pyrrolidine, morpholine, piperidine, piperazine, and tetrahydrothiazole; wherein each ring is optionally substituted with 1 to 4 groups independently selected from amino, cyano, methyl, halogen, halomethyl, and hydroxy. or a pharma- ceutically acceptable salt thereof.

[0030] In a first aspect of the second embodiment, the present disclosure provides a compound represented by formula (II): A, [ka] and; n is 1; R 16 But -(CR 17a )(R 17 )C(O)NR 16a ) m' -C(R 17a )(R 17 )-CO2H; Each R16a is hydrogen; m' is 2, 3, or 4; Each R 17a is hydrogen; Each R 17 are independently hydrogen, -(CH2) z NH2, -XR 31 and -CH2C≡CH; z is 4; X is a chain of 26 to 155 atoms, the atoms being selected from carbon and oxygen, which chain may contain 1, 2, or 3 -NHC(O)- or -C(O)NH- groups as incorporated herein; the chain may be optionally substituted with 1 or 2 groups independently selected from -COH, -C(O)NH, -CHC(O)NH, and -CHCOH; and R 31 but, [ka] Selected from; Y is selected from a bond, O or S. or a pharma- ceutically acceptable salt thereof.

[0031] In a third embodiment, the disclosure provides a method of enhancing, stimulating, and / or enhancing an immune response in a patient in need of treatment, comprising administering to the subject a therapeutically effective amount of a compound of formula (I) or a pharma- ceutically acceptable salt thereof. In a first aspect of the third embodiment, the disclosure further provides a method comprising administering another agent before, after, or simultaneously with administering the compound of formula (I) or a pharma- ceutically acceptable salt thereof. In a second aspect, the another agent is an antibacterial agent, an antiviral agent, a cytotoxic agent, and / or an immune response modulating agent.

[0032] In a fourth embodiment, the disclosure provides a method of inhibiting the growth, proliferation, or metastasis of cancer cells in a patient in need of treatment, comprising administering to the subject a therapeutically effective amount of a compound of formula (I), or a pharma- ceutical acceptable salt thereof. In a first aspect of the fourth embodiment, the cancer is selected from melanoma, renal cell carcinoma, squamous non-small cell lung cancer (NSCLC), non-squamous NSCLC, colorectal cancer, castration-resistant prostate cancer, ovarian cancer, gastric cancer, hepatocellular carcinoma, pancreatic cancer, squamous cell carcinoma of the head and neck, cancer of the esophagus, gastrointestinal tract, and breast, and hematopoietic tumors.

[0033] In a fifth embodiment, the disclosure provides a method of treating an infectious disease in a patient in need of treatment, comprising administering to the subject a therapeutically effective amount of a compound of formula (I) or a pharma- ceutically acceptable salt thereof. In a first aspect of the fifth embodiment, the infectious disease is caused by a virus. In a second aspect, the virus is selected from HIV, Hepatitis A, Hepatitis B, Hepatitis C, herpes virus, and influenza.

[0034] In a sixth embodiment, the disclosure provides a method of treating septic shock in a patient in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of formula (I) or a pharma- ceutical acceptable salt thereof.

[0035] In a seventh embodiment, the disclosure provides a method for enhancing, stimulating, and / or enhancing an immune response in a patient in need of treatment, comprising administering to the subject a therapeutically effective amount of a compound of formula (II) or a pharma- ceutically acceptable salt thereof. In a first aspect of the seventh embodiment, the disclosure further provides a method comprising administering another agent before, after, or simultaneously with administering the compound of formula (II) or a pharma- ceutically acceptable salt thereof. In a second aspect, the other agent is an antibacterial agent, an antiviral agent, a cytotoxic agent, and / or an immune response modifier. In a third aspect, the other agent is an HDAC inhibitor. In a fourth aspect, the other agent is a TLR7 agonist and / or a TLR8 agonist or a dual TLR7 / 8 agonist.

[0036] In an eighth embodiment, the disclosure provides a method of inhibiting the growth, proliferation, or metastasis of cancer cells in a patient in need of treatment, comprising administering to the subject a therapeutically effective amount of a compound of formula (II), or a pharma- ceutical acceptable salt thereof. In a first aspect of the eighth embodiment, the cancer is selected from melanoma, renal cell carcinoma, squamous non-small cell lung cancer (NSCLC), non-squamous NSCLC, colorectal cancer, castration-resistant prostate cancer, ovarian cancer, gastric cancer, hepatocellular carcinoma, pancreatic cancer, squamous cell carcinoma of the head and neck, cancer of the esophagus, gastrointestinal tract, and breast, and hematopoietic tumors.

[0037] In a ninth embodiment, the disclosure provides a method of treating an infectious disease in a patient in need of treatment, comprising administering to the subject a therapeutically effective amount of a compound of formula (II) or a pharma- ceutically acceptable salt thereof. In a first aspect of the ninth embodiment, the infectious disease is caused by a virus. In a second aspect, the virus is selected from HIV, Hepatitis A, Hepatitis B, Hepatitis C, herpes virus, and influenza.

[0038] In a tenth embodiment, the disclosure provides a method of treating septic shock in a patient in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of formula (II) or a pharma- ceutical acceptable salt thereof.

[0039] In compounds of formula (I) where the side chain R is part of a ring substituted with methyl, it is to be understood that the methyl group may be present on any substitutable carbon atom of the ring, including a carbon that is part of the macrocyclic parent structure.

[0040] The following groups are preferred at each R position: The amino acids may be in the D- or L-configuration and may be substituted as described elsewhere in this disclosure.

[0041] In the compounds of formula (I), preferred R 1 is selected from the side chains of the following: phenylalanine, tyrosine, 3-thien-2-yl, 4-methylphenylalanine, 4-chlorophenylalanine, 3-methoxyphenylalanine, isotryptophan, 3-methylphenylalanine, 1-naphthylalanine, 3,4-difluorophenylalanine, 4-fluorophenylalanine, 3,4-dimethoxyphenylalanine, 3,4-dichlorophenylalanine, 4-difluoromethylphenylalanine, 2-methylphenylalanine, 2-naphthylalanine, tryptophan, 4-pyridinyl, 4-bromophenylalanine, 3-pyridinyl, 4-trifluoromethylphenylalanine, 4-carboxyphenylalanine, 4-methoxyphenylalanine, biphenylalanine, and 3-chlorophenylalanine, and 2,4-diaminobutane.

[0042] R 2 In compounds of formula (I) where R is not a ring moiety, preferred R 2 is selected from the side chains of alanine, serine, and glycine.

[0043] In the compounds of formula (I), preferred R 3is selected from the side chains of asparagine, aspartic acid, glutamic acid, glutamine, serine, ornithine (Orn), lysine, histidine, threonine, leucine, alanine, Dap, and Dab.

[0044] R 4 In compounds of formula (I) where R is not a ring moiety, preferred R 4 is selected from the side chains of valine, alanine, isoleucine, and glycine.

[0045] In the compounds of formula (I), preferred R 5 is selected from the side chains of histidine, asparagine, Dap, Dap(COCH3), serine, glycine, Dab, Dab(COCH3), alanine, lysine, aspartic acid, alanine, and 3-thiazolylalanine.

[0046] In the compounds of formula (I), preferred R 6 is selected from the side chains of leucine, aspartic acid, asparagine, glutamic acid, glutamine, serine, lysine, 3-cyclohexane, threonine, ornithine, Dab, alanine, arginine, and Orn(COCH3).

[0047] R 7 In compounds of formula (I) where R is not a ring moiety, preferred R 7 is selected from the side chains of glycine, Dab, serine, lysine, arginine, ornithine, histidine, asparagine, glutamine, alanine, and Dab (C(O)cyclobutane).

[0048] Preferred R in the compounds of formula (I) 8 is selected from the side chains of tryptophan and 1,2-benzisothiazolinylalanine.

[0049] Preferred R in the compounds of formula (I) 9is selected from the side chains of serine, histidine, lysine, ornithine, Dab, threonine, lysine, glycine, glutamic acid, valine, Dap, arginine, aspartic acid, and tyrosine.

[0050] Preferred R in the compounds of formula (I) 10 is selected from the optionally substituted side chains of tryptophan, benzoisothiazolylalanine, 1-naphthylalanine, and methionine.

[0051] Preferred R in the compounds of formula (I) 11 is selected from the side chains of norleucine, leucine, asparagine, phenylalanine, methionine, ethoxymethane, alanine, tryptophan, isoleucine, phenylpropane, glutamic acid, hexane, and heptane.

[0052] R 12 In compounds of formula (I) where R is not a ring moiety, preferred R 12 is selected from the side chains of norleucine, alanine, ethoxymethane, methionine, serine, phenylalanine, methoxyethane, leucine, tryptophan, isoleucine, glutamic acid, hexane, heptane, and glycine.

[0053] Preferred R in the compounds of formula (I) 13 is selected from the side chains of arginine, ornithine, alanine, Dap, Dab, leucine, aspartic acid, glutamic acid, serine, lysine, threonine, cyclopropylmethane, glycine, valine, isoleucine, histidine, and 2-aminobutane.

[0054] In another embodiment, the disclosure provides a compound selected from the scope examples of the first aspect, or a pharma- ceutically acceptable salt, tautomer, or stereoisomer thereof.

[0055] In another embodiment, there is provided a compound selected from any subset of the list of compounds within the scope of the first aspect.

[0056] In another embodiment, [ka] [ka] [ka] [ka] [ka] and [ka] or a pharma- ceutically acceptable salt thereof.

[0057] In another aspect, the disclosure provides a method of enhancing, stimulating and / or increasing an immune response in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or Formula (II), or a pharma- ceutical acceptable salt thereof.

[0058] In another aspect, the disclosure provides a method of inhibiting the interaction of PD-L1 with PD-1 and / or CD80 in a subject, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or Formula (II), or a pharma- ceutical acceptable salt thereof.

[0059] In another aspect, the disclosure provides a method of enhancing, stimulating, and / or enhancing an immune response in a patient in need of treatment, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or Formula (II), or a pharma- ceutically acceptable salt thereof. In a first embodiment of the second aspect, the method further comprises administering another agent before, after, or simultaneously with administering the compound of Formula (I) or Formula (II), or a pharma- ceutically acceptable salt thereof. In a second embodiment, the other agent is selected from an antibacterial agent, an antiviral agent, a cytotoxic agent, a TLR7 agonist, a TLR8 agonist, a TLR7 / 8 dual agonist, an HDAC inhibitor, and an immune response modifier.

[0060] In another aspect, the disclosure provides a method of inhibiting the growth, proliferation, or metastasis of cancer cells in a patient in need of treatment, comprising administering to the subject a therapeutically effective amount of a compound of formula (I) or formula (II), or a pharma- ceutical acceptable salt thereof. In a first embodiment of the third aspect, the cancer is selected from melanoma, renal cell carcinoma, squamous non-small cell lung cancer (NSCLC), non-squamous NSCLC, colorectal cancer, castration-resistant prostate cancer, ovarian cancer, gastric cancer, hepatocellular carcinoma, pancreatic cancer, squamous cell carcinoma of the head and neck, cancer of the esophagus, gastrointestinal tract, and breast, and hematological malignancies.

[0061] In another aspect, the disclosure provides a method of treating an infectious disease in a patient in need of treatment, comprising administering to the subject a therapeutically effective amount of a compound of formula (I) or formula (II), or a pharma- ceutically acceptable salt thereof. In a first embodiment of the fourth aspect, the infectious disease is caused by a virus. In a second embodiment, the virus is selected from HIV, hepatitis A, hepatitis B, hepatitis C, herpes virus, and influenza.

[0062] In another aspect, the disclosure provides a method of treating septic shock in a patient in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or Formula (II), or a pharma- ceutical acceptable salt thereof.

[0063] In another aspect, the disclosure provides a method of inhibiting the interaction of PD-L1 with PD-1 and / or CD80 in a subject, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or Formula (II), or a pharma- ceutical acceptable salt thereof. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0064] Unless otherwise specified, any atom with unsatisfied valences is assumed to have sufficient hydrogen atoms to satisfy the valences.

[0065] The singular forms "a," "an," and "the" include the plural forms unless the context clearly indicates otherwise.

[0066] As used herein, the term "or" is a logical or (i.e., and / or) and does not mean an exclusive or unless otherwise indicated by, for example, the terms "either," "unless," "alternatively," and similar terms.

[0067] The term "alkyl" as used herein refers to both branched and straight chain saturated aliphatic hydrocarbon groups, for example, having 1 to 12 carbon atoms, 1 to 6 carbon atoms, and 1 to 4 carbon atoms. Examples of alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (e.g., n-propyl and i-propyl), butyl (e.g., n-butyl, i-butyl, sec-butyl, and t-butyl), and pentyl (e.g., n-pentyl, isopentyl, neopentyl), n-hexyl, 2-methylpentyl, 2-ethylbutyl, 3-methylpentyl, and 4-methylpentyl. When a number appears in subscript after the symbol "C," the subscript more specifically qualifies the number of carbon atoms that a particular group may contain. For example, "C 1-4 "Alkyl" means straight and branched chain alkyl groups having 1 to 4 carbon atoms.

[0068] The term "cycloalkyl" as used herein refers to a group derived from a non-aromatic monocyclic or polycyclic hydrocarbon molecule by removing one hydrogen atom from a saturated ring carbon atom. Representative examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclopentyl, and cyclohexyl. When the symbol "C" is followed by a number in subscript, the subscript more specifically qualifies the number of carbon atoms that a particular cycloalkyl group may contain. For example, "C 3-6 "Cycloalkyl" refers to a cycloalkyl group having 3 to 6 carbon atoms.

[0069] The term "hydroxyalkyl" includes both straight-chain and branched-chain saturated alkyl groups substituted with one or more hydroxyl groups. For example, "hydroxyalkyl" includes -CHOH, -CHCHOH, and -CHCHOH. 1-4 Contains hydroxyalkyl.

[0070] The term "aryl" as used herein refers to a group of atoms obtained by removing one hydrogen attached to an aromatic ring from a molecule that contains an aromatic ring. Representative examples of aryl groups include, but are not limited to, phenyl and naphthyl. The aryl ring can be unsubstituted or can have one or more substituents, as valences permit.

[0071] The terms "halo" and "halogen" as used herein refer to F, Cl, Br, or I.

[0072] The aromatic ring of the present invention contains 0 to 3 heteroatoms selected from -N-, -S- and -O-. The aromatic ring also includes heteroaryl groups as defined below.

[0073] The term "heteroaryl" refers to substituted and unsubstituted aromatic 5- or 6-membered monocyclic and 9- or 10-membered bicyclic groups having at least one heteroatom (O, S, or N) in at least one ring, the heteroatom-containing ring preferably having 1, 2, or 3 heteroatoms independently selected from O, S, and / or N. Heteroaryl groups in each ring containing a heteroatom may contain 1 or 2 oxygen or sulfur atoms, and / or 1 to 4 nitrogen atoms, provided that the total number of heteroatoms in each ring is 4 or less, and each ring contains at least one carbon atom. The fused rings that make up the bicyclic group may be aromatic and contain only carbon atoms. The nitrogen and sulfur atoms may be optionally oxidized, and the nitrogen atoms may be optionally quaternized. Bicyclic heteroaryl groups must contain only aromatic rings. The heteroaryl group may be attached at any available nitrogen or carbon atom. The heteroaryl ring system may be unsubstituted or may have one or more substituents.

[0074] Examples of single-ring heteroaryl groups include pyrrolyl, pyrazolyl, pyrazolinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, furanyl, thiophenyl, oxadiazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, and triazinyl.

[0075] Examples of bicyclic heteroaryl groups include indolyl, benzothiazolyl, benzodioxolyl, benzoxazolyl, benzothienyl, quinolinyl, tetrahydroisoquinolinyl, isoquinolinyl, benzimidazolyl, benzopyranyl, indolizinyl, benzofuranyl, chromonyl, coumarinyl, benzopyranyl, cinnolinyl, quinoxalinyl, indazolyl, and pyrrolopyridyl.

[0076] As used herein, the phrase "or a pharma- ceutically acceptable salt thereof" refers to at least one compound, or at least one salt of the compound, or a combination thereof. For example, "a compound of formula (I) or a pharma- ceutically acceptable salt thereof" includes, but is not limited to, a compound of formula (I), two compounds of formula (I), a pharma- ceutically acceptable salt of a compound of formula (I), one or more pharma- ceutically acceptable salts of a compound of formula (I) and a compound of formula (I), and two or more pharma- ceutically acceptable salts of a compound of formula (I).

[0077] As used herein, an "adverse event" or "AE" is any sign (including laboratory abnormalities), symptom, or disease that is inappropriate, generally unintended, or more appropriately, undesirable and associated with a treatment. For example, an adverse event may be associated with activation of the immune system or proliferation of immune cells (e.g., T cells) in response to a treatment. A treatment may result in one or more associated AEs, each of which may be of the same or different severity. A method that can "alter an adverse event" refers to a different treatment regimen that reduces the incidence and / or severity of one or more AEs.

[0078] As used herein, "hyperproliferative disease" refers to a condition in which cell proliferation is increased beyond normal levels.For example, hyperproliferative disease or disorder includes malignant diseases (e.g., esophageal cancer, colon cancer, bile duct cancer) and non-malignant diseases (e.g., atherosclerosis, benign hyperplasia, and benign prostatic hyperplasia).

[0079] The term "immune response" refers to the actions of, for example, lymphocytes, antigen-presenting cells, phagocytes, granulocytes, and soluble macromolecules to selectively damage, destroy, or eliminate from the body invading pathogens, pathogen-infected cells or tissues, cancer cells, or, in the case of autoimmune or inflammatory diseases, normal human cells or tissues.

[0080] The terms "programmed cell death ligand 1", "PD-L1", "PDL1", "hPD-L1", "hPD-LI", and "B7-H1" are used interchangeably and include human PD-L1 variants, isoforms, homologs, and analogs that share at least one epitope in common with PD-L1. The complete sequence of PD-L1 is available in GENBANK® under accession number NP_054862.

[0081] The terms "programmed cell death 1", "protein PD-1", "PD-1", "PD1", "hPD-1" and "hPD-I" are used interchangeably and include variants, isoforms, homologs, and analogs of human PD-1 that share at least one epitope in common with PD-1. The complete sequence of PD-1 is available in GENBANK® under accession number U64863.

[0082] The term "treatment" refers to inhibiting the disease, disorder, or condition, i.e., arresting its progression; and (iii) alleviating the disease, disorder, or condition, i.e., reducing the disease, disorder, and / or condition, and / or symptoms associated with the disease, disorder, and / or condition.

[0083] The present disclosure is intended to encompass all isotopes of atoms contained in the present compounds. Isotopes include atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include deuterium and tritium. Isotopes of carbon include 13 C and 14 Isotopically labeled compounds of the present disclosure can be prepared by conventional techniques generally known to those of skill in the art, or by methods similar to those described herein, substituting the appropriate isotopically labeled reagent for the non-labeled reagent used elsewhere. Such compounds may have a variety of potential uses, for example, as standards and reagents in the determination of biological activity. In the case of stable isotopes, such compounds may have advantageously altered biological, pharmacological, or pharmacokinetic properties.

[0084] Another aspect of the subject matter described herein is the use of the disclosed compounds as radiolabeled ligands for the development of ligand binding assays or for monitoring the adsorption, metabolism, distribution, receptor binding or occupancy, or disposition of the compounds in vivo. For example, the macrocyclic compounds described herein may be produced with radioisotopes, and the resulting radiolabeled compounds may be used for the development of binding assays or metabolic experiments. Alternatively, the macrocyclic compounds described herein may be converted to radiolabeled forms by catalytic tritiation using methods known to those of skill in the art for the above purposes.

[0085] The macrocyclic compounds of the present disclosure may also be used for PET imaging by attaching radioisotopes using methods known to those of skill in the art.

[0086] Those skilled in the art will recognize that amino acids have the following general structure: [ka] where R and R' are as described herein. Unless otherwise indicated, the term "amino acid" as used herein, alone or as part of another group, has a carbon with an attached amino group and a carboxyl group, referred to as, but not limited to, the "α" carbon, where R and / or R' can be natural or unnatural side chains containing hydrogen. The absolute configuration "S" at the "α" carbon is commonly referred to as the "L" or "natural" configuration. When both the "R" and "R'" substituents are hydrogen, the amino acid is glycine and is not chiral.

[0087] Unless specifically specified, the amino acids described herein may be in the D or L form and may be substituted as described elsewhere in this disclosure. Where stereochemistry is not specified, it should be understood that the disclosure encompasses all stereoisomers, or mixtures thereof, that function to inhibit the interaction between PD-1 and PD-L1 and / or CD80 and PD-L1. Individual stereoisomers of the compounds may be synthetically prepared from commercially available starting materials that contain chiral centers, or by preparation of a mixture of enantiomeric products followed by separation (e.g., synthesis of a diastereomeric mixture followed by separation or recrystallization, chromatographic techniques, or direct separation of the enantiomers by chiral column chromatography). Starting compounds of particular stereochemistry are either commercially available or may be synthesized and resolved by techniques known to those of skill in the art.

[0088] Certain compounds of the present disclosure may exist in different stable stereoisomers that can be separated. Torsional asymmetry due to restricted rotation about an asymmetric single bond (e.g., steric hindrance or ring strain) may be separated into separate conformers. The present disclosure includes each stereoisomer of these compounds and mixtures thereof.

[0089] Certain compounds of the present disclosure may exist in tautomers, which are compounds that are obtained by the phenomenon that protons in a molecule move to different atoms in the molecule.The term "tautomer" also refers to one of two or more structural isomers that exist in equilibrium and can be quickly converted from one isomer to another.In the present disclosure, all tautomers of the compounds described herein are included.

[0090] The pharmaceutical compounds of the present disclosure may include one or more pharma- ceutically acceptable salts. A "pharma- ceutically acceptable salt" refers to a salt that retains the desired biological activity of the parent compound and does not have undesirable toxicity (see, e.g., Berge, SM et al., J. Pharm. Sci., 66:1-19 (1977)). Such salts may be obtained during the final isolation and purification of the compounds described herein, or may be obtained separately by reacting a free base functional group of the compound with a suitable acid or an acidic group of the compound with a suitable base. Acid addition salts include salts derived from non-toxic inorganic acids (e.g., hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, phosphorous acid, etc.) and non-toxic organic acids (e.g., aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxyalkanoic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc.). Base addition salts include salts derived from alkaline earth metals, such as sodium, potassium, magnesium, calcium, and the like, as well as non-toxic organic amines, such as N,N'-dibenzylethylenediamine, N-methylglucamine, chloroprocaine, choline, diethanolamine, ethylenediamine, procaine, and the like.

[0091] Administration of a therapeutic agent as described herein includes, but is not limited to, administration of a therapeutically effective amount of the therapeutic agent. As used herein, the term "therapeutically effective amount" refers to an amount of a therapeutic agent to treat a condition treatable by administration of a composition comprising a PD-1 / PD-L1 binding inhibitor as described herein, including, but not limited to, an amount sufficient to produce a therapeutic or ameliorative effect. Such effects may include, for example, but are not limited to, treatment of the conditions listed herein. The precise effective amount in a subject will depend on the size and health of the subject, the nature and extent of the condition being treated, the recommendations of the prescribing physician, and the therapeutic agent or combination of therapeutic agents selected for administration. Therefore, it is not useful to specify an exact effective amount in advance.

[0092] In another aspect, the disclosure relates to a method of inhibiting tumor cell proliferation in a subject using the macrocyclic compounds of the disclosure. As shown herein, the compounds of the disclosure can bind to PD-L1, inhibit the interaction between PD-L1 and PD-1, compete with the binding of PD-L1 to an anti-PD-1 monoclonal antibody known to inhibit the interaction of PD-1, promote IFNγ secretion in CMV-specific T cells, and promote IFNγ secretion in HIV-specific T cells. As a result, the compounds of the disclosure are useful for modulating immune responses, treating diseases (e.g., cancer or infectious diseases), stimulating autoimmune responses for protection, or stimulating antigen-specific immune responses, for example, by administering a PD-L1 inhibitory compound simultaneously with an antigen of interest.

[0093] Pharmaceutical Compositions In another aspect, the present disclosure provides compositions (e.g., pharmaceutical compositions comprising one or a combination of the compounds described herein formulated with a pharma- ceutical acceptable carrier). The pharmaceutical compositions of the present disclosure may also be administered in combination therapy and may be combined with other therapeutic agents. For example, the combination therapy may include a macrocyclic compound in combination with at least one other anti-inflammatory or immunosuppressant agent. Examples of therapeutic agents that may be used in combination therapy are described in detail below in the section on the use of the compounds of the present disclosure.

[0094] As used herein, "pharmaceutical acceptable carrier" includes any physiologically acceptable solvent, dispersion medium, coating agent, antibacterial and antifungal agent, isotonic and absorption delaying agents, etc. In some embodiments, the carrier is suitable for intravenous, intramuscular, subcutaneous, parenteral, intrathecal or epidermal administration, for example, by injection or infusion. Depending on the route of administration, the active compound may be coated with a material to protect the compound from the action of acids and other natural conditions that may inactivate the compound.

[0095] The pharmaceutical composition of the present disclosure may also contain a pharma- ceutically acceptable antioxidant. Examples of pharma-ceutically acceptable antioxidants include (1) water-soluble antioxidants (e.g., ascorbic acid, cysteine ​​hydrochloride, sodium hydrogen sulfate, sodium metabisulfite, sodium sulfite, etc.); (2) oil-soluble antioxidants (e.g., ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, α-tocopherol, etc.); and (3) metal chelating agents (e.g., citric acid, ethylenediaminetetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, etc.).

[0096] The pharmaceutical compositions of the present disclosure may be administered by one or more routes of administration using one or more of a variety of methods known to those of skill in the art. As will be appreciated by those of skill in the art, the route and / or method of administration will vary depending on the desired outcome. In some embodiments, the route of administration of the macrocyclic compounds of the present disclosure includes intravenous, intramuscular, intradermal, intraperitoneal, subcutaneous, intrathecal, or other parenteral routes of administration (e.g., injection or infusion). As used herein, the phrase "parenteral administration" refers to a method of administration other than enteral and topical administration, usually by injection, including, but not limited to, intravenous, intramuscular, intraarterial, intrathecal, intraarticular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural, and intrasternal injection and infusion.

[0097] Injectable sterile solution can be prepared by adding the active compound in the required amount in a suitable solvent with one or a combination of the above-listed components, and then carrying out sterilization precision filtration as necessary.Generally, dispersion is prepared by adding the active compound to a sterile vehicle (containing the basic dispersion medium and other components as listed above).Some of the sterile powders for preparing sterile injectable solution are prepared by vacuum drying and freeze-drying technology.By this method, a powder is obtained that contains the active ingredient and the desired components of the solution that has been previously sterilized and filtered.

[0098] Examples of suitable aqueous and non-aqueous carriers that can be used in the pharmaceutical compositions of the present disclosure include water, ethanol, polyol (e.g., glycerol, propylene glycol, polyethylene glycol, etc.) and suitable mixtures thereof, vegetable oil (e.g., olive oil), and injectable organic ester (e.g., ethyl oleate).Proper fluidity can be maintained, for example, by using a coating agent (e.g., lecithin), by maintaining the desired particle size in the case of dispersion, and by using a surfactant.

[0099] These compositions may also contain adjuvants, such as preservatives, wetting agents, emulsifying agents, and dispersing agents. To ensure the prevention of microbial contamination, both sterilization procedures and the addition of various antibacterial and antifungal agents (e.g., parabens, chlorobutanol, phenol, sorbic acid, etc.) may be used. It may also be desirable to add isotonic agents to the compositions, such as sugars, sodium chloride, etc. Furthermore, the absorption of injectable pharmaceuticals may be prolonged by including agents that delay absorption, such as aluminum monostearate and gelatin.

[0100] Pharmaceutically acceptable carriers include sterile aqueous solution or dispersion, and sterile powder for extemporaneous preparation in injectable sterile solution or dispersion.The use of solvents and reagents for pharmaceutical active substances is known to those skilled in the art.Unless any conventional solvent or agent is incompatible with active compound, it is expected to be used in the pharmaceutical composition of the present disclosure.Auxiliary active compounds can also be included in the composition.

[0101] Therapeutic compositions generally must be sterile and stable under the conditions of manufacture and storage. The compositions may be formulated as solutions, microemulsions, liposomes, or other forms suitable for high drug concentrations. The carrier may be, for example, a solvent or dispersion medium containing water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. Proper fluidity may be maintained, for example, by the use of coating agents (e.g., lecithin), by maintaining the desired particle size in the case of dispersions, or by the use of surfactants. In many cases, it is desirable to add isotonic agents to the compositions, for example, sugars, polyalcohols (e.g., mannitol, sorbitol), or sodium chloride. For example, the absorption of injectable compositions may be prolonged by incorporating agents that delay absorption, such as monostearate salts and gelatin, into the composition.

[0102] Alternatively, the compounds of the present disclosure may be administered parenterally, for example topically, epithelial or mucosally, such as nasal, oral, vaginal, rectal, sublingual or topical.

[0103] Any pharmaceutical composition of the present disclosure may be orally administered, for example, by any suitable acceptable oral formulation. Examples of oral formulations include, but are not limited to, tablets, troches, lozenges, aqueous and oily suspensions, dispersible powders or granules, emulsions, hard and soft capsules, liquid capsules, syrups, and elixirs. Pharmaceutical compositions for oral administration may be prepared according to any method known in the art for preparing pharmaceutical compositions for oral administration. In order to provide a medicament that is easy to swallow, the pharmaceutical compositions described in the present disclosure may include at least one substance selected from sweeteners, flavoring agents, coloring agents, demulcents, antioxidants, and preservatives.

[0104] Tablets can be prepared, for example, by mixing at least one compound of formula (I) and / or at least one pharma- ceutically acceptable salt thereof with at least one non-toxic, pharma-ceutically acceptable additive suitable for tablet preparation. Examples of additives include, but are not limited to, inert diluents (e.g., calcium carbonate, sodium carbonate, lactose, calcium phosphate, and sodium phosphate), granulating and disintegrating agents (e.g., microcrystalline cellulose, croscarmellose sodium, corn starch, and alginic acid), binding agents (e.g., starch, gelatin, polyvinylpyrrolidone, and gum arabic), and lubricants (e.g., magnesium stearate, stearic acid, and talc). In addition, tablets can be uncoated or coated by known techniques to mask the unpleasant taste of unpleasant drugs or to delay disintegration and absorption of the active ingredient in the digestive tract, thus prolonging the effect of the active ingredient for a longer period of time. Examples of water-soluble taste-masking materials include, but are not limited to, hydroxypropylmethylcellulose and hydroxypropylcellulose. Examples of time delay materials include, but are not limited to, ethyl cellulose and cellulose acetate butyrate.

[0105] Hard gelatin capsules can be prepared, for example, by mixing at least one compound of formula (I) and / or at least one salt thereof with at least one inert solid diluent (e.g., calcium carbonate, calcium phosphate, and kaolin).

[0106] Soft gelatin capsules can be prepared, for example, by mixing at least one compound of formula (I) and / or at least one pharma- ceutically acceptable salt thereof with at least one water-soluble carrier (e.g., polyethylene glycol) and at least one oil medium (e.g., peanut oil, liquid paraffin, and olive oil).

[0107] Aqueous suspensions may, for example, be prepared by mixing at least one compound of formula (I) and / or at least one pharma- ceutically acceptable salt thereof with at least one excipient suitable for the manufacture of aqueous suspensions, such as, but not limited to, suspending agents (e.g., sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, alginic acid, polyvinylpyrrolidone, gum tragacanth, and gum arabic), dispersing or wetting agents (e.g., naturally occurring phosphatides (e.g., lecithin), condensation products of alkylene oxides with fatty acids (e.g., polyoxyethylene stearate), condensation products of ethylene oxide with long chain aliphatic alcohols (e.g., heptadecaethyleneoxy esters ... and the like). Cicetanol), condensation products of ethylene oxide with partial esters derived from fatty acids and hexitols (e.g., polyoxyethylene sorbitol monooleate), and condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides (e.g., polyethylene sorbitan monooleate). The aqueous suspension may also contain at least one preservative (e.g., ethyl p-hydroxybenzoate and n-propyl p-hydroxybenzoate), at least one coloring agent, at least one flavoring agent, and / or at least one sweetening agent (e.g., but not limited to, sucrose, saccharin, and aspartame).

[0108] Oil suspensions can be prepared, for example, by suspending at least one compound of formula (I) and / or at least one pharma- ceutically acceptable salt thereof in either vegetable oil (e.g., peanut oil, sesame oil, and coconut oil) or mineral oil (e.g., liquid paraffin). Oil suspensions can also include at least one thickening agent (e.g., beeswax, hard paraffin, and cetyl alcohol). To provide a palatable oil suspension, at least one sweetener already described above and / or at least one flavoring agent can be added to the oil suspension. Oil suspensions can further include at least one preservative, including but not limited to, for example, an antioxidant (e.g., butylated hydroxyanisole, and alpha-tocopherol).

[0109] Dispersible powders and granules can be prepared, for example, by mixing at least one compound of formula (I) and / or at least one pharma- ceutically acceptable salt thereof with at least one dispersing agent and / or wetting agent, at least one suspending agent, and / or at least one preserving agent. Suitable dispersing agents, wetting agents, and suspending agents have already been described above. Examples of preservatives include, but are not limited to, antioxidants (e.g., ascorbic acid). In addition, dispersible powders and granules can also include at least one excipient (e.g., but are not limited to, sweeteners, flavoring agents, and coloring agents).

[0110] The emulsion of at least one compound of formula (I) and / or at least one pharma- ceutically acceptable salt thereof can be prepared, for example, as an oil-in-water emulsion. The oil phase of the emulsion containing the compound of formula (I) can be composed of known ingredients in a known manner. The oil phase can be provided, for example, but not limited to, by vegetable oils (e.g., olive oil and peanut oil), mineral oils (e.g., liquid paraffin), and mixtures thereof. The oil phase can include only an emulsifier, but can also include a mixture of at least one emulsifier and a fat or oil, or both a fat and an oil. Suitable emulsifiers include, but are not limited to, naturally occurring phosphatides (e.g., soybean lecithin), esters or partial esters derived from fatty acids and hexitol anhydrides (e.g., sorbitan monooleate), and condensation products of partial esters and ethylene oxide (e.g., polyoxyethylene sorbitan monooleate). In some embodiments, a hydrophilic emulsifier is included together with a lipophilic emulsifier that acts as a stabilizer. It is also desirable to include both oil and fat in some cases.Together, the emulsifier, with or without stabilizer, makes up the so-called emulsifying wax, and the wax, with oil and fat, makes up the so-called emulsifying ointment base, which forms the oily dispersed phase of the cream.The emulsion may also include sweeteners, flavorings, preservatives, and / or antioxidants.The emulsifiers and emulsion stabilizers suitable for use in the formulations of the present disclosure include Tween 60, Span 80, cetostearyl alcohol, myristyl alcohol, glyceryl monostearate, sodium lauryl sulfate, glyceryl distearate, alone or with wax; or other materials known in the art.

[0111] The active compounds may be prepared with a carrier that will protect against rapid release, such as a controlled release formulation, such as implants, transdermal patches, and microencapsulated delivery systems. Biodegradable, biocompatible polymers may be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Many methods for the preparation of such formulations are patented or generally known to those skilled in the art. See, e.g., Robinson, JR, ed., Sustained and Controlled Release Drug Delivery Systems, Marcel Dekker, Inc., New York (1978).

[0112] The therapeutic composition can be administered by medical devices known to those skilled in the art.For example, in some embodiments, the therapeutic composition of the present disclosure can be administered by needleless hypodermic injection device (such as the device disclosed in U.S. Patent No. 5,399,163, 5,383,851, 5,312,335, 5,064,413, 4,941,880, 4,790,824 or 4,596,556). Examples of known implants and modules useful in the present disclosure include an implantable microinfusion pump for constant rate administration as disclosed in U.S. Patent No. 4,487,603; a therapeutic device for transdermal administration as disclosed in U.S. Patent No. 4,486,194; an infusion pump for precise rate delivery of drugs as disclosed in U.S. Patent No. 4,447,233; an implantable variable flow rate infusion device for continuous drug delivery as disclosed in U.S. Patent No. 4,447,224; an osmotic drug delivery system with multi-chamber compartments as disclosed in U.S. Patent No. 4,439,196; and an osmotic drug delivery system as disclosed in U.S. Patent No. 4,475,196. These patents are incorporated herein by reference. Many other similar implants, delivery systems, and modules are known to those skilled in the art.

[0113] In some embodiments, the compounds of the present disclosure can be formulated to ensure proper distribution in vivo. For example, many highly hydrophilic compounds cannot cross the blood-brain barrier (BBB). To ensure that the therapeutic compounds of the present disclosure (if necessary) penetrate the BBB, they can be formulated, for example, in liposomes. For the method of producing liposomes, see, for example, U.S. Patent Nos. 4,522,811, 5,374,548, and 5,399,331. Liposomes can contain one or more moieties that are selectively transported to specific cells or organs, thus enhancing the effect of targeted drug delivery (see, for example, Ranade, VV, J. Clin. Pharmacol., 29:685 (1989)). Examples of targeting moieties include folate or biotin (see, e.g., U.S. Pat. No. 5,416,016 (Low et al.)); mannosides (Umezawa et al., Biochem. Biophys. Res. Commun., 153:1038 (1988)); macrocycles (Bloeman, PG et al., FEBS Lett., 357:140 (1995); Owais, M. et al., Antimicrob. Agents Chemother., 39:180 (1995)); surfactant protein A receptor (Briscoe et al., Am. J. Physiol., 1233:134 (1995)); p120 (Schreier et al., J. Biol. Chem., 269:9090 (1994)). See also Keinanen, K. et al., FEBS Lett., 346:123 (1994); Killion, JJ et al., Immunomethods 4:273 (1994).

[0114] Peptide synthesis The macrocyclic peptides of the present disclosure can be produced by methods known to those skilled in the art. For example, they can be chemically synthesized, recombinantly synthesized in a cell-free system, recombinantly synthesized in a cell, or isolated from an organism. The chemical synthesis of the macrocyclic peptides of the present disclosure can be carried out using a variety of well-known methods in the art, such as stepwise solid-phase synthesis, semi-synthesis via conformationally supported religation of peptide fragments, enzymatic ligation of cloned or synthesized peptide segments, and chemical ligation. Preferred methods for the synthesis of the macrocyclic peptides and analogs thereof described herein include chemical synthesis using various solid phase synthesis techniques as described, for example, in Chan, WC et al, eds., Fmoc Solid Phase Synthesis, Oxford University Press, Oxford (2000); Barany, G. et al, The Peptides: Analysis, Synthesis, Biology, Vol. 2: "Special Methods in Peptide Synthesis, Part A", pp. 3-284, Gross, E. et al, eds., Academic Press, New York (1980); Atherton, E., Sheppard, RC Solid Phase Peptide Synthesis: A Practical Approach, IRL Press, Oxford, England (1989); and Stewart, JM Young, JD Solid-Phase Peptide Synthesis, 2nd Edition, Pierce Chemical Co., Rockford, IL (1984).A method based on temporary protection of the α-amino group with a (9-fluorenylmethyloxycarbonyl) group (Fmoc) in combination with temporary protection of the amino acid side chain with a tert-butyl group (tBu) is preferred (see, for example, Atherton, E. et al, "The Fluorenylmethoxycarbonyl Amino Protecting Group", in The Peptides: Analysis, Synthesis, Biology, Vol. 9: "Special Methods in Peptide Synthesis, Part C", pp. 1-38, Undenfriend, S. et al, eds., Academic Press, San Diego (1987)).

[0115] Peptides can be synthesized stepwise on an insoluble polymeric support (also called a "resin"), starting from the C-terminus of the peptide. Synthesis begins with the attachment of the C-terminal amino acid of the peptide to the resin via the formation of an amide or ester bond, which ultimately results in the synthesis of the resulting peptide as a C-terminal amide or C-terminal carboxylic acid, respectively.

[0116] The C-terminal amino acid and all other amino acids used in the synthesis have their α-amino group and (if present) their respective side chain functional groups protected so that the α-amino protecting group may be selectively removed during synthesis. Coupling of an amino acid is performed by activating its carboxyl group as an active ester and reacting it with the free α-amino group of the resin-bound N-terminal amino acid. A series of α-amino group deprotection and coupling are repeated until the complete peptide sequence is constructed. The peptide is then cleaved from the resin with simultaneous deprotection of the side chain functional groups, usually in the presence of a suitable scavenger to prevent side reactions. The resulting peptide is finally purified by reversed-phase HPLC.

[0117] The synthesis of the peptide-resins required as precursors to the final peptides utilizes commercially available cross-linked polystyrene polymer resins (Novabiochem, San Diego, CA; Applied Biosystems, Foster City, CA). Preferred solid supports for C-terminal carboxamides include 4-(2',4'-dimethoxyphenyl-Fmoc-aminomethyl)-phenoxyacetyl-p-methylbenzhydrylamine resin (Rink Amide MBHA resin), 9-Fmoc-amino-xanthen-3-yloxy-Merrifield resin (Sieber amide resin), and 4-(9-Fmoc)aminomethyl-3,5-dimethoxyphenoxy)valerylaminomethyl-Merrifield resin (PAL resin). Coupling of the first and subsequent amino acids can be performed using HOBt, 6-Cl-HOBt or HOAt activated esters activated with DIC / HOBt, HBTU / HOBt, BOP, PyBOP, or DIC / 6-C1-HOBt, HCTU, DIC / HOAt or HATU, respectively. Preferred support solids for protected peptide fragments include 2-chlorotrityl chloride resin and 9-Fmoc-amino-xanthen-3-yloxy-Merrifield resin (Sieber amide resin). For 2-chlorotrityl chloride resin, the first amino acid is best loaded by reacting the Fmoc-protected amino acid with the resin in dichloromethane and DIEA. If necessary, a small amount of DMF can be added to dissolve the amino acid.

[0118] Synthesis of the peptide analogs described herein can be carried out using a single-channel or multi-channel peptide synthesizer, such as a Liberty microwave synthesizer (CEM), or a Prelude (6 channels) or Symphony (12 channels) or Symphony X (24 channels) (Protein Technologies, Inc.).

[0119] Useful Fmoc amino acid derivatives are shown below. Examples of vertically protected amino acids for solid phase synthesis: [ka]

[0120] The peptide-resin precursors to obtain the respective peptides may be cleaved and deprotected by any standard procedure (see, for example, King, DS et al, Int. J. Peptide Protein Res., 36:255-266 (1990)). A preferred method is to use TFA in the presence of TIS as a scavenger and DTT or TCEP as a disulfide reducing agent. Basically, the peptide-resin was stirred in TFA / TIS / DTT (v:v:w=95:5:1-97:3:1, 1-3 mL per 100 mg of peptide-resin) for 1.5-3 hours at room temperature. The resin was then filtered, the TFA solution was cooled, and Et2O solution was added. The precipitate was collected by centrifugation and the ether layer was decanted (3x). The resulting crude peptide was either directly redissolved in DMF or DMSO or CH3CN / H2O for purification by preparative HPLC or used directly in the next step. Peptides of the desired purity can be obtained by purification using preparative HPLC (e.g., Waters 4000 or Shimadzu LC-8A liquid chromatography). The crude peptide solution was injected into a YMC S5 ODS column and eluted (column: 20x100mm, linear gradient of MeCN / water (both containing 0.1% TFA), flow rate: 14-20mL / min, elution solution monitoring: UV (217 or 220nm)). The structure of the purified peptide can be confirmed by electrospray ionization MS analysis.

[0121] Listed below are what are referred to herein as unnatural amino acids. [ka] [ka]

[0122] The following abbreviations are used in the examples and elsewhere herein: [Table 1] [Table 2]

[0123] Example 0001 - Solid Phase Peptide Synthesis and Peptide Cyclization The procedures described in this example were used to synthesize the macrocyclic peptides shown in whole or in part in Table 1. Scheme 1 – General synthetic strategy used for thioether macrocyclic peptides. [ka] General Protocol for Solid Phase Peptide Synthesis (SPPS) and Macrocyclization Chlorotrityl resin preloaded with Fmoc-Pra-OH (0.100 mmol) was swelled with CHCl and then DMF on a Symphony peptide synthesizer (Protein Technology Inc. Tucson, AZ), Prelude peptide synthesizer (Protein Technology Inc. Tucson, AZ), or Symphony X peptide synthesizer (Protein Technology Inc. Tucson, AZ) under mixing and a gentle N2 stream. The solvent was drained and the first amino acid coupling was carried out as follows: The Fmoc group was removed from the resin-supported building block by washing the resin twice with a solution of 20% piperidine / DMF with mixing every 30 seconds under a gentle N2 stream. The resin was washed 5–6 times with DMF. Fmoc-Gly-OH (0.2M in DMF) was then added, followed by the coupling reagent (i.e., HATU (Chem-Impex Int'l, 0.4M in DMF)) and base (i.e., N-methylmorpholine (Aldrich, 0.8M in DMF)). The reaction mixture was stirred for 1-2 hours under a gentle stream of nitrogen. The reagents were drained from the reaction vessel and the resin was washed 5-6 times with DMF. The resulting resin-supported Fmoc-protected dipeptide was then sequentially deprotected and repeatedly coupled with the third amino acid, etc. to give the desired resin-supported product.

[0124] The Fmoc group was removed from the N-terminus by washing the resin twice with a solution of 20% piperidine / DMF under a gentle stream of nitrogen. The resin was washed with DMF (5-6 times). The peptide-resin was treated with chloroacetic anhydride (0.2 M, DMF) followed by NMM (0.8 M, DMF) and the reaction was repeated. After draining all the reagents and solvents, the resin was washed with DMF and DCM and then dried.

[0125] A small amount of the peptide cleaved from the resin was subjected to LCMS analysis (the amount to be analyzed was treated with a small amount of TFA / TIS / DTT (96:4:1) solution at room temperature to confirm the formation of the desired linear peptide).

[0126] The peptide was extensively deprotected and cleaved from the resin by treatment with TFA / TIS / DTT (96:4:1) solution for 1.5 h. The resin was removed by filtration and washed with a small amount of cleavage mixture, and the combined filtrates were added to cold Et2O. The solution was cooled to 0 °C to precipitate the peptide from solution. The slurry was centrifuged to pellet the solid, and the supernatant was decanted. The solid was washed by adding more Et2O and repeating this procedure three times. To the air-dried solid, a solution of DIEA / DMF (1-3 mL DIEA, 40-45 mL DMF) or a solution of 0.1 M NH4HCO3 / acetonitrile (1 / 1-3 / 1 (v / v)) was added, and the pH of the solution was adjusted to 8 or higher. The solution was stirred for 16-72 h and monitored by LCMS. The reaction solution was purified by reverse-phase preparative HPLC to give the desired product.

[0127] General analytical protocols and synthetic methods Analytical data: Mass spectrometry: "ESI-MS(+)" means electrospray ionization mass spectrometry in positive mode, and "ESI-MS(-)" means electrospray ionization mass spectrometry in negative mode. "ESI-HRMS(+)" means high-resolution electrospray ionization mass spectrometry in positive mode, and "ESI-HRMS(-)" means high-resolution electrospray ionization mass spectrometry in negative mode. Detected masses are reported in units of "m / z". Compounds with exact masses greater than 1000 are often detected as doubly or triply charged ions. The crude material was purified by preparative LC / MS and the fractions containing the desired product were combined and dried on a centrifugal evaporator.

[0128] Analytical LC / MS conditions A: Column: Waters Acquity UPLC BEH C18, 2.1x50mm, particle size: 1.7μm; Mobile phase A: 5:95 acetonitrile:water (containing 10mM ammonium acetate); Mobile phase B: 95:5 acetonitrile:water (containing 10mM ammonium acetate); Temperature: 50°C; Gradient: 0-100% B over 3 min, followed by 100% B for 0.75 min; Flow rate: 1.0mL / min; Detection: UV (220nm).

[0129] Analytical LC / MS conditions B: Column: Waters Acquity UPLC BEH C18, 2.1x50mm, particle size: 1.7μm; Mobile phase A: 5:95 acetonitrile:water (containing 0.1% trifluoroacetic acid); Mobile phase B: 95:5 acetonitrile:water (containing 0.1% trifluoroacetic acid); Temperature: 50°C; Gradient: 0-100% B over 3 min, followed by 100% B for 0.75 min; Flow rate: 1.0mL / min; Detection: UV (220nm)

[0130] Analytical LC / MS conditions C: Column: Waters Acquity UPLC BEH C18, 2.1x50mm, particle size: 1.7μm; Mobile phase A: 5:95 acetonitrile:water (containing 10mM ammonium acetate); Mobile phase B: 95:5 acetonitrile:water (containing 10mM ammonium acetate); Temperature: 70°C; Gradient: 0-100% B over 3 min, followed by 100% B for 2.0 min; Flow rate: 0.75mL / min; Detection: UV (220nm).

[0131] Analytical LC / MS conditions D: Column: Waters Acquity UPLC BEH C18, 2.1x50mm, particle size: 1.7μm; Mobile phase A: 5:95 acetonitrile:water (containing 0.1% trifluoroacetic acid); Mobile phase B: 95:5 acetonitrile:water (containing 0.1% trifluoroacetic acid); Temperature: 70°C; Gradient: 0-100% B over 3 min, followed by 100% B for 2.0 min; Flow rate: 0.75mL / min; Detection: UV (220nm)

[0132] Analytical LC / MS conditions E: Column: Kinetex XB C18, 3.0x75mm, particle size: 2.6μm; Mobile phase A: 10mM ammonium formate in water:acetonitrile (98:2); Mobile phase B: 10mM ammonium formate in water:acetonitrile (2:98); Gradient: 20-100% B over 4 min, followed by 100% B for 0.6 min; Flow rate: 1.0mL / min; Detection: UV (254nm)

[0133] Analytical LC / MS conditions F: Column: Ascentis Express C18, 2.1x50mm, particle size: 2.7μm; Mobile phase A: 10mM ammonium acetate in water:acetonitrile (95:5); Mobile phase B: 10mM ammonium acetate in water:acetonitrile (5:95); Temperature: 50°C; Gradient: 0-100% B over 3 min; Flow rate: 1.0mL / min; Detection: UV (220nm)

[0134] Analytical LC / MS conditions G: Column: X Bridge C18, 4.6x50mm, particle size: 5μm; Mobile phase A: 0.1% TFA / water; Mobile phase B: acetonitrile; Temperature: 35℃; Gradient: 5-95% B over 4 min; Flow rate: 4.0mL / min; Detection: UV (220nm)

[0135] Analytical LC / MS conditions H: Column: X Bridge C18, 4.6x50mm, particle size: 5μm; Mobile phase A: 10mM NH4OAc; Mobile phase B: Methanol, temperature: 35℃; Gradient: 5-95%B over 4min; Flow rate: 4.0mL / min; Detection: UV(220nm)

[0136] Analytical LC / MS conditions I: Column: X Bridge C18, 4.6x50mm, particle size: 5μm; Mobile phase A: 10mM NH4OAc; Mobile phase B: acetonitrile, temperature: 35℃; Gradient: 5-95%B over 4min; Flow rate: 4.0mL / min; Detection: UV(220nm)

[0137] Analytical LC / MS conditions J: Column: Waters Acquity UPLC BEH C18, 2.1x50mm, particle size: 1.7μm; Mobile phase A: 5:95 acetonitrile:water (containing 0.05% trifluoroacetic acid); Mobile phase B: 95:5 acetonitrile:water (containing 0.05% trifluoroacetic acid); Temperature: 70°C; Gradient: 0-100% B over 1.5 min, followed by 100% B for 2.0 min; Flow rate: 0.75mL / min; Detection: UV (254nm)

[0138] Analytical LC / MS conditions K: Column: Waters Acquity UPLC BEH C18, 2.1x50mm, particle size: 1.7μm; Mobile phase A: 100% water (containing 0.05% trifluoroacetic acid); Mobile phase B: 100% acetonitrile (containing 0.05% trifluoroacetic acid); Temperature: 50°C; Gradient: 2-98% B over 1.0 min, followed by 98% B for 1.0-1.5 min; Flow rate: 0.80mL / min; Detection: UV (220nm)

[0139] Analytical LC / MS conditions L: Column: Waters Acquity UPLC BEH C18, 2.1x50mm, particle size: 1.7μm; Buffer: 10mM ammonium acetate; Mobile phase A: Buffer / CH3CN(95 / 5); Mobile phase B: Buffer / ACN(5 / 95); Temperature: 50℃; Gradient: 20-98% B over 2.0 min, followed by 100% B for 0.2 min; Flow rate: 0.70mL / min; Detection: UV(220nm)

[0140] Analytical LC / MS conditions M: Column: Waters Acquity UPLC BEH C18, 3.0x50mm, particle size: 1.7μm; Mobile phase A: 95% water and 5% water (with 0.1% trifluoroacetic acid); Mobile phase B: 95% acetonitrile and 5% water (with 0.1% trifluoroacetic acid); Temperature: 50°C; Gradient: 20-100% B over 2.0 min, followed by 100% B for 2.0-2.3 min; Flow rate: 0.7mL / min; Detection: UV (220nm).

[0141] Analytical LC / MS conditions N: Column: Waters Acquity UPLC BEH C18, 2.1x50mm, particle size: 1.7μm; Mobile phase A: 100% water (containing 0.05% trifluoroacetic acid); Mobile phase B: 100% acetonitrile (containing 0.05% trifluoroacetic acid); Temperature: 50°C; Gradient: 2-98% B over 5.0 min, followed by 98% B for 5.0-5.5 min; Flow rate: 0.80mL / min; Detection: UV (220nm).

[0142] Analytical LC / MS conditions O: Column: Waters Acquity UPLC BEH C18, 2.1x50mm, particle size: 1.7μm; Mobile phase A: 5:95 acetonitrile:water (containing 0.05% trifluoroacetic acid); Mobile phase B: 95:5 acetonitrile:water (containing 0.05% trifluoroacetic acid); Temperature: 50°C; Gradient: 2%-98%B over 2 min, followed by 98%B for 0.5 min; Flow rate: 0.8mL / min; Detection: UV (220nm)

[0143] Analytical LC / MS conditions P: Column: Waters Acquity UPLC BEH C18, 2.1x50mm, particle size: 1.7μm; Mobile phase A: 5:95 acetonitrile:water (containing 0.05% trifluoroacetic acid); Mobile phase B: 95:5 acetonitrile:water (containing 0.05% trifluoroacetic acid); Temperature: 50°C; Gradient: 0%-100% B over 3 min, followed by 100% B for 0.5 min; Flow rate: 1.0mL / min; Detection: UV (220nm)

[0144] Analytical LC / MS conditions Q: Column: Waters Acquity UPLC BEH C18, 2.1x50mm, particle size: 1.7μm; Mobile phase A: 5:95 acetonitrile:water (containing 0.05% trifluoroacetic acid); Mobile phase B: 95:5 acetonitrile:water (containing 0.05% trifluoroacetic acid); Temperature: 50°C; Gradient: 0%-100% B over 1 min, followed by 100% B for 0.5 min; Flow rate: 1.0mL / min; Detection: UV (220nm)

[0145] Analytical LC / MS conditions R: Column: Waters Acquity UPLC BEH C18, 2.1x50mm, particle size: 1.7μm; Buffer: 10mM ammonium acetate; Mobile phase A: Buffer / CH3CN (95 / 5); Mobile phase B: Buffer / ACN (5 / 95); Temperature: 50°C; Gradient: 0%-100% B over 1 min, followed by 100% B for 0.5 min; Flow rate: 1.0mL / min; Detection: UV (220nm)

[0146] Analytical LC / MS conditions S: Column: Waters Acquity UPLC BEH C18, 2.1x50mm, particle size: 1.7μm; Mobile phase A: 100% water (containing 0.05% trifluoroacetic acid); Mobile phase B: 100% acetonitrile (containing 0.05% trifluoroacetic acid); Gradient: 2-98% B over 1.6 min, followed by 98% B for 0.2 min; Flow rate: 0.80mL / min; Detection: UV (220nm)

[0147] Analytical LC / MS conditions T: Column: Waters Acquity UPLC BEH C18, 2.1x50mm, particle size: 1.7μm; Mobile phase A: 5:95 acetonitrile:water (containing 0.05% trifluoroacetic acid); Mobile phase B: 95:5 acetonitrile:water (containing 0.05% trifluoroacetic acid); Gradient: 2%-98%B over 2.6min, followed by 98%B for 0.4min; Flow rate: 0.8mL / min; Detection: UV (220nm)

[0148] Analytical LC / MS conditions U: Column: Waters Acquity UPLC BEH C18, 2.1x50mm, particle size: 1.7μm; Mobile phase A: 5:95 acetonitrile:water (containing 10mM ammonium acetate); Mobile phase B: 95:5 acetonitrile:water (containing 10mM ammonium acetate); Gradient: 30-100% B over 3 min, followed by 100% B for 0.75 min; Flow rate: 1.0mL / min; Detection: UV (220nm)

[0149] General steps: Steps for Prelude: All manipulations are performed automatically on a peptide synthesizer (Prelude, Protein Technologies). Unless otherwise noted, all procedures are performed in 45 mL polypropylene reaction vessels fitted with a frit at the bottom. Both the top and bottom of the reaction vessel are connected to the peptide synthesizer (Prelude). DMF and DCM can be added through the top of the vessel to evenly wash the vessel walls. Other reagents are added through the bottom of the reaction vessel and pass through the frit to contact the resin. All solutions are vented from the bottom of the reaction vessel. "Periodic agitation" refers to brief N2 gassing through the bottom frit, lasting approximately 5 seconds every 30 seconds. Amino acid solutions were generally not used more than 2 weeks after preparation. HATU solutions were used within 7-14 days of preparation.

[0150] Sieber amide resin = 9-Fmoc-aminoxanthene-3-yloxy polystyrene resin Here, "3-yloxy" indicates the position and type of bond with the polystyrene resin. The resin used was polystyrene with a Sieber linker (nitrogen Fmoc-protected, 100-200 mesh, 1% DVB, loading: 0.71 mmol / g). Rink = (2,4-dimethoxyphenyl)(4-alkoxyphenyl)methanamine Here, "4-alkoxy" indicates the position and type of bond with the polystyrene resin. The resin used was Merrifield polymer with a Rink linker (polystyrene, nitrogen protected by Fmoc, 100-200 mesh, 1% DVB, loading: 0.56 mmol / g). 2-Chlorotrityl chloride resin (2-chlorotriphenylmethyl chloride resin), 50-150 mesh, 1% DVB, Load: 1.54 mmol / g Fmoc-glycine-2-chlorotrityl chloride resin, 200-400 mesh, 1% DVB, loading: 0.63 mmol / g PL-FMP resin: (4-formyl-3-methoxyphenoxymethyl) polystyrene

[0151] The common amino acids used are listed below, with the side-chain protecting groups shown in parentheses. Fmoc-Ala-OH; Fmoc-Arg(Pbf)-OH; Fmoc-Asn(Trt)-OH; Fmoc-Asp(tBu)-OH; Fmoc-Bip-OH; Fmoc-Cys(Trt)-OH; Fmoc-Dab(Boc)-OH; Fmoc-Dap(Boc)-OH; Fmoc-Gly-OH; Fmoc-His(Trt)-OH; Fmoc-Hyp(tBu)-OH; Fmoc-Ile-OH; Fmoc-Leu-OH; Fmoc-Lys(Boc)-OH; Fmoc-Nle-OH; Fmoc-Met-OH; Fmoc-[N-Me]Ala-OH; Fmoc-Orn(Boc)-OH, Fmoc-Phe-OH; Fmoc-Pro-OH; Fmoc-Sar-OH; Fmoc-Ser(tBu)-OH; Fmoc-Thr(tBu)-OH; Fmoc-Trp(Boc)-OH; Fmoc-Tyr(tBu)-OH; Fmoc-Val-OH; and the corresponding D-amino acids.

[0152] The "Prelude Procedure" describes experiments performed at 0.100 mmol scale, where the scale is determined by the amount of Sieber or Rink or 2-chlorotrityl or PL-FMP resin. This scale corresponds to the Sieber amide resin (approximately 140 mg) described above. All procedures may be scaled down or up from the 0.100 mmol scale by adjusting the volumes by multiples. Prior to amino acid coupling, all peptide syntheses begin with the resin swelling procedure described below under "Resin Swelling Procedure." For coupling of amino acids to the N-terminus of primary amines, the "Single Coupling Procedure" described below was performed. For coupling of amino acids to the N-terminus of secondary amines or to the N-terminus of Arg(Pbf) and D-Arg(Pbf), the "Double Coupling Procedure" described below was performed.

[0153] Resin swelling procedure: To a 45 mL polypropylene solid phase reaction vessel was added Sieber amide resin (140 mg, 0.100 mmol). DMF (5.0 mL) was added to the vessel through the top of the reaction vessel and the mixture was periodically stirred for 10 min, after which the resin was washed (swelled) twice with a "DMF top wash" in which the solvent was drained through a frit.

[0154] Single coupling action: To the reaction vessel containing the resin from the previous step was added piperidine:DMF (20:80 v / v, 5.0 mL). The mixture was periodically stirred for 5.0 min, then the solution was drained through the frit. To the reaction vessel was added piperidine:DMF (20:80 v / v, 5.0 mL). The mixture was periodically stirred for 5.0 min, then the solution was drained through the frit. The resin was washed six times in succession. For each wash, DMF (6.0 mL) was added through the top of the vessel, the resulting mixture was periodically stirred for 1.0 min, then the solution was drained through the frit. To the reaction vessel was added amino acid (0.2 M in DMF, 5.0 mL, 10 equiv), then HATU (0.4 M in DMF, 2.5 mL, 10 equiv), and finally NMM (0.8 M in DMF, 2.5 mL, 20 equiv). The mixture was periodically stirred for 60-120 min, then the reaction solution was drained through the frit. The resin was washed four times in succession. For each wash, DMF (5.0 mL) was added from the top of the vessel, the resulting mixture was periodically stirred for 1.0 min, and the solution was then drained through the frit. The resulting resin was used directly in the next step.

[0155] Double coupling procedure: To the reaction vessel containing the resin from the previous step was added piperidine:DMF (20:80 v / v, 5.0 mL). The mixture was stirred periodically for 5.0 min, then the solution was drained through the frit. To the reaction vessel was added piperidine:DMF (20:80 v / v, 5.0 mL). The mixture was stirred periodically for 5.0 min, then the solution was drained through the frit. The resin was washed six times in succession. For each wash, DMF (6.0 mL) was added through the top of the vessel, and the resulting mixture was stirred periodically for 1.0 min, then the solution was drained through the frit. To the reaction vessel was added amino acid (0.2 M in DMF, 5.0 mL, 10 equiv), then HATU (0.4 M in DMF, 2.5 mL, 10 equiv), and finally NMM (0.8 M in DMF, 2.5 mL, 20 equiv). The mixture was stirred periodically for 1-1.5 h, then the reaction solution was drained through the frit. The resin was washed two times in succession. For each wash, DMF (5.0 mL) was added from the top of the vessel, the resulting mixture was stirred periodically for 1.0 min, and the solution was drained through the frit. The reaction vessel was charged with amino acid (0.2 M in DMF, 5.0 mL, 10 equiv.), then HATU (0.4 M in DMF, 2.5 mL, 10 equiv.), and finally NMM (0.8 M in DMF, 2.5 mL, 20 equiv.). The mixture was stirred periodically for 1-1.5 h, and then the reaction solution was drained through the frit. The resin was washed four times in succession. For each wash, DMF (5.0 mL) was added from the top of the vessel, the resulting mixture was stirred periodically for 1.0 min, and the solution was drained through the frit. The resulting resin was used directly in the next step.

[0156] Single Coupling Manual Addition Procedure A: To the reaction vessel containing the resin from the previous step, piperidine:DMF (20:80 v / v, 5.0 mL) was added. The mixture was stirred periodically for 5 min, then the solution was drained through the frit. To the reaction vessel, piperidine:DMF (20:80 v / v, 5.0 mL) was added. The mixture was stirred periodically for 5 min, then the solution was drained through the frit. The resin was washed six times in succession. For each wash, DMF (5.0 mL) was added through the top of the vessel, the resulting mixture was stirred periodically for 30 s, then the solution was drained through the frit. The reaction was stopped, and while the bottom of the vessel was still attached to the apparatus, the reaction vessel was opened and the unnatural amino acid (2-4 equiv) in DMF (1-2 mL) was manually added through the top of the vessel by pipette, then the vessel was closed. The automated program was resumed and HATU (0.4 M in DMF, 1.3 mL, 4 equiv.) and NMM (1.3 M in DMF, 1.0 mL, 8 equiv.) were added successively. The mixture was periodically stirred for 2-3 h, and then the reaction solution was drained through the frit. The resin was washed five times in succession. In each wash, DMF (5.0 mL) was added through the top of the vessel, and the resulting mixture was periodically stirred for 30 s, after which the solution was drained through the frit. The resulting resin was used directly in the next step.

[0157] Single coupling manual addition procedure B: To the reaction vessel containing the resin from the previous step, piperidine:DMF (20:80 v / v, 5.0 mL) was added. The mixture was stirred periodically for 5 min, then the solution was drained through the frit. To the reaction vessel, piperidine:DMF (20:80 v / v, 5.0 mL) was added. The mixture was stirred periodically for 5 min, then the solution was drained through the frit. The resin was washed six times in succession. For each wash, DMF (5.0 mL) was added through the top of the vessel, the resulting mixture was stirred periodically for 30 s, then the solution was drained through the frit. The reaction was stopped, and while the bottom of the vessel was still attached to the apparatus, the reaction vessel was opened and the unnatural amino acid (2-4 equiv) in DMF (1-1.5 mL) was manually added through the top of the vessel via pipette, followed by HATU (2-4 equiv, same equivalent as the unnatural amino acid) manually, and then the vessel was closed. The automated program was resumed and NMM (1.3 M in DMF, 1.0 mL, 8 equiv.) was then added. The mixture was periodically stirred for 2-3 h, and then the reaction solution was drained through the frit. The resin was washed five times in succession. For each wash, DMF (5.0 mL) was added through the top of the vessel, and the resulting mixture was periodically stirred for 30 s, after which the solution was drained through the frit. The resulting resin was used directly in the next step.

[0158] Peptoid loading treatment (50 μmol): To the reaction vessel containing the resin from the previous step was added piperidine:DMF (20:80 v / v, 4.0 mL). The mixture was periodically stirred for 5 min, then the solution was drained through the frit. To the reaction vessel was added piperidine:DMF (20:80 v / v, 4.0 mL). The mixture was periodically stirred for 5 min, then the solution was drained through the frit. The resin was washed six times in succession. For each wash, DMF (5.0 mL) was added through the top of the vessel and the resulting mixture was periodically stirred for 60 s, then the solution was drained through the frit. To the reaction vessel was added bromoacetic acid (0.4 M in DMF, 2.0 mL, 16 eq.) followed by DIC (0.4 M in DMF, 2.0 mL, 16 eq.). The mixture was periodically stirred for 1 h, then the reaction solution was drained through the frit. The resin was washed five times in succession. For each wash, DMF (5.0 mL) was added through the top of the vessel, the resulting mixture was periodically stirred for 30 seconds, and the solution was then drained through the frit. Amine (0.4 M in DMF, 2.0 mL, 16 equiv.) was added to the reaction vessel. The mixture was periodically stirred for 1 hour, and then the reaction solution was drained through the frit. The resin was washed five times in succession. For each wash, DMF (5.0 mL) was added through the top of the vessel, the resulting mixture was periodically stirred for 30 seconds, and the solution was then drained through the frit. The resulting resin was used directly in the next step.

[0159] Chloroacetic anhydride coupling: To the reaction vessel containing the resin from the previous step was added piperidine:DMF (20:80 v / v, 5.0 mL). The mixture was periodically stirred for 5 minutes, then the solution was drained through the frit. To the reaction vessel was added piperidine:DMF (20:80 v / v, 5.0 mL). The mixture was periodically stirred for 5 minutes, then the solution was drained through the frit. The resin was washed six times in succession. For each wash, DMF (6.0 mL) was added through the top of the vessel, and the resulting mixture was periodically stirred for 1 minute, then the solution was drained through the frit. To the reaction vessel was added chloroacetic anhydride solution (0.4 M in DMF, 5.0 mL, 20 equiv.) followed by N-methylmorpholine (0.8 M in DMF, 5.0 mL, 40 equiv.). The mixture was periodically stirred for 15 minutes, then the reaction solution was drained through the frit. The resin was washed two times in succession. For each wash, DMF (6.0 mL) was added through the top of the vessel and the resulting mixture was stirred periodically for 1 min before the solution was drained through the frit. To the reaction vessel was added chloroacetic anhydride solution (0.4 M in DMF, 5.0 mL, 20 eq.) followed by N-methylmorpholine (0.8 M in DMF, 5.0 mL, 40 eq.). The mixture was stirred periodically for 15 min and then the reaction solution was drained through the frit. The resin was washed five times in succession. For each wash, DMF (6.0 mL) was added through the top of the vessel and the resulting mixture was stirred periodically for 1 min before the solution was drained through the frit. The resin was washed four times in succession. For each wash, DCM (6.0 mL) was added through the top of the vessel and the resulting mixture was stirred periodically for 1 min before the solution was drained through the frit. The resin was then dried under a stream of nitrogen for 10 min and the resulting resin was used directly in the next step.

[0160] Steps in Symphony: All operations are performed automatically on a 12-channel peptide synthesizer (Symphony, Protein Technologies). Unless otherwise noted, all procedures are performed in 25 mL polypropylene reaction vessels fitted with a frit at the bottom. Both the top and bottom of the reaction vessel are connected to the peptide synthesizer (Symphony). DMF and DCM can be added from the top of the vessel to evenly wash the vessel walls. Other reagents are added from the bottom of the reaction vessel and pass through the frit to contact the resin. All solutions are vented from the bottom of the reaction vessel. "Periodic agitation" refers to brief N2 gassing through the bottom frit, lasting approximately 5 seconds every 30 seconds. Amino acid solutions were generally not used more than 2 weeks after preparation. HATU solutions were used within 7-14 days of preparation.

[0161] Sieber amide resin = 9-Fmoc-aminoxanthene-3-yloxy polystyrene resin Here, "3-yloxy" indicates the position and type of bond with the polystyrene resin. The resin used was polystyrene with a Sieber linker (nitrogen Fmoc-protected, 100-200 mesh, 1% DVB, loading: 0.71 mmol / g). Rink = (2,4-dimethoxyphenyl)(4-alkoxyphenyl)methanamine Here, "4-alkoxy" indicates the position and type of bond with the polystyrene resin. The resin used was Merrifield polymer with a Rink linker (polystyrene, nitrogen protected by Fmoc, 100-200 mesh, 1% DVB, loading: 0.56 mmol / g). 2-Chlorotrityl chloride resin (2-chlorotriphenylmethyl chloride resin), 50-150 mesh, 1% DVB, Load: 1.54 mmol / g PL-FMP resin: (4-formyl-3-methoxyphenoxymethyl) polystyrene Fmoc-glycine-2-chlorotrityl chloride resin, 200-400 mesh, 1% DVB, loading: 0.63 mmol / g

[0162] The common amino acids used are listed below, with the side-chain protecting groups shown in parentheses. Fmoc-Ala-OH; Fmoc-Arg(Pbf)-OH; Fmoc-Asn(Trt)-OH; Fmoc-Asp(tBu)-OH; Fmoc-Bip-OH; Fmoc-Cys(Trt)-OH; Fmoc-Dab(Boc)-OH; Fmoc-Dap(Boc)-OH; Fmoc-Gly-OH Fmoc-Gly-OH; Fmoc-His(Trt)-OH; Fmoc-Hyp(tBu)-OH; Fmoc-Ile-OH; Fmoc-Leu-OH; Fmoc-Lys(Boc)-OH; Fmoc-Nle-OH; Fmoc-[N-Me]Nle-OH; Fmoc-Orn(Boc)-OH, Fmoc-Phe-OH; Fmoc-Pro-OH; Fmoc-Sar-OH; Fmoc-Ser(tBu)-OH; Fmoc-Thr(tBu)-OH; Fmoc-Trp(Boc)-OH; Fmoc-Tyr(tBu)-OH; Fmoc-Val-OH; and the corresponding D-amino acids.

[0163] "Symphony Procedure" describes experiments performed on a 0.05 mmol scale, where the scale is determined by the amount of Sieber or Rink or chlorotrityl linker or PL-FMP bound to the resin. This scale corresponds to the Sieber resin mentioned above (approximately 70 mg). All procedures may be scaled up from the 0.05 mmol scale by adjusting the volumes stated in multiples.

[0164] Prior to amino acid coupling, all peptide syntheses began with a resin swelling procedure as described below in "Resin Swelling Procedure." For coupling of amino acids to the N-terminus of primary amines, the "Single Coupling Procedure" was performed as described below. For coupling of amino acids to the N-terminus of secondary amines or to the N-terminus of Arg(Pbf) and D-Arg(Pbf), the "Double Coupling Procedure" was performed as described below.

[0165] Resin swelling procedure: The resin (0.05 mmol) was added to a 25 mL polypropylene solid-phase reaction vessel. The resin was washed (swelled) by adding DMF (2.0–3.0 mL, 1–2 times) to the reaction vessel, periodically stirring the mixture for 10 min, and draining the solvent through the frit. For some resins, the resin was washed (swelled) by adding CH2Cl2 (3–5 mL, 2 times) to the reaction vessel, periodically stirring the mixture for 30 min, draining the solvent through the frit, and then adding DMF (2.0–3.0 mL, 1–6 times), periodically stirring the mixture for 2–10 min, and draining the solvent through the frit.

[0166] Single coupling action: DMF (2.5–3.75 mL) was added three times to the reaction vessel containing the resin from the previous steps, the mixture was stirred for 30 s, and the solvent was drained through the frit each time. Piperidine:DMF (20:80 v / v, 3.0–3.75 mL) was added to the resin, the mixture was stirred periodically for 5.0 min, and the solution was then drained through the frit. Piperidine:DMF (20:80 v / v, 3.0–3.75 mL) was added to the reaction vessel, the mixture was stirred periodically for 5.0 min, and the solution was then drained through the frit. Some were subjected to the deprotection step the third time. The resin was washed six times in succession. For each wash, DMF (2.5–3.75 mL) was added to the vessel, the resulting mixture was stirred periodically for 30 s, and the solution was then drained through the frit. The reaction vessel was charged with amino acid (0.2 M, in DMF, 2.0–2.5 mL, 8–10 equiv.), then HATU (0.4 M, in DMF, 1.0–1.25 mL, 8–10 equiv.), and finally NMM (0.8 M, in DMF, 1.0–1.25 mL, 20 equiv.). The mixture was periodically stirred for 30–120 min, and then the reaction solution was drained through the frit. The resin was washed six times in succession. In each wash, DMF (2.5–3.0 mL) was added, and the resulting mixture was periodically stirred for 30 s, after which the solution was drained through the frit. The resulting resin was used directly in the next step.

[0167] Single coupling manual addition procedure: DMF (3.0–3.75 mL) was added three times to the reaction vessel containing the resin from the previous steps, and the mixture was stirred for 30 seconds, after which the solvent was drained through the frit each time. Piperidine:DMF (20:80 v / v, 3.0–3.75 mL) was added to the resin. The mixture was stirred periodically for 5.0 minutes, and then the solution was drained through the frit. Piperidine:DMF (20:80 v / v, 3.0–3.75 mL) was added to the reaction vessel, and the mixture was stirred periodically for 5.0 minutes, and then the solution was drained through the frit. The mixture was stirred periodically for 5.0 minutes, and then the solution was drained through the frit. The resin was washed six times in succession. For each wash, DMF (3.0–3.75 mL) was added to the vessel, and the resulting mixture was stirred periodically for 30 seconds, and then the solution was drained through the frit. The reaction vessel was charged with premixed amino acids (2.0–5.0 equiv.) and HATU (0.4 M, in DMF, 2.0–5.0 equiv.) in a molar ratio of 1:1:2 for amino acids, HATU, and NMM, followed by NMM (0.8 M, in DMF, 4.0–10.0 equiv.). The mixture was periodically stirred for 2–6 h, and then the reaction solution was drained through the frit. The resin was washed four times in succession. DMF (3.75 mL) was added for each wash, and the resulting mixture was periodically stirred for 30 s, after which the solution was drained through the frit. The resulting resin was used directly in the next step.

[0168] Double coupling procedure: DMF (2.5–3.75 mL) was added three times to the reaction vessel containing the resin from the previous steps, the mixture was stirred for 30 seconds, and the solvent was drained through the frit each time. Piperidine:DMF (20:80 v / v, 3.0–3.75 mL) was added to the reaction vessel. The mixture was stirred periodically for 5 minutes, and then the solution was drained through the frit. Piperidine:DMF (20:80 v / v, 3.0–3.75 mL) was added to the reaction vessel, the mixture was stirred periodically for 5 minutes, and then the solution was drained through the frit. The resin was washed six times in succession. DMF (3.0–3.75 mL) was added for each wash, and the resulting mixture was stirred periodically for 30 seconds, and then the solution was drained through the frit. To the reaction vessel was added amino acid (0.2 M, in DMF, 2.0–2.5 mL, 8–10 equiv.), then HATU (0.4 M, in DMF, 1.0–1.25 mL, 10 equiv.), and finally NMM (0.8 M, in DMF, 1.0–1.25 mL, 16–20 equiv.). The mixture was periodically stirred for 1 h, and then the reaction solution was drained through the frit. The resin was washed twice with DMF (3.0–3.75 mL), and the resulting mixture was periodically stirred for 30 s, after which the solution was drained through the frit each time. The reaction vessel was charged with amino acid (0.2 M, in DMF, 2.0–2.5 mL, 8–10 equiv.), then HATU (0.4 M, in DMF, 1.0–1.25 mL, 8–10 equiv.), and finally NMM (0.8 M, in DMF, 1.0–1.25 mL, 16–20 equiv.). The mixture was periodically stirred for 1–2 h, and then the reaction solution was drained through the frit. The resin was washed six times in succession. In each wash, DMF (3.0–3.75 mL) was added, and the resulting mixture was periodically stirred for 30 s, after which the solution was drained through the frit. The resulting resin was used directly in the next step.

[0169] Peptoid loading treatment (50 μmol): To the reaction vessel containing the resin from the previous step was added piperidine:DMF (20:80 v / v, 3.75 mL). The mixture was periodically stirred for 5 minutes, then the solution was drained through the frit. To the reaction vessel was added piperidine:DMF (20:80 v / v, 3.75 mL). The mixture was periodically stirred for 5 minutes, then the solution was drained through the frit. The resin was washed six times in succession. For each wash, DMF (3.75 mL) was added to the vessel and the resulting mixture was periodically stirred for 30 seconds, then the solution was drained through the frit. To the reaction vessel was added bromoacetic acid (0.4 M in DMF, 2.5 mL, 10 equiv.) followed by DIC (0.4 M in DMF, 2.5 mL, 10 equiv.). The mixture was periodically stirred for 60 minutes, then the reaction solution was drained through the frit. The resin was washed two times in succession. For each wash, DMF (3.75 mL) was added to the vessel and the resulting mixture was periodically agitated for 30 seconds before the solution was drained through the frit. Amine (0.4 M in DMF, 2.5 mL, 10 equiv.) was added to the reaction vessel and the mixture was periodically agitated for 60 minutes before the reaction solution was drained through the frit. The resin was washed five times in succession. For each wash, DMF (3.75 mL) was added to the vessel and the resulting mixture was periodically agitated for 30 seconds before the solution was drained through the frit. The resulting resin was used directly in the next step.

[0170] Chloroacetic anhydride coupling: DMF (3.0–3.75 mL) was added three times to the reaction vessel containing the resin from the previous steps, the mixture was stirred for 30 seconds, and the solvent was drained through the frit each time. Piperidine:DMF (20:80 v / v, 3.0–3.75 mL) was added to the reaction vessel containing the resin from the previous steps. The mixture was stirred periodically for 5 minutes, and then the solution was drained through the frit. Piperidine:DMF (20:80 v / v, 3.0–3.75 mL) was added to the reaction vessel. The mixture was stirred periodically for 5 minutes, and then the solution was drained through the frit. The resin was washed six times in succession. For each wash, DMF (3.0–3.75 mL) was added through the top of the vessel, and the resulting mixture was stirred periodically for 30 seconds, and then the solution was drained through the frit. To the reaction vessel was added chloroacetic anhydride (0.4 M in DMF, 3.0-3.75 mL, 30 equiv.), followed by NMM (0.8 M in DMF, 2.5 mL, 40 equiv.). The mixture was stirred periodically for 15 min, then the reaction solution was drained through the frit. The resin was washed once by adding DMF (5.0-6.25 mL) through the top of the vessel, stirring the resulting mixture periodically for 30 s, then draining the solution through the frit. To the reaction vessel was added chloroacetic anhydride solution (0.4 M in DMF, 3.75 mL, 30 equiv.), followed by NMM (0.8 M in DMF, 2.5 mL, 40 equiv.). The mixture was stirred periodically for 15 min, then the reaction solution was drained through the frit. The resin was washed six times in succession. For each wash, DMF (2.5 mL) was added through the top of the vessel, stirring the resulting mixture periodically for 30 s, then draining the solution through the frit. The resin was washed four times in succession. For each wash, DCM (2.5 mL) was added from the top of the vessel and the resulting mixture was periodically swirled for 30 seconds before the solution was drained through the frit. The resulting resin was dried under a stream of nitrogen for 10 minutes before being used directly in the next step.

[0171] Steps for Symphony X: All operations are performed automatically on a peptide synthesizer (Symphony X, Protein Technologies). Unless otherwise noted, all procedures are performed in 45 mL polypropylene reaction vessels fitted with a frit at the bottom. Both the top and bottom of the reaction vessel are connected to the peptide synthesizer (Symphony X). DMF and DCM can be added from the top of the vessel to evenly wash the vessel walls. Other reagents are added from the bottom of the reaction vessel and pass through the frit to contact the resin. All solutions are evacuated from the bottom of the reaction vessel. "Periodic agitation" refers to a brief N2 gas burst from the bottom frit, lasting approximately 5 seconds every 30 seconds. "Single shot" mode addition refers to the addition of all solution contained in a single shot conical tube (Falcon) of any volume, usually less than 5 mL. Amino acid solutions were generally not used more than 2 weeks after preparation. HATU solutions were used within 14 days of preparation.

[0172] Sieber amide resin = 9-Fmoc-aminoxanthene-3-yloxy polystyrene resin Here, "3-yloxy" indicates the position and type of bond with the polystyrene resin. The resin used was polystyrene with a Sieber linker (nitrogen Fmoc-protected, 100-200 mesh, 1% DVB, loading: 0.71 mmol / g). Rink = (2,4-dimethoxyphenyl)(4-alkoxyphenyl)methanamine Here, "4-alkoxy" indicates the position and type of bond with the polystyrene resin. The resin used was Merrifield polymer with a Rink linker (polystyrene, nitrogen protected by Fmoc, 100-200 mesh, 1% DVB, loading: 0.56 mmol / g). 2-Chlorotrityl chloride resin (2-chlorotriphenylmethyl chloride resin), 50-150 mesh, 1% DVB, Load: 1.54 mmol / g Fmoc-glycine-2-chlorotrityl chloride resin, 200-400 mesh, 1% DVB, loading: 0.63 mmol / g PL-FMP resin: (4-formyl-3-methoxyphenoxymethyl) polystyrene

[0173] The common amino acids used are listed below, with the side-chain protecting groups shown in parentheses. Fmoc-Ala-OH; Fmoc-Arg(Pbf)-OH; Fmoc-Asn(Trt)-OH; Fmoc-Asp(tBu)-OH; Fmoc-Bip-OH; Fmoc-Cys(Trt)-OH; Fmoc-Dab(Boc)-OH; Fmoc-Dap(Boc)-OH; Fmoc-Gly-OH; Fmoc-His(Trt)-OH; Fmoc-Hyp(tBu)-OH; Fmoc-Ile-OH; Fmoc-Leu-OH; Fmoc-Lys(Boc)-OH; Fmoc-Nle-OH; Fmoc-Met-OH; Fmoc-[N-Me]Ala-OH; Fmoc-Orn(Boc)-OH, Fmoc-Phe-OH; Fmoc-Pro-OH; Fmoc-Sar-OH; Fmoc-Ser(tBu)-OH; Fmoc-Thr(tBu)-OH; Fmoc-Trp(Boc)-OH; Fmoc-Tyr(tBu)-OH; Fmoc-Val-OH; and the corresponding D-amino acids.

[0174] "Symphony X Procedure" describes experiments performed at 0.05 mmol scale, where the scale is determined by the amount of Sieber or Rink or 2-chlorotrityl or PL-FMP bound to the resin. This scale corresponds to the Sieber resin mentioned above (approximately 70 mg). All procedures may be scaled up or down from the 0.05 mmol scale by adjusting the volumes listed in multiples.

[0175] Prior to amino acid coupling, all peptide syntheses begin with a resin swelling procedure as described below in "Resin swelling procedure". Coupling of amino acids to the N-terminus of primary amines was performed using the "Single coupling procedure" described below. Coupling of amino acids to the N-terminus of secondary amines or to the N-terminus of Arg(Pbf) and D-Arg(Pbf) or D-Leu was performed using the "Double coupling procedure" described below or a 2-hour "Single coupling procedure". Unless otherwise stated, the final step of the automated synthesis is the introduction of an acetyl group as described in "Chloroacetic anhydride coupling procedure". All syntheses end with a final wash and drying step as described in "Standard final wash and drying procedure".

[0176] Resin swelling procedure: To a 45 mL polypropylene solid phase reaction vessel was added Sieber amide resin (70 mg, 0.050 mmol). DMF (5.0 mL) was added to the vessel through the top of the reaction vessel, the mixture was periodically stirred for 3 min, and the resin was washed (swelled) three times with a "DMF top wash" in which the solvent was drained through a frit.

[0177] Single coupling action: To the reaction vessel containing the resin from the previous step was added piperidine:DMF (20:80 v / v, 4.0 mL). The mixture was periodically stirred for 5 min, then the solution was drained through the frit. To the reaction vessel was added piperidine:DMF (20:80 v / v, 4.0 mL). The mixture was periodically stirred for 5 min, then the solution was drained through the frit. The resin was washed six times in succession. For each wash, DMF (5.0 mL) was added through the top of the vessel, the resulting mixture was periodically stirred for 30 s, then the solution was drained through the frit. To the reaction vessel was added amino acid (0.2 M in DMF, 2.0 mL, 8 equiv), then HATU (0.4 M in DMF, 1.0 mL, 8 equiv), and finally NMM (0.8 M in DMF, 1.0 mL, 16 equiv). The mixture was periodically stirred for 1-2 h, then the reaction solution was drained through the frit. The resin was washed five times in succession. For each wash, DMF (5.0 mL) was added through the top of the vessel, and the resulting mixture was periodically vortexed for 30 seconds before the solution was drained through the frit. The resulting resin was used directly in the next step.

[0178] Single coupling (4 equiv.) procedure: To the reaction vessel containing the resin from the previous step was added piperidine:DMF (20:80 v / v, 4.0 mL). The mixture was periodically stirred for 5 min, then the solution was drained through the frit. To the reaction vessel was added piperidine:DMF (20:80 v / v, 4.0 mL). The mixture was periodically stirred for 5 min, then the solution was drained through the frit. The resin was washed six times in succession. For each wash, DMF (5.0 mL) was added through the top of the vessel, the resulting mixture was periodically stirred for 30 s, then the solution was drained through the frit. To the reaction vessel was added amino acid (0.2 M in DMF, 1.0 mL, 4 equiv), then HATU (0.2 M in DMF, 1.0 mL, 4 equiv), and finally NMM (0.8 M in DMF, 1.0 mL, 16 equiv). The mixture was periodically stirred for 1-2 h, then the reaction solution was drained through the frit. The resin was washed five times in succession. For each wash, DMF (5.0 mL) was added through the top of the vessel, and the resulting mixture was periodically vortexed for 30 seconds before the solution was drained through the frit. The resulting resin was used directly in the next step.

[0179] Double coupling procedure: To the reaction vessel containing the resin from the previous step was added piperidine:DMF (20:80 v / v, 4.0 mL). The mixture was periodically stirred for 5 min, then the solution was drained through the frit. To the reaction vessel was added piperidine:DMF (20:80 v / v, 4.0 mL). The mixture was periodically stirred for 5 min, then the solution was drained through the frit. The resin was washed six times in succession. For each wash, DMF (5.0 mL) was added through the top of the vessel, the resulting mixture was periodically stirred for 30 s, then the solution was drained through the frit. To the reaction vessel was added amino acid (0.2 M in DMF, 2.0 mL, 8 eq), then HATU (0.4 M in DMF, 1.0 mL, 8 eq), and finally NMM (0.8 M in DMF, 1.0 mL, 16 eq). The mixture was periodically stirred for 1 h, then the reaction solution was drained through the frit. The resin was washed two times in succession. For each wash, DMF (5.0 mL) was added through the top of the vessel, the resulting mixture was periodically stirred for 30 seconds, and then the solution was drained through the frit. To the reaction vessel was added amino acid (0.2 M in DMF, 2.0 mL, 8 equiv.), then HATU (0.4 M in DMF, 1.0 mL, 8 equiv.), and finally NMM (0.8 M in DMF, 1.0 mL, 16 equiv.). The mixture was periodically stirred for 1-2 hours, and then the reaction solution was drained through the frit. The resin was washed five times in succession. For each wash, DMF (5.0 mL) was added through the top of the vessel, the resulting mixture was periodically stirred for 30 seconds, and then the solution was drained through the frit. The resulting resin was used directly in the next step.

[0180] Double coupling (4 equiv.) procedure: To the reaction vessel containing the resin from the previous step was added piperidine:DMF (20:80 v / v, 4.0 mL). The mixture was periodically stirred for 5 min, then the solution was drained through the frit. To the reaction vessel was added piperidine:DMF (20:80 v / v, 4.0 mL). The mixture was periodically stirred for 5 min, then the solution was drained through the frit. The resin was washed six times in succession. For each wash, DMF (5.0 mL) was added through the top of the vessel, the resulting mixture was periodically stirred for 30 s, then the solution was drained through the frit. To the reaction vessel was added amino acid (0.2 M in DMF, 1.0 mL, 4 eq), then HATU (0.2 M in DMF, 1.0 mL, 4 eq), and finally NMM (0.8 M in DMF, 1.0 mL, 16 eq). The mixture was periodically stirred for 1 h, then the reaction solution was drained through the frit. The resin was washed two times in succession. For each wash, DMF (5.0 mL) was added through the top of the vessel, the resulting mixture was periodically stirred for 30 seconds, and then the solution was drained through the frit. To the reaction vessel was added amino acid (0.2 M in DMF, 1.0 mL, 4 equiv.), then HATU (0.2 M in DMF, 1.0 mL, 4 equiv.), and finally NMM (0.8 M in DMF, 1.0 mL, 16 equiv.). The mixture was periodically stirred for 1-2 hours, and then the reaction solution was drained through the frit. The resin was washed five times in succession. For each wash, DMF (5.0 mL) was added through the top of the vessel, the resulting mixture was periodically stirred for 30 seconds, and then the solution was drained through the frit. The resulting resin was used directly in the next step.

[0181] Single Coupling Manual Addition Procedure A: To the reaction vessel containing the resin from the previous step, piperidine:DMF (20:80 v / v, 4.0 mL) was added. The mixture was stirred periodically for 5 min, then the solution was drained through the frit. To the reaction vessel, piperidine:DMF (20:80 v / v, 4.0 mL) was added. The mixture was stirred periodically for 5 min, then the solution was drained through the frit. The resin was washed six times in succession. For each wash, DMF (5.0 mL) was added through the top of the vessel, the resulting mixture was stirred periodically for 30 s, then the solution was drained through the frit. The reaction was stopped, and while the bottom of the vessel was still attached to the apparatus, the reaction vessel was opened and unnatural amino acid (2-4 equiv) in DMF (1-1.5 mL) was manually added through the top of the vessel by pipette, then the vessel was closed. The automated program was resumed and HATU (0.4 M in DMF, 1.0 mL, 8 equiv.) and NMM (0.8 M in DMF, 1.0 mL, 16 equiv.) were added successively. The mixture was periodically stirred for 2-3 h, and then the reaction solution was drained through the frit. The resin was washed five times in succession. In each wash, DMF (5.0 mL) was added through the top of the vessel, and the resulting mixture was periodically stirred for 30 s, after which the solution was drained through the frit. The resulting resin was used directly in the next step.

[0182] Single coupling manual addition procedure B: To the reaction vessel containing the resin from the previous step, piperidine:DMF (20:80 v / v, 4.0 mL) was added. The mixture was stirred periodically for 5 min, then the solution was drained through the frit. To the reaction vessel, piperidine:DMF (20:80 v / v, 4.0 mL) was added. The mixture was stirred periodically for 5 min, then the solution was drained through the frit. The resin was washed six times in succession. For each wash, DMF (5.0 mL) was added through the top of the vessel, the resulting mixture was stirred periodically for 30 s, then the solution was drained through the frit. The reaction was stopped, and with the bottom of the vessel still attached to the apparatus, the reaction vessel was opened and the unnatural amino acid (2-4 equiv) in DMF (1-1.5 mL) was manually added through the top of the vessel via pipette, followed by HATU (2-4 equiv, same equivalent as the unnatural amino acid) manually, and then the vessel was closed. The automated program was resumed and NMM (0.8 M in DMF, 1.0 mL, 16 equiv.) was added continuously. The mixture was periodically stirred for 2-3 h, and then the reaction solution was drained through the frit. The resin was washed five times in succession. In each wash, DMF (5.0 mL) was added through the top of the vessel, and the resulting mixture was periodically stirred for 30 s, after which the solution was drained through the frit. The resulting resin was used directly in the next step.

[0183] Single coupling manual addition procedure C: To the reaction vessel containing the resin from the previous step, piperidine:DMF (20:80 v / v, 4.0 mL) was added. The mixture was stirred periodically for 5 min, then the solution was drained through the frit. To the reaction vessel, piperidine:DMF (20:80 v / v, 4.0 mL) was added. The mixture was stirred periodically for 5 min, then the solution was drained through the frit. The resin was washed six times in succession. For each wash, DMF (5.0 mL) was added through the top of the vessel, the resulting mixture was stirred periodically for 30 s, and then the solution was drained through the frit. The reaction was stopped, and while the bottom of the vessel was still connected to the apparatus, the reaction vessel was opened and unnatural amino acid (2-4 equiv.) / HATU (same molar amount as unnatural amino acid), and NMM (4-8 equiv.) in DMF (1-1.5 mL) was manually added through the top of the vessel with a pipette. The automated program was resumed, the mixture was stirred periodically for 2-3 h, then the reaction solution was drained through the frit. The resin was washed five times in succession. For each wash, DMF (5.0 mL) was added from the top of the vessel, and the resulting mixture was periodically vortexed for 30 seconds before the solution was drained through the frit. The resulting resin was used directly in the next step.

[0184] Single coupling manual addition procedure D: To the reaction vessel containing the resin from the previous step, piperidine:DMF (20:80 v / v, 4.0 mL) was added. The mixture was stirred periodically for 5 min, then the solution was drained through the frit. To the reaction vessel, piperidine:DMF (20:80 v / v, 4.0 mL) was added. The mixture was stirred periodically for 5 min, then the solution was drained through the frit. The resin was washed six times in succession. For each wash, DMF (5.0 mL) was added through the top of the vessel, the resulting mixture was stirred periodically for 30 s, and then the solution was drained through the frit. The reaction was stopped, and while the bottom of the vessel was still connected to the apparatus, the reaction vessel was opened and unnatural amino acid (2-4 equiv.) / DIC (same molar amount as unnatural amino acid), and HOAt (same molar amount as unnatural amino acid) in DMF (1-1.5 mL) was manually added through the top of the vessel with a pipette. The automated program was resumed, the mixture was stirred periodically for 2-3 h, then the reaction solution was drained through the frit. The resin was washed five times in succession. For each wash, DMF (5.0 mL) was added from the top of the vessel, the resulting mixture was periodically vortexed for 30 seconds, and the solution was then drained through the frit. The resulting resin was used directly in the next step.

[0185] Peptoid loading treatment (50 μmol): To the reaction vessel containing the resin from the previous step was added piperidine:DMF (20:80 v / v, 3.0 mL). The mixture was periodically stirred for 5 min, then the solution was drained through the frit. To the reaction vessel was added piperidine:DMF (20:80 v / v, 3.0 mL). The mixture was periodically stirred for 5 min, then the solution was drained through the frit. The resin was washed six times in succession. For each wash, DMF (3.0 mL) was added through the top of the vessel, and the resulting mixture was periodically stirred for 30 s, then the solution was drained through the frit. To the reaction vessel was added bromoacetic acid (0.4 M in DMF, 1.0 mL, 8 equiv.), followed by DIC (0.4 M in DMF, 1.0 mL, 8 equiv.). The mixture was periodically stirred for 1 h, then the reaction solution was drained through the frit. The resin was washed two times in succession. For each wash, DMF (4.0 mL) was added through the top of the vessel, the resulting mixture was vortexed for 30 seconds, and the solution was drained through the frit. Amine (0.4 M in DMF, 2.0 mL, 16 equiv.) was added to the reaction vessel. The mixture was vortexed for 1 hour, and then the reaction solution was drained through the frit. The resin was washed five times in succession. For each wash, DMF (3.0 mL) was added through the top of the vessel, the resulting mixture was vortexed for 30 seconds, and the solution was drained through the frit. The resulting resin was used directly in the next step.

[0186] Chloroacetic anhydride coupling: To the reaction vessel containing the resin from the previous step, piperidine:DMF (20:80 v / v, 3.0 mL) was added. The mixture was periodically stirred for 3.5 or 5 minutes, then the solution was drained through the frit. To the reaction vessel, piperidine:DMF (20:80 v / v, 3.0 mL) was added. The mixture was periodically stirred for 5 minutes, then the solution was drained through the frit. The resin was washed six times in succession. For each wash, DMF (3.0 mL) was added through the top of the vessel, and the resulting mixture was periodically stirred for 30 seconds, after which the solution was drained through the frit. To the reaction vessel, chloroacetic anhydride (0.4 M in DMF, 2.5 mL, 20 equiv.) was added, followed by N-methylmorpholine (0.8 M in DMF, 2.0 mL, 32 equiv.). The mixture was periodically stirred for 15 minutes, then the reaction solution was drained through the frit. The resin was washed two times in succession. For each wash, DMF (3.0 mL) was added through the top of the vessel, the resulting mixture was periodically stirred for 1.0 min, and the solution was drained through the frit. To the reaction vessel was added chloroacetic anhydride (0.4 M in DMF, 2.5 mL, 20 eq.), followed by N-methylmorpholine (0.8 M in DMF, 2.0 mL, 32 eq.). The mixture was periodically stirred for 15 min, and the reaction solution was then drained through the frit. The resin was washed five times in succession. For each wash, DMF (3.0 mL) was added through the top of the vessel, the resulting mixture was periodically stirred for 1.0 min, and the solution was then drained through the frit. The resulting resin was used directly in the next step.

[0187] Final cleaning and drying procedures: The resin from the previous steps was washed six times in succession. For each wash, DCM (5.0 mL) was added from the top of the vessel and the resulting mixture was periodically stirred for 30 seconds before the solution was drained through the frit. The resin was then dried under a stream of nitrogen for 10 minutes. The resulting resin was used directly in the next step.

[0188] General deprotection, cyclization, N-methylation, click reaction, and Suzuki coupling procedures: Broad-range deprotection method A: All steps were performed manually unless otherwise noted. The procedure for "Extensive Deprotection Method A" describes an experiment performed on a 0.050 mmol scale, where the scale is determined by the amount of Sieber or Rink or Wang or chlorotrityl resin or PL-FMP resin. This procedure may be scaled up from the 0.05 mmol scale by adjusting the volumes listed in multiples. To a 50 mL conical tube (Falcon) was added the resin and 2.0-5.0 mL of cleavage solution (TFA:TIS:DTT, v / v / w=95:5:1). The volume of cleavage solution used varied for each linear peptide. In general, a large amount of cleavage solution is required for a large number of protecting groups in the side chains of the peptide. The mixture was shaken at room temperature for 1-2 hours (usually about 1.5 hours), and cold diethyl ether (35-50 mL) was added to the suspension. A large amount of white solid precipitated when the mixture was mixed vigorously. The mixture was centrifuged for 3-5 min and then decanted to remove the solution from the solid. The solid was suspended in Et2O (30-40 mL), the mixture was then centrifuged for 3-5 min and decanted to remove the solution from the solid. Finally, the solid was suspended in Et2O (30-40 mL), the mixture was centrifuged for 3-5 min and then decanted to remove the solution from the solid, and the crude peptide was obtained as a white to off-white solid along with the cleaved resin after drying under a stream of nitrogen and / or under vacuum. The crude product obtained on the same day was used for the cyclization step.

[0189] All procedures were performed manually unless otherwise noted. The procedure for "Extensive Deprotection Method B" describes an experiment performed on a 0.050 mmol scale, where the scale is determined by the amount of Sieber or Rink or Wang or chlorotrityl resin or PL-FMP resin. This procedure may be scaled up from the 0.05 mmol scale by adjusting the volumes listed in multiples. To a 30 mL polyprep chromatography column (Bio-Rad), the resin and 2.0-5.0 mL of cleavage solution (TFA:TIS:H2O:DTT, v / v / w=94:3:3:1) were added. The volume of cleavage solution used varied for each linear peptide. In general, a large number of protecting groups in the peptide side chains requires a large amount of cleavage solution. The mixture was shaken at room temperature for 1-2 hours (usually about 1.5 hours), the acidic solution was added to cold diethyl ether (40 mL), and the resin was washed twice with TFA solution (0.5 mL). The mixture was centrifuged for 3-5 min and then decanted to remove the solution from the solid. The solid was suspended in Et2O (35 mL) and the mixture was then centrifuged for 3-5 min and decanted to remove the solution from the solid. Finally, the solid was suspended in Et2O (35 mL) and the mixture was centrifuged for 3-5 min and decanted to remove the solution from the solid, affording the crude peptide as a white to off-white solid after drying under a stream of nitrogen and / or under vacuum. The crude product obtained on the same day was used for the cyclization step.

[0190] Cyclization method A: All procedures were performed manually unless otherwise stated. The procedure for "Cyclization Method A" describes an experiment carried out on a 0.050 mmol scale, where the scale is determined by the amount of Sieber or Rink or Chlorotrityl or Wang or PL-FMP resin used to synthesize the peptide. This scale does not depend on the directly determined amount of peptide used in the procedure. This procedure may be scaled up from the 0.05 mmol scale by adjusting the volumes stated. The crude peptide solid obtained by the extensive deprotection method was dissolved in DMF (30-45 mL) at room temperature in a centrifuge tube (50 mL), and DIEA (1.0-2.0 mL) was added to this solution. The pH value of the reaction mixture was 8. The solution was then shaken at room temperature for several hours or overnight or for 2-3 days. The reaction solution was concentrated to dryness in a SpeedVac or EZ-2 (Genevac), and the resulting crude residue was then dissolved in DMF or DMF / DMSO (2 mL). After filtration, the solution was subjected to single compound reverse phase HPLC purification to obtain the desired cyclic peptide.

[0191] Cyclization method B: All procedures were performed manually unless otherwise noted. The procedure for "Cyclization Method B" describes an experiment performed on a 0.050 mmol scale, where the scale is determined by the amount of Sieber or Rink or chlorotrityl or Wang or PL-FMP resin used to synthesize the peptide. This scale does not depend on the directly determined amount of peptide used in the procedure. This procedure may be scaled up from the 0.05 mmol scale by adjusting the volumes stated. The resulting crude peptide solid was dissolved in CH3CN / 0.1 M aqueous ammonium bicarbonate (1:1, v / v, 30-45 mL) in a centrifuge tube (50 mL). The solution was then shaken at room temperature for several hours. The reaction solution was checked by pH paper and LCMS, and may be adjusted by adding 0.1 M aqueous ammonium bicarbonate (5-10 mL) until the pH was greater than 8. After completion of the reaction based on disappearance of the linear peptide by LCMS, the reaction solution was concentrated to dryness in a SpeedVac or EZ-2 (Genevac). The resulting residue was added with CH3CN:H2O (2:3, v / v, 30 mL) and concentrated to dryness in a SpeedVac or EZ-2 (Genevac). This procedure was repeated (usually twice). The resulting crude solid was then dissolved in DMF or DMF / DMSO or CH3CN / H2O / formic acid. After filtration, the solution was subjected to single compound reverse phase HPLC purification to obtain the desired cyclic peptide.

[0192] On-resin N-methylation method A To the resin (50 μmol) in a tube (Bio-Rad) was added CHCl (2 mL) and shaken at room temperature for 5 min. 2-Nitrobenzene-1-sulfonyl chloride (44.3 mg, 200 μmol, 4 equiv.) was added followed by 2,4,6-trimethylpyridine (0.040 mL, 300 μmol, 6 equiv.). The reaction was shaken at room temperature for 2 h. The solvent was drained and the resin was rinsed with CHCl (5 mLx3), DMF (5 mLx3), then THF (5 mLx3). To the resin was added THF (1 mL), triphenylphosphine (65.6 mg, 250 μmol, 5 equiv.), methanol (0.020 mL, 500 μmol, 10 equiv.) and diethyl azodicarboxylate or DIAD (0.040 mL, 250 μmol, 5 equiv.). The mixture was shaken at room temperature for 2-16 h. The reaction was repeated with the addition of triphenylphosphine (65.6 mg, 250 μmol, 5 equiv), methanol (0.020 mL, 500 μmol, 10 equiv) and diethyl azodicarboxylate or DIAD (0.040 mL, 250 μmol, 5 equiv). The mixture was shaken at room temperature for 1-16 h. The solvent was drained and the resin was washed with THF (5 mLx3) and CHCl3 (5 mLx3). The resin was air-dried and used directly in the next step. The resin was shaken in DMF (2 mL). 2-Mercaptoethanol (39.1 mg, 500 μmol) was added followed by DBU (0.038 mL, 250 μmol, 5 equiv). The reaction solution was shaken for 1.5 h and the solvent was drained. The resin was washed with DMF (4x). It was air-dried and used directly in the next step.

[0193] On-resin N-methylation method B (Turner, RA et al, Org. Lett., 15(19):5012-5015 (2013)) All procedures were performed manually unless otherwise noted. The procedure for "On-resin N-methylation Method A" describes an experiment performed on a 0.100 mmol scale, where the scale is determined by the amount of resin-bound Sieber or Rink linker used to synthesize the peptide. This scale does not depend on the directly determined amount of peptide used in the procedure. This procedure may be scaled up from the 0.10 mmol scale by adjusting the volumes listed in multiples. The resin was transferred to a fritted syringe (25 mL). Piperidine:DMF (20:80 v / v, 5.0 mL) was added to the resin. The mixture was shaken for 3 minutes, then the solution was drained through the frit. The resin was washed three times with DMF (4.0 mL). Piperidine:DMF (20:80 v / v, 4.0 mL) was added to the reaction vessel. The mixture was shaken for 3 minutes, then the solution was drained through the frit. The resin was washed successively three times with DMF (4.0 mL) and three times with DCM (4.0 mL). The resin was suspended in DMF (2.0 mL), ethyl trifluoroacetate (0.119 mL, 1.00 mmol), and l,8-diazabicyclo[5.4.0]undec-7-ene (0.181 mL, 1.20 mmol). The mixture was placed on a shaker for 60 min and the solution was drained through a frit. The resin was washed successively three times with DMF (4.0 mL) and three times with DCM (4.0 mL). The resin was washed three times with dry THF (2.0 mL) to remove residual water. To an oven-dried vial (4.0 mL) was added THF (1.0 mL), triphenylphosphine (131 mg, 0.500 mmol), and dry 4 Å molecular sieves (20 mg). The solution was transferred to the resin and diisopropyl azodicarboxylate (0.097 mL, 0.5 mmol) was added slowly. The resin was stirred for 15 min, the solution drained through the frit, and the resin was washed three times with dry THF (2.0 mL) to remove residual water. To an oven-dried 4.0 mL vial was added THF (1.0 mL), triphenylphosphine (131 mg, 0.50 mmol), and dry 4 Å molecular sieves (20 mg). The solution was transferred to the resin and diisopropyl azodicarboxylate (0.097 mL, 0.5 mmol) was added slowly. The resin was stirred for 15 min, and the solution drained through the frit.The resin was washed successively with 3× DMF (4.0 mL) and 3× DCM (4.0 mL). The resin was suspended in ethanol (1.0 mL) and THF (1.0 mL) and sodium borohydride (37.8 mg, 1.000 mmol) was added. The mixture was stirred for 30 min and drained. The resin was washed successively with 3× DMF (4.0 mL) and 3× DCM (4.0 mL).

[0194] On-resin N-alkylation Method A: Alkylating agent (0.046 g, 1.000 mmol), triphenylphosphine (0.131 g, 0.500 mmol), and DIAD (0.097 mL, 0.500 mmol) in the corresponding alcohol in THF (3 mL) were added to the nosylated resin (0.186 g, 0.100 mmol) and the reaction mixture was stirred for 16 h at room temperature. The resin was washed three times with THF (5 mL) and the above procedure was repeated one to three times. The progress of the reaction was monitored by TFA micro-cleavage of a small sample of the resin treated with a solution of TIS (50 μL) in TFA (1 mL) for 1.5 h.

[0195] On-resin N-alkylation method B: The nosylated resin (0.100 mmol) was washed three times with N-methylpyrrolidone (NMP, 3 mL). A solution of NMP (3 mL), alkyl bromide (20 eq, 2.000 mmol) and DBU (20 eq, 0.301 mL, 2.000 mmol) was added to the resin and the mixture was stirred for 16 h at room temperature. The resin was washed with NMP (3 mL) and the above procedure was repeated one more time. The progress of the reaction was monitored by TFA micro-cleavage of a small sample of the resin treated with a solution of TIS (50 μL) / TFA (1 mL) for 1.5 h.

[0196] Steps for forming N-nosylation: A solution of collidine (10 equiv) in DCM (2 mL) was added to the resin followed by a solution of Nos-Cl (8 equiv) in DCM (1 mL) and the mixture was stirred for 16 h at room temperature. The resin was washed three times with DCM (4 mL) and three times with DMF (4 mL). Three alternating washes with DCM and DMF were repeated, followed by a final four washes with DCM (4 mL).

[0197] Procedure for removing N-nosylation: The resin (0.100 mmol) was swollen by washing three times with DMF (3 mL) and three times with NMP (3 mL). A solution of NMP (3 mL), DBU (0.075 mL, 0.500 mmol) and 2-mercaptoethanol (0.071 mL, 1.000 mmol) was added to the resin and the mixture was stirred for 5 min at room temperature. After filtration and washing with NMP (3 mL), the resin was treated again with a solution of NMP (3 mL), DBU (0.075 mL, 0.500 mmol) and 2-mercaptoethanol (0.071 mL, 1.000 mmol) for 5 min at room temperature. The resin was washed three times with NMP (3 mL), four times with DMF (4 mL) and four times with DCM (4 mL) and returned to the Symphony reaction vessel for completion of the synthesis on the peptide synthesizer (Symphony).

[0198] General preparations for amine loading on PL-FMP resin: PL-FMP resin (Novabiochem, 1.00 mmol per gram substitution) was swollen with DMF (20 mL / mmol) at room temperature. The solvent was drained and DMF (10 mL) was added to the reaction vessel followed by the amine (2.5 mmol) and acetic acid (0.3 mL). After stirring for 10 min, sodium triacetoxyboroate (2.5 mmol) was added and the reaction was stirred overnight. The resin was washed with DMF (1x), THF / H2O / AcOH (6:3:1, 2x), DMF (2x), DCM (3x) and dried. The resulting amine-loaded PL-FMP resin can be characterized as follows: 100 mg of the above resin was reacted with benzyl chloride (5 eq.) and DIEA (10 eq.) in DCM (2 mL) at room temperature for 0.5 h. The resin was washed with DMF (2x), MeOH (1x), and DCM (3x), and the sample was then cleaved with 40% TFA / DCM (1 h). The product was collected and analyzed by HPLC and MS. The collected sample was dried and weighed, and the resin loading was calculated.

[0199] General steps before loading Fmoc amino acids onto chlorotrityl resin: 2-Chloro-chlorotrityl resin (50-150 mesh, 1.54 meq / g, 1.94 g, 3.0 mmol) was added to a fritted glass reaction vessel and swollen with DCM (5 mL) for 5 min. A solution of acid (3.00 mmol, 1.0 equiv) in DCM (5 mL) was added to the resin followed by DIEA (2.61 mL, 15.00 mmol, 5.0 equiv). The reaction was shaken at room temperature for 60 min. DIEA (0.5 mL) and methanol (3 mL) were added and shaken for an additional 15 min. The reaction solution was filtered through a frit and the resin was rinsed with DCM (4x5 mL), DMF (4x5 mL), DCM (4x5 mL), diethyl ether (4x5 mL) and dried under a stream of nitrogen. Loading of the resin can be confirmed by the following method. A sample of the resin (13.1 mg) was treated with 20% piperidine / DMF (v / v, 2.0 mL) for 10 min with shaking. This solution (1 mL) was transferred to a volumetric flask (25.0 mL) and diluted with methanol to a volume of 25.0 mL. A blank solution of 20% piperidine / DMF (v / v, 1.0 mL) was diluted to 25.0 mL with methanol in a volumetric flask. After setting the UV to 301 nm and setting the absorbance of the blank solution to 0, the sample solution was read with an absorbance of 1.9411. The loading of the resin was calculated to be 0.6736 mmol / g, since (1.9411 / 20 mg)*6.94=0.6736.

[0200] Click reaction on resin Method A: This procedure describes experiments performed at 0.050 mmol scale and may be scaled up or down from 0.050 mmol scale by adjusting the volumes stated in multiples. The resins containing the alkynes (50 μmol each) were transferred to tubes (Bio-Rad) and swollen with DCM (2x5 mLx5 min) followed by DMF (2x5 mLx5 min). Into a bottle (200 mL), 30 volumes of the following substances were added: ascorbic acid (vitamin C, 0.026 g, 0.150 mmol), bis(2,2,6,6-tetramethyl-3,5-heptanedionato)copper(II) (10.75 mg, 0.025 mmol), DMF (1.5 mL), 2,6-lutidine (0.058 mL, 0.50 mmol) and THF (1.5 mL), followed by DIEA (0.087 mL, 0.50 mmol) and the corresponding azide (1.0-2.0 equiv.) used in the examples, and the mixture was stirred until everything was dissolved. The DMF in the tubes (Bio-Rad) was drained and the solutions from the click reactions above (3 mL each) were added to each tube (Bio-Rad). The tubes were shaken overnight on a shaker and the solutions were drained through the frits. The resin was washed with DMF (3x2mL) and DCM (3x2mL).

[0201] On-resin click reaction method B: This procedure describes experiments performed at 0.050 mmol scale and may be scaled up or down from 0.050 mmol scale by adjusting the volumes stated in multiples. The resins containing the alkynes (50 μmol each) were transferred to tubes (Bio-Rad) and swollen with DCM (2x5 mLx5 min) followed by DMF (2x5 mLx5 min). In a separate bottle, DMSO (4.0 mL) was bubbled with nitrogen for 15 min. To this DMSO was added sonicated copper iodide (9.52 mg, 0.050 mmol, 1.0 equiv), lutidine (58 μL, 0.500 mmol, 10.0 equiv) and DIEA (87 μL, 0.050 mmol, 10.0 equiv). The solution was purged again with nitrogen and the DCM was drained through the frit. In a separate vial, ascorbic acid (8.8 mg, 0.050 mmol, 1.0 equiv) was dissolved in water (600 μL) and the solution was bubbled with nitrogen for 10 min. The coupling partner (0.050 mmol-0.10 mmol, 1.0-2.0 equiv) was dispensed into the tube, followed by the above mentioned solutions of DMSO, copper and base, and finally the aqueous ascorbic acid. The solution was covered with a nitrogen blanket and capped. The tube was agitated on a rotary mixer for 16 h. The solution was drained through the frit and the resin was washed with DMF (3x2 mL) and DCM (3x2 mL).

[0202] Suzuki Coupling Reaction on Resin: To a tube (Bio Rad) was added dried Rink resin (50 μmol) containing a 4-bromo-phenylalanine side chain and an N-terminally Fmoc-protected linear polypeptide. The resin was swollen with DMF (2x5 mL). To this was added a solution of p-tolylboronic acid (0.017 g, 0.125 mmol) in DMF (2 mL), potassium phosphate (0.2 mL, 0.400 mmol), followed by the catalyst [1,1'-bis(di-tert-butylphosphino)ferrocene]dichloropalladium(II) [PdCl2(dtbpf)] (3.26 mg, 5.00 μmol). The tube was shaken overnight at room temperature. The solution was drained and the resin was washed with DMF (5x3 mL), followed by alternating washes with DCM (2x3 mL), DMF (2x3 mL), and then DCM (5x3 mL). A small sample of the resin was micro-cleaved with TIS (235 μL) / TFA (1 mL) for 1 h at room temperature, and the remaining resin was used for the next step of N-terminal peptide coupling or capping with chloroacetic acid.

[0203] Solution-phase click reaction method A: To a scintillation vial (20 mL), 100 times the required amount of sodium ascorbate (sodium (R)-2-((S)-1,2-dihydroxyethyl)-4-hydroxy-5-oxo-2,5-dihydrofuran-3-olate) and copper(II) sulfate pentahydrate (CuSO4:sodium ascorbate = 1:3 to 1:5 (molar ratio)) was added and the reaction was diluted with water. This solution was stirred at room temperature for 1 to 10 minutes, and the resulting yellowish slurry was added to each reaction solution. To the vial containing the alkyne and azide (1.0-2.0 equiv.), the required amount of the above copper solution (CuSO4) was added (0.3-1.0 equiv. relative to alkyne). The mixture was stirred at room temperature for 1-3 h and progress was monitored by LC / MS. More azide or copper solution could be added to promote triazole formation if necessary. After the reaction was complete, the mixture was diluted with aqueous CH3CN:NH4CO3 (v / v 1:1), filtered, and purified by reverse phase HPLC the same day.

[0204] Solution-phase click reaction method B: Stock solutions of CuSO4 and sodium ascorbate were prepared by diluting dried copper(II) sulfate pentahydrate and sodium ascorbate (1:2–1:3 molar ratio) to a concentration of 0.1–0.3 M relative to copper sulfate pentahydrate. To a solution of peptide alkyne / DMF (0.05–0.1 M) was added the corresponding azide used in the examples (1.0–2.0 equiv.), followed by the freshly prepared aqueous copper solution (0.03–1.0 equiv.) as described above. The mixture was stirred at room temperature and monitored by LCMS. More azide or copper solution could be added to promote triazole formation if necessary. After completion of the reaction, the mixture was diluted, filtered, and purified by reverse-phase HPLC on the same day.

[0205] General purification procedure: The crude material was purified using preparative LC / MS (Conditions: Column: XBridge C18, 200mm x 19mm, particle size: 5μm; Mobile phase A: 5:95 acetonitrile:water (containing 0.05% trifluoroacetic acid); Mobile phase B: 95:5 acetonitrile:water (containing 0.05% trifluoroacetic acid); Gradient: constant proportion of B eluted at 0 min, then linearly increasing from this proportion to higher proportions of B over 20-30 min, then 100% B eluted at 0 min; Flow rate: 20-40mL / min; Column temperature: 25°C). Fractions were collected as determined by MS and UV signal. Fractions containing the desired product were combined and dried using a centrifugal evaporator. If the material was not pure based on analytical data, it was further purified by preparative LC / MS (Conditions: Column: XBridge C18, 200mm x 30mm, particle size: 5μm; Mobile phase A: 5:95 acetonitrile:water (containing ammonium acetate); Mobile phase B: 95:5 acetonitrile:water (containing ammonium acetate); Gradient: constant ratio of B at 0 min, then linear increase of B from the initial ratio over 20-30 min, then 100% B at 0 min; Flow rate: 20-40mL / min; Column temperature: 25°C). Fractions were collected as judged by MS signal. Fractions containing the desired product were combined and dried in a centrifugal evaporator. Product yield and purity were determined. Alternatively, based on the initial analytical data, the crude material was purified using preparative LC / MS (Conditions: Column: XBridge C18, 200mm x 30mm, particle size: 5μm; Mobile phase A: 5:95 acetonitrile:water (containing ammonium acetate); Mobile phase B: 95:5 acetonitrile:water (containing ammonium acetate); Gradient: constant ratio of B at 0 min, linear increase of B from the initial ratio over 20 min, then 100% B at 0 min; Flow rate: 40mL / min; Column temperature: 25°C). Fractions were collected as determined by MS signal. Fractions containing the desired product were combined and dried using a centrifugal evaporator. If the material was not pure based on analytical data, it was further purified by preparative LC / MS (Conditions: Column: XBridge C18, 200mm x 19mm, particle size: 5μm; Mobile phase A: 5:95 acetonitrile:water (containing 0.05% trifluoroacetic acid); Mobile phase B: 95:5 acetonitrile:water (containing 0.05% trifluoroacetic acid); Gradient: constant proportion of B eluted at 0 min, then linearly increasing from this proportion to a higher proportion over 20 min, then 100% B eluted at 0 min; Flow rate: 20mL / min; Column temperature: 25°C). Fractions were collected as judged by MS and UV signal. Fractions containing the desired product were combined and dried in a centrifugal evaporator. Product yield and purity were determined.

[0206] Synthesis of Unnatural Amino Acids: Synthesis of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)-3-(1-(2-(tert-butoxy)-2-oxoethyl)-1H-indol-3-yl)propanoic acid Scheme: [ka]

[0207] Step 1 To a solution of (S)-benzyl 2-(((benzyloxy)carbonyl)amino)-3-(1H-indol-3-yl)propanoate (25.0 g, 58.3 mmol) and cesium carbonate (20.9 g, 64.2 mmol) in DMF (200 mL) at 0° C. was added tert-butyl 2-bromoacetate (9.36 mL, 64.2 mmol). The solution was allowed to warm slowly to room temperature and stirred for 18 h. The reaction mixture was poured into ice water:1N HCl (1:1) and then extracted with EtOAc. The organic layer was washed with brine, collected, dried over MgSO4, filtered, and concentrated in vacuo. The resulting solid was subjected to flash chromatography (330 g column, eluting with 0-50% EtOAc:Hex over 20 column volumes) to give (S)-benzyl 2-(((benzyloxy)carbonyl)amino)-3-(1-(2-(tert-butoxy)-2-oxoethyl)-1H-indol-3-yl)propanoate as a white solid (29.6 g, 93%).

[0208] Step 2: H2 was bubbled slowly through a mixture of (S)-benzyl 2-(((benzyloxy)carbonyl)amino)-3-(1-(2-(tert-butoxy)-2-oxoethyl)-1H-indol-3-yl)propanoate (29.6 g, 54.5 mmol) and Pd-C (1.45 g, 1.36 mmol) in MeOH (200 mL) at room temperature for 10 min. The mixture was then stirred under a positive pressure of H2 while monitoring the conversion by LCMS. After 48 h, the reaction mixture was filtered through diatomaceous earth and evaporated to give crude (S)-2-amino-3-(1-(2-(tert-butoxy)-2-oxoethyl)-1H-indol-3-yl)propanoic acid (17.0 g), which was used in step 3 without further purification.

[0209] Step 3 To a solution of (S)-2-amino-3-(1-(2-(tert-butoxy)-2-oxoethyl)-1H-indol-3-yl)propanoic acid (5.17 g, 16.2 mmol) and sodium bicarbonate (6.8 g, 81 mmol) in acetone:water (50.0 mL:100 mL) was added (9H-fluoren-9-yl)methyl (2,5-dioxopyrrolidin-1-yl)carbonate (5.48 g, 16.2 mmol). The mixture was stirred overnight, after which LCMS analysis showed complete conversion. The vigorously stirred mixture was acidified by slow addition of 1N HCl solution. Once acidified, the mixture was diluted with DCM (150 mL) and the isolated organic phase was then washed with water followed by brine. The organic layer was collected, dried over sodium sulfate and concentrated under reduced pressure to give the crude product. The crude material was purified by silica gel chromatography (330 g column, eluting with 20-80% EtOAc:Hex over 20 column 25 volumes) to give (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(1-(2-(tert-butoxy)-2-oxoethyl)-1H-indol-3-yl)propanoic acid as a white foam (7.26 g, 83%). 1 H NMR (500MHz, methanol-d4) δ 7.80(d, J=7.6Hz, 2H), 7.67-7.60(m, 2H), 7.39(t, J=7.5Hz, 2H), 7.32-7.22(m, 3H), 7.18(td, J=7.6, 0.9Hz, 1H), 7.08(td, J=7.5, 0.9Hz, 1H), 7.04(s, 1H), 4.54(dd, J=8.4, 4.9Hz, 1H), 4.36-4.23(m, 2H), 4.23-4.14(m, 1H), 30 3.43-3.35(m, 2H), 3.25-3.09(m, 1H), 1.55-1.38(m, 9H); ESI-MS(+) m / z=541.3(M+H)

[0210] Preparation of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-(2-(tert-butoxy)-2-oxoethoxy)phenyl)propanoic acid Scheme: [ka]

[0211] Step 1 To a cooled stirred solution of (S)-benzyl 2-(((benzyloxy)carbonyl)amino)-3-(4-hydroxyphenyl)propanoate (70 g, 173 mmol) and K2CO3 (35.8 g, 259 mmol) in DMF (350 mL) was added tert-butyl-2-bromoacetate (30.6 mL, 207 mmol) dropwise and the resulting mixture was stirred at room temperature overnight. The reaction mixture was diluted with 10% brine (1000 mL) and extracted with ethyl acetate (2x250 mL). The combined organic layers were washed with water (500 mL), saturated brine (500 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give a colorless gum. The crude compound was purified by flash column chromatography (eluent: 20% ethyl acetate / petroleum ether) to give a white solid (78 g, 85%).

[0212] Step 2 (S)-Benzyl 2-(((benzyloxy)carbonyl)amino)-3-(4-(2-(tert-butoxy)-2-oxoethoxy)phenyl)propanoate (73 g, 140 mmol) was dissolved in MeOH (3000 mL) and purged with nitrogen for 5 min. To the above purged mixture was added Pd / C (18 g, 16.91 mmol) and stirred under hydrogen pressure (3 kg) for 15 h. The reaction mixture was filtered through diatomaceous earth (Celite®) and washed with methanol (1000 mL). The filtrate was concentrated under reduced pressure to give a white solid (36 g, 87%).

[0213] Step 3: Step 3 To a stirred solution of (S)-2-amino-3-(4-(2-(tert-butoxy)-2-oxoethoxy)phenyl)propanoic acid (38 g, 129 mmol) and sodium bicarbonate (43.2 g, 515 mmol) in water (440 mL) was added dropwise Fmoc-OSu (43.4 g, 129 mmol) dissolved in dioxane (440 mL) and the resulting mixture was stirred at room temperature overnight. The reaction mixture was diluted with 1.5 N HCl (200 mL) and water (500 mL) and extracted with ethyl acetate (2x250 mL). The combined organic layers were washed with water (250 mL), brine (250 mL), dried over Na2SO4, filtered and concentrated to give a pale yellow gum. The crude compound was purified by column chromatography (eluent: 6% MeOH / chloroform) to give a pale green gum. The gum was further triturated with petroleum ether to give an off-white solid (45 g, 67%). 1 H NMR (400MHz, DMSO-d6) δ 112.86-12.58(m, 1H), 7.88(d, J=7.5Hz, 2H), 7.73-7.61(m, 3H), 7.58-7.47(m, 1H), 7.44-7.27(m, 4H), 7.18(d, J=8.5Hz, 2H), 6.79(d, J=8.5Hz, 2H), 4.57(s, 2H), 4.25-4.10(m, 4H), 3.34(br s, 3H), 3.02(dd, J=13.8, 4.3Hz, 1H), 2.81(dd, J=14.1, 10.5Hz, 1H), 1.41(s, 9H)

[0214] Linker / Tail Synthesis: 12-{4-[(tert-butoxy)carbonyl]phenoxy}dodecanoic acid (COOH-(CH2) 11 Preparation of -Op-phenyl-COOtBu) [ka]

[0215] Step 1. 12-Bromododecanoic acid (6 g, 21.49 mmol) was stirred in MeOH (35 mL) and toluene (100 mL) at room temperature. Trimethyl orthoformate (20 mL) was added followed by Amberlyst 15 (1.4 g). The mixture was stirred at 58 °C for 16-24 h, the reaction was cooled, the resin was filtered off, and the resin was washed with CH2Cl2 (2x). The mixture was evaporated to dryness and followed by LCMS (analysis condition N, retention time = 4.31, 293 (M+H)). The resulting residue was essentially pure methyl 12-bromododecanoate, which was used directly in the next step.

[0216] Step 2. To a solution of methyl 12-bromododecanoate (2.12 g, 7.21 mmol) and tert-butyl 4-hydroxybenzoate (1.4 g, 7.21 mmol) in MeCN (7 mL) was added K2CO3 (2.0 g, 14.42 mmol). The reaction was heated at 85 °C for 24 h, cooled and the solids were filtered off. The filtrate was diluted with EtOAc and H2O, and the organic layer was dried over MgSO4 and concentrated to give a residue which was used as is. LCMS (analysis condition N: 407.3 (M+H), retention time = 4.94 min). The same scale reaction was repeated (3x) to give tert-butyl 4-((12-methoxy-12-oxododecyl)oxy)benzoate (7.56 g) as a white solid.

[0217] Step 3. tert-Butyl 4-((12-methoxy-12-oxododecyl)oxy)benzoate (8.78 g, 21.6 mmol) was dissolved in THF (50 mL) and 1N NaOH (25.9 mL, 25.9 mmol) was added. The slightly turbid reaction was stirred at room temperature overnight and became clear. The reaction was stirred overnight and then 1N HCl (30 mL) was added followed by extraction with EtOAc (2x). The organic layer was washed with H2O, brine, dried over MgSO4, filtered, concentrated and dried to give 12-{4-[(tert-butoxy)carbonyl]phenoxy}dodecanoic acid (7.0 g, 17.83 mmol, 83% yield) as a white solid. Analytical Condition N: Retention time 4.39 min, m / z [M+H] + 393.3

[0218] The following compounds were prepared following a similar procedure as described above. [Table 3]

[0219] 14-{4-[(tert-butoxy)carbonyl]phenoxy}tetradecanoic acid (COOH-(CH2) 13 Preparation of -Op-phenyl-COOtBu) [ka]

[0220] Step 1. Following the same procedure as for methyl 12-bromododecanoate, tert-butyl 4-((14-hydroxytetradecyl)oxy)benzoate (6 g, 96%) was obtained as a white solid (analysis condition N: retention time = 4.95 min, m / z [M+H] + 407.4).

[0221] Step 2. tert-Butyl 4-((14-hydroxytetradecyl)oxy)benzoate (6 g, 14.76 mmol) was dissolved in DMF (40 mL) and pyridinium dichromate (19.43 g, 51.6 mmol) was added portionwise at 0 °C. The reaction was stirred at 0 °C to room temperature overnight. LCMS showed mostly the desired acid with some starting acid and intermediate aldehyde. DMF (10 mL) and one more equivalent of PDC were added. The mixture was stirred at room temperature for another day and the reaction was filtered through Celite and washed with EtOAc. The filtrate was washed with saturated citric acid, water, brine, dried over MgSO4, filtered and concentrated. Some of this mixture was lost during workup. The resulting residue was loaded onto a silica gel column (120 g) and purified with hexane / EtOAc (eluted with 20-40% EtOAc, fractions: 37-59). Concentration gave 14-{4-[(tert-butoxy)carbonyl]phenoxy}tetradecanoic acid (3.4 g, 8.08 mmol, 54.8% yield) (analysis condition N: retention time = 4.76 min, m / z [M+H] + 421).

[0222] 16-{4-[(tert-butoxy)carbonyl]phenoxy}hexadecanoic acid (COOH-(CH2) 15 Preparation of -Op-phenyl-COOtBu) [ka]

[0223] Step 1. Following the same procedure as for methyl 12-bromododecanoate, tert-butyl 4-((16-hydroxyhexadecyl)oxy)benzoate (26.2 g, 98% yield) was obtained.

[0224] Step 2. A round-bottom flask (single neck, 1000 mL) was charged with 1,2-dichloroethane (520 mL), tert-butyl 4-((16-hydroxyhexadecyl)oxy)benzoate (32.0 g, 73.6 mmol) and stirred until the solution became clear. To this was added iron(III) nitrate nonahydrate (3.21 g, 7.95 mmol), TEMPO (1.277 g, 8.17 mmol), and potassium chloride (0.576 g, 7.73 mmol) successively under O2 atmosphere. The flask was sealed and stirred overnight with a balloon of O2 attached. The reaction was filtered through Celite, the Celite was washed with CHCl3, and evaporated to dryness to give a yellow solid. The crude material was stirred in petroleum ether solution (150 mL) for 10 min, filtered, and dried under vacuum to give a pale yellow solid (27.9 g, 81% yield). 1 H NMR (DMSO-d6, 400MHz) δ 11.95(br s, 1H), 7.83(d, J=8.4Hz, 2H), 6.99(d, J=8.8Hz, 2H), 4.02(t, J=6.4Hz, 2H), 2.18(t, J=7.2Hz, 2H), 1.71(m, 2H), 1.54-1.23(m, 35H)ppm; Analysis condition E, retention time = 3.086 minutes, m / z [MH] - 447.4.

[0225] Preparation of 10-(4-sulfophenoxy)decanoic acid (COOH-(CH2)9-Op-phenyl-SO3H) [ka]

[0226] Step 1. Sodium 4-hydroxybenzenesulfonate (1.479 g, 7.54 mmol), DMSO (10 mL), and a stir bar were added to a vial (40 mL). The mixture was stirred at room temperature until clear, and K2CO3 (1.269 g, 22.63 mmol) was added in one portion, followed by methyl 10-bromodecanoate (2 g, 7.54 mmol). The mixture was stirred at 50-55°C overnight, cooled, and the reaction solution was filtered and the precipitate was rinsed several times with DMF and then several times with water. The precipitate was air-dried to give 4-((10-methoxy-10-oxodecyl)oxy)benzenesulfonic acid as a white solid (2.3 g). MS m / z [MH] - 357.4

[0227] Step 2. 4-((10-Methoxy-10-oxodecyl)oxy)benzenesulfonic acid (2.3 g, 6.42 mmol) was added to THF (15 mL). 1N NaOH (9.62 mL, 9.62 mmol) was added to the resulting white slurry and the reaction became clear. The reaction was stirred at room temperature and a white precipitate formed. After 1 h, LCMS showed it contained mostly hydrolysis product and a small amount of methyl ester starting material. The reaction mixture was allowed to stir for 6 h. The white precipitate was collected (1.4 g) and the filtrate was concentrated, acidified with 3N HCl, stirred at room temperature for 2 h, then filtered. The white precipitate (1.4 g) was also treated with 3N HCl, stirred at room temperature for 3 h, filtered, and washed with H2O (3x). The white precipitates were combined and air-dried to give 10-(4-sulfophenoxy)decanoic acid (1.65 g, yield 74.7%) (analysis condition N: retention time = 0.94 min, m / z [M+H] + 345.2).

[0228] RS(O) 0-2 -Preparation of Ph-COOH General procedure for the reaction of bromoalkyl acids with mercaptobenzoic acids or mercaptobenzoic esters: Procedure A: Bromododecanoic acid (1 eq.) and mercaptobenzoic acid (1 eq.) are mixed in a solution of THF and iPr2NEt. The ratio of THF and iPr2NEt can vary from 10:1 to 1:1. The mixture is stirred at room temperature for 1 h to 7 days. After removing the solvent, the residue obtained is used as is. Procedure B: Bromododecanoic acid ester (1 eq.) and mercaptobenzoic acid (1 eq.) are mixed in a solution of THF and iPr2NEt. The ratio of THF and iPr2NEt can vary from 10:1 to 1:1. The mixture is stirred at room temperature for 1 h to 7 days. After removing the solvent, the residue obtained is dissolved in THF or dioxane or DMF or MeOH, NaOH (1-20 eq., 1N aqueous solution) is added, and the mixture is stirred at room temperature for 1 h to 7 days. After removing the solvent, the residue obtained is used as is. [Table 4] [Table 5]

[0229] General procedure for oxidation of S atoms to sulfoxides and sulfones: mCPBA or H2O2 (1-5 equiv.) was added to a solution of thiol derivative (1 equiv.) in CH2Cl2. After stirring at room temperature for 1 h to 7 days, sodium bisulfite (5-10 equiv.) was added to the solution. Peroxide 25 test paper was used to check whether excess peroxide was neutralized. After removing the solvent, the resulting residue was purified by preparative HPLC. [Table 6] Analytical data: [Table 7]

[0230] RS(O) 0-2 -Production of Ph-SO3H General procedure for the reaction of bromoalkyl acids with mercaptobenzenesulfonic acid: Procedure A: Bromododecanoic acid (1 eq.) and mercaptobenzenesulfonic acid (1 eq.) are mixed in a solution of THF and iPr2NEt. The ratio of THF and iPr2NEt can vary from 10:1 to 1:1. The mixture is stirred at room temperature for 1 h to 7 days. After removing the solvent, the resulting residue is used as is. Procedure B: Mix bromododecanoic acid ester (1 eq.) and mercaptobenzenesulfonic acid (1 eq.) in a solution of THF and iPr2NEt. The ratio of THF and iPr2NEt can vary from 10:1 to 1:1. The mixture is stirred at room temperature for 1 h to 7 days. After removing the solvent, the resulting residue is dissolved in THF or dioxane or DMF or MeOH, NaOH (1-20 eq., 1N aqueous solution) is added, and the mixture is stirred at room temperature for 1 h to 7 days. After removing the solvent, the resulting residue is used as is. [Table 8] [Table 9]

[0231] General procedure for oxidation of S atoms to sulfoxides and sulfones: mCPBA or H2O2 (1-5 equiv.) was added to a solution of thiol derivative (1 equiv.) in CH2Cl2. After stirring at room temperature for 1 h to 7 days, sodium bisulfite (5-10 equiv.) was added to the solution. Peroxide 25 test strips were used to check whether excess peroxide was neutralized. After removing the solvent, the resulting residue was purified by preparative HPLC. [Table 10] [Table 11]

[0232] Preparation of (2S)-4-[(20-azido-3,6,9,12,15,18-hexaoxaicosan-1-yl)carbamoyl]-2-(10-{4-[(tert-butoxy)carbonyl]phenoxy}decanamido)butanoic acid (N3-Pg6-γGlu-C10-Op-phenyl-COOtBu) [ka]

[0233] Step 1. A mixture of Fmoc-Glu-OtBu (0.935 g, 2.197 mmol) and PFTU (0.941 g, 2.197 mmol) was diluted with DMF (10 mL) and DIEA (0.768 mL, 4.39 mmol) was added slowly via syringe while stirring under nitrogen. The mixture was stirred for 2 h and LCMS showed the formation of the activated ester. 20-Azido-3,6,9,12,15,18-hexaoxaicosan-1-amine (0.7 g, 1.998 mmol) was added and the reaction was stirred at room temperature overnight. 1N HCl was added and the mixture was extracted with EtOAc (2x). The organic layer was washed with H2O, brine, dried over Na2SO4, filtered and concentrated. The resulting residue was purified by normal phase ISCO (elution: 100-90% DCM / MeOH) to give (S)-25-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-1-azido-22-oxo-3,6,9,12,15,18-hexaoxa-21-azahexacosane-26-oic acid (0.87 g, 62.1%) as a colorless oil. Analytical condition T, retention time = 1.39 min, m / z [M+H]+ 702.3

[0234] Step 2. Chlorotrityl resin (3.1 g, 4.96 mmol) was washed with DCM (5x) and then diluted with DCM (20 mL). To this solution was then added (S)-25-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-1-azido-22-oxo-3,6,9,12,15,18-hexaoxa-21-azahexacosane-26-oic acid (0.87 g, 1.240 mmol), followed by DIEA (1.732 mL, 9.92 mmol). The reaction immediately turned burgundy. The reaction was shaken overnight at room temperature and the resin was then diluted with methanol / DIEA (9:1) solution (20 mL), quickly filtered, and washed with DCM (3x) and DMF (3x). The resin was treated twice with 20% piperidine / DMF to deprotect the Fmoc group (10 min each time). After draining the piperidine solution, the resin, which turned orange-yellow, was washed with DMF (6x) and stored at 4°C until it was used directly in the next step.

[0235] Step 3. The above resin (0.6 mmol) was swollen with DMF (3x) and 10-(4-(tert-butoxycarbonyl)phenoxy)decanoic acid, COOH-(CH2)9-Op-phenyl-COOtBu (0.328 g, 0.900 mmol) in DMF (10 mL) was added, followed by HATU (2.250 mL, 0.4 M, 0.900 mmol) solution and N-methylmorpholine (0.330 mL, 3.00 mmol) and the reaction was shaken overnight. After draining, it was washed with DMF (5x) and then DCM (5x). The resin was dried and HFIP / DCM (1:4) (20 mL) was added to the resin for 1 h. This process was repeated and the filtrates were combined and concentrated to give (2S)-4-[(20-azido-3,6,9,12,15,18-hexaoxaicosan-1-yl)carbamoyl]-2-(10-{4-[(tert-butoxy)carbonyl]phenoxy}decanamido)butanoic acid (250 mg, 0.303 mmol, 50.4% yield) as a light brown film (analysis condition N: retention time = 3.54 min, m / z [M+H] + 826.6).

[0236] Preparation of (2S)-2-(12-{4-[(tert-butoxy)carbonyl]phenoxy}dodecanamido)-4-[(6,9,12,15,18,21,24,27,30,33,36-undecaoxa-1,2λ4,3-triazaoctatriacontan-1,2-dien-38-yl)carbamoyl]butanoic acid (N3-Pg11-γGlu-C12-Op-phenyl-COOtBu) [ka]

[0237] Step 1. NH2-Glu(allyl)-OH on chlorotrityl resin (1.5 mmol) obtained by the procedure described in "General procedure before loading Fmoc amino acids onto chlorotrityl resin" was added with 16-(tert-butoxy)-16-oxohexadecanoic acid (COOH-(CH2) 11 The resin was dried overnight and a small amount of the resin was cleaved with HFIP / DCM (1:4) for 20 min to give the desired product (analysis condition N: retention time = 4.32 min, m / z [M+H] 512).

[0238] Step 2. The resin (1.5 mmol) was then washed with CH2Cl2 (3x) and a solution of Pd(PPh3)4 (0.06 equiv.) in CH2Cl2 (20 mL) and phenylsilane (1.294 mL, 10.50 mmol) was added to the resin under a stream of nitrogen and shaken at room temperature for 1 h. The solvent was drained and the reaction was repeated. The solvent was drained and the resin was washed with CH2Cl2 (5x), MeOH (3x), and DMF (5x).

[0239] Step 3. The resin from step 2 (1.5 mmol) was swollen in DMF for 20 min and drained. To the resin was added a solution of 35-azido-3,6,9,12,15,18,21,24,27,30,33-undecaoxapentatriacontan-1-amine (1.284 g, 2.250 mmol) in DMF (5 mL), HATU (0.4 M, 6.75 mL, 2.70 mmol), and DIEA (1.834 mL, 10.50 mmol). DMF (5 mL) was added and the solution was transferred to a reaction vessel and shaken overnight at room temperature. The solvent was drained and rinsed with DMF (5x) and DCM (3x). The resin was cleaved with CH2Cl2 / HFIP (4:1) (50 mL x3x1 h) at room temperature. The combined filtrate was concentrated and dried under vacuum to give crude (S)-1-azido-40-(12-(4-(tert-butoxycarbonyl)phenoxy)dodecanamido)-37-oxo-3,6,9,12,15,18,21,24,27,30,33-undecaoxa-36-azahenetetracontan-41-oic acid (1.55 g) as a light brown viscous material, which was used directly in the next step click reaction on the resin (analysis condition N: retention time 3.89 min, m / z [M+H] + 1074.6).

[0240] Preparation of DDE-Lys(Pg9-Pg9-γGlu-C10-O-Ph-COOtBu) resin [ka] [ka]

[0241] Step 1. TFA (0.188 mL, 2.443 mmol) was added to a stirred solution of 2-(1-hydroxyethylidene)-5,5-dimethylcyclohexane-1,3-dione (4.45 g, 24.43 mmol) and N6-(((9H-fluoren-9-yl)methoxy)carbonyl)-L-lysine (6 g, 16.29 mmol) in ethanol (80 mL). The heterogeneous mixture was heated at 83 °C for 20 h, the solution remained opaque. LCMS showed a large amount of starting amine had been consumed. EtOH (50 mL) was added and heating continued at 85 °C for an additional day. Small amounts of starting amine were still observed by LCMS. The reaction was cooled to room temperature, then concentrated in vacuo on a rotary evaporator and azeotroped three times with toluene. The crude material was purified by normal phase silica gel ISCO (120 g column) to give N6-(((9H-fluoren-9-yl)methoxy)carbonyl)-N2-(1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl)-L-lysine (7.5 g, 14.08 mmol, 86% yield) as a white foamy solid, which was used for the resin loading step (analysis condition Q: retention time = 1.08 min, m / z [M+H] + 533.6).

[0242] Step 2. Chlorotrityl resin (56.32 mmol, loading 1.43 mmol / g) was washed with DCM (5x) and then diluted with DCM (150 mL). To this solution was then added N6-(((9H-fluoren-9-yl)methoxy)carbonyl)-N2-(1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl)-L-lysine (7.5 g, 14.08 mmol), followed by DIEA (17.22 mL, 99 mmol) and shaken overnight at room temperature. The resin was then diluted with methanol / DIEA (9:1) solution (90 mL) and shaken for 5-10 min. The resin was filtered, washed with DCM (5x) and DMF (3x), then Et2O (2x) and dried (loading ca. 0.3 mmol / g, 20 mmol). A small amount of the resin was cleaved with CH2Cl2 / HFIP (4:1) for 30 min at room temperature. LCMS confirmed the formation of the expected N6-(((9H-fluoren-9-yl)methoxy)carbonyl)-N2-(1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl)-L-lysine (analysis condition Q: retention time 1.07 min; m / z [M+H] + 553.6) was shown.

[0243] Steps 3 and 4. 3-Oxo-2,7,10-trioxa-4-azadodecane-12-acid (2.60 g, 6.75 mmol), HATU (0.4 M, 16.88 mL, 6.75 mmol) in DMF, followed by N-methylmorpholine (2.078 mL, 18.90 mmol) were added to the above resin (2.7 mmol) and shaken overnight. The solution was drained, the resin was washed with DMF (6x) and dried. The resin was treated with 20% piperidine in DMF and shaken (2x15 min). The solution was drained and the resin was washed with DMF (6x). The reaction was repeated as a coupling and deprotection step. The resulting resin was divided into two batches and used for the next step. Before removing the last Fmoc group, a small amount of the resin was cleaved (HFLP / CH2Cl2=1:4). LCMS showed one major peak corresponding to the expected (2S)-2-{[1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl]amino}-6-(2-{2-[2-(2-{2-[2-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)ethoxy]ethoxy}acetamido)ethoxy]ethoxy}acetamido)hexanoic acid (analysis condition Q: retention time = 0.98 min, m / z [M+H] + 823).

[0244] Step 5. The above resin (approximately 1.35 mmol) was swollen in DMF for 20 min and drained. (S)-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(tert-butoxy)-5-oxopentanoic acid (1.723 g, 4.05 mmol) in DMF (15 mL), HATU (0.4 M, 10.13 mL, 4.05 mmol) in DMF, and N-methylmorpholine (0.891 mL, 8.10 mmol) were added to the resin and shaken for 4 h. The solution was drained and the resin was washed with DMF (6x). The resin was then treated with 20% piperidine in DMF and shaken (2x15 min). The solution was drained and the resin was washed with DMF (5x). The resin was divided into two batches and used in the next step.

[0245] Step 6. The resin (approximately 0.9 mmol) was swollen in DMF for 20 min and drained. A solution of 10-(4-(tert-butoxycarbonyl)phenoxy)decanoic acid (0.492 g, 1.350 mmol) in DMF (10 mL), a solution of HATU (0.4 M, 3.38 mL, 1.35 mmol) in DMF, and N-methylmorpholine (0.495 mL, 4.50 mmol) were added to the resin and shaken overnight. The solution was drained and the resin was washed with DMF (6x) and CHCl (6x). A small amount of the resin was cleaved (HFLP / CH2Cl2 = 1:4) and LCMS showed one major peak corresponding to the expected (2S)-6-[2-(2-{2-[2-(2-{2-[(4S)-5-(tert-butoxy)-4-(10-{4-[(tert-butoxy)carbonyl]phenoxy}decaneamido)-5-oxopentanamido]ethoxy}ethoxy)acetamido]ethoxy}ethoxy)acetamido]-2-{[1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl]amino}hexanoic acid (0.9 mmol, loaded ca. 0.4 mmol / g) (analysis condition Q: retention time = 3.89 min, m / z [M+H] + 1133).

[0246] Preparation of NHFmoc-Peg3-gGlu-gGlu-C10-Op-Phenyl-COOtBu resin [ka]

[0247] Step 1. NH2-Glu(allyl)-OH loaded chlorotrityl resin (5 mmol) obtained using the "General procedure before loading Fmoc amino acids onto chlorotrityl resin" was swollen in DMF for 20 min. The solution was drained and the resin was added with a solution of (R)-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(tert-butoxy)-5-oxopentanoic acid (3.83 g, 9.00 mmol) in DMF (15 mL), HATU, and then N-methylmorpholine (1.979 mL, 18.00 mmol) and shaken overnight. The solution was drained and the resin was washed with DMF (6x). The resin was then treated with 20% piperidine / DMF (2x for 15 min each). The solution was drained and the resin was washed with DMF (6x) and used directly in the next step.

[0248] Step 2. The resin (1.5 mmol) was swollen in DMF for 20 min and drained. A solution of 10-(4-(tert-butoxycarbonyl)phenoxy)decanoic acid (0.984 g, 2.70 mmol) in DMF (30 mL), HATU, and N-methylmorpholine were added to the resin and shaken overnight. The solution was drained and the resin was washed with DMF (6x) and then with CHCl (6x) and dried.

[0249] Step 3. The resin (1.5) was rinsed with CHCl (3x) and a solution of Pd(PPh) (0.06 equiv.) in CHCl (20 mL) and phenylsilane was added to the resin. The reaction was shaken at room temperature for 1 h and drained. The reaction was repeated and drained. The resin was washed with CHCl (5x), MeOH (3x), and DMF (5x) and a small amount of the resin was cleaved with CHCl / HFIP (4:1) at room temperature for 30 min. LCMS showed the formation of the expected ((S)-5-(tert-butoxy)-4-(10-(4-(tert-butoxycarbonyl)phenoxy)decaneamido)-5-oxopentanoyl)-glutamic acid (analytical condition N: retention time 3.73 min; m / z [M+H] + 679).

[0250] Step 4. The above resin (1.5 mmol) was swollen in DMF for 20 min and drained. A solution of (9H-fluoren-9-yl)methyl(3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)carbamate hydrochloride (2.51 g, 5.25 mmol) in DMF (5 mL), HATU (13.13 mL, 5.25 mmol), and DIEA (2.62 mL, 15.00 mmol) were added to the resin. An additional 5 mL of DMF was added and the solution was transferred to a reaction vessel and shaken overnight at room temperature. The solution was drained and the resin was washed with DMF (6x), CHCl (6x), EtO (2x), and then dried to obtain the resin (1.9 g at 1.4 mmol, loading approximately 0.5-0.6 mmol / g for SPPS). Cleavage was performed with a small amount of resin in CH2Cl2 / HFIP (4:1) for 20 min. LCMS showed the formation of the expected (S)-22-((S)-5-(tert-butoxy)-4-(10-(4-(tert-butoxycarbonyl)phenoxy)decaneamido)-5-oxopentanamido)-1-(9H-fluoren-9-yl)-3,19-dioxo-2,8,11,14-tetraoxa-4,18-diazatricosane-23-oic acid (analytical condition N: retention time 4.43 min; m / z [M+H] + 1104).

[0251] Preparation of tBuOOC-Ph-O-C12-CONH-Dab(Fmoc)-OH chlorotrityl resin [ka]

[0252] Step 1. Chlorotrityl resin (1.98 g, 6.34 mmol) was washed with DCM (5x) and then diluted with DCM (50 mL). To this solution was then added Dde-L-Dab(Fmoc)-OH (1.0 g, 1.982 mmol) followed by DIEA (2.77 mL, 15.85 mmol) and shaken for 1 h. The resin was then diluted with a solution of methanol / Hunig's base (9:1) (20 mL), quickly filtered, and washed with DCM (3x) and DMF (3x). The resin was treated three times with 2% hydrazine / DMF to remove Dde, washed with DMF (5x) and DCM (5x), dried, and used as is (0.5 mmol / g loading before Dde deprotection, 0.545 after deprotection). Used as is.

[0253] Step 2. The above resin (150 mg, 0.075 mmol) was washed with DMF (5x) and then diluted with DMF (5 mL). To this solution was then added a solution of 12-(4-(tert-butoxycarbonyl)phenoxy)dodecanoic acid (44.2 mg, 0.113 mmol) and HATU (42.8 mg, 0.113 mmol) in DMF (5 mL), followed by N-methylmorpholine (0.033 mL, 0.300 mmol) and shaken for 16 h. This was washed with DMF (5x) and dried. A small amount was cleaved with 20% HFIPA / DCM to obtain the desired (S)-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-2-(12-(4-(tert-butoxycarbonyl)phenoxy)dodecanamido)butanoic acid (analysis conditions: retention time 2.445 min, m / z [MH] - 713.3).

[0254] Preparation of SO3H-Ph-O-C12-CONH-Dab(Fmoc)-OH chlorotrityl resin [ka] The resin from step 1 (250 mg, 0.125 mmol) was washed with DMF (5x) and then diluted with DMF (5 mL). This solution was then added with 12-((4-sulfophenyl)thio)dodecanoic acid (72.9 mg, 0.188 mmol) and HATU (71.3 mg, 0.188 mmol) in DMF (5 mL), followed by a solution of N-methylmorpholine (0.055 mL, 0.500 mmol) and shaken for 16 h. This was washed with DMF (5x) and dried. A small amount was cleaved with 20% HFIP / DCM to give the desired (S)-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-2-(12-((4-sulfophenyl)thio)dodecanamido)butanoic acid (analysis conditions: retention time 1.557 min, m / z [M+H] + 711.1).

[0255] Fmoc-NH-(PEG) n -N3 Manufacturing [ka] To a solution of 2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethan-1-amine (329.5 mg, 1.510 mmol, 1 equiv) in acetonitrile:water (1:1, 5.03 mL, 0.3 M) was added Fmoc-OSu (535 mg, 1.585 mmol) in one portion. The reaction was stirred and monitored by LCMS. After approximately 4 h at room temperature, LCMS confirmed product formation. It was concentrated under reduced pressure and the crude material was used without further purification (analysis condition K: retention time = 1.02 min; ESI-MS (+) m / z [M+Na] + : 463.3).

[0256] The following compounds were prepared according to the procedure described above for Fmoc-NH-(PEG)3-N3: Fmoc-NH-(PEG)5-N3 [ka] Analysis conditions K: retention time = 1.01 min; ESI-MS(+)m / z [M+H] + : 529.3

[0257] Fmoc-NH-(PEG)6-N3

Chem.

[0258] Fmoc-NH-(PEG)9-N3

Chem.

[0259] Fmoc-NH-(PEG) 11 -N3

Chem.

[0260] Production of triazole-PEG functional resin Example: Dde-Atriaz(PEG3-NH-Fmoc)-Cl-Trt resin

Chem.

[0261] Preparation of Dde-Ala(3-triazole-PEG3-NHFmoc)-Cl-Trt resin: In a solid-phase reaction vessel, the above Dde-Pra-Cl-Trt resin (2.313 g, 1.388 mmol) was swollen with DCM for 10 min and then drained. A stock solution of Cu(I)Br and ascorbic acid (1:1 molar ratio) in DMSO (0.02 M) was prepared and degassed with nitrogen bubbling for 10 min. N3-PEG3-NHFmoc (0.795 g, 1.804 mmol) was added to the resin and transferred with minimal DMSO. A DMSO stock solution of Cu / ascorbic acid (55 mL), DIEA (2.424 mL, 13.88 mmol), and 2,6-lutidine (1.617 mL, 13.88 mmol) was then added and the mixture was purged with nitrogen and capped. This was stirred at room temperature for 3 hours and then drained. The resin was washed with DMF (volume 50 mL), 2x0.1M ammonium pyrrolodithiocarbamate solution / DMF, DMF, and finally DCM until the brown / yellow color of the solution disappeared and the resin became yellow. This was dried in vacuum overnight and a small amount of the resin was cleaved with 5% TFA:DCM. LCMS confirmed the desired click reaction product and the reaction was carried forward without further analysis (analysis condition O: retention time = 1.45 min; ESI-MS (+) m / z [M+H] + : 718.4).

[0262] The following resins were prepared according to the procedure for Dde-Atriaz(PEG3-NH-Fmoc)-Cl-Trt resin described above. Dde-Atriaz(PEG5-NH-Fmoc)-Cl-Trt resin [ka] Analysis conditions O: retention time = 1.46 minutes; ESI-MS(+)m / z [M+H] + : 806.3

[0263] Dde-Atriaz(PEG6-NH-Fmoc)-Cl-Trt resin [ka] Analysis conditions O: retention time = 1.46 minutes; ESI-MS(+)m / z [M+H] + : 850.3

[0264] Dde-Atriaz(PEG9-NH-Fmoc)-Cl-Trt resin [ka] Analysis conditions O: retention time = 1.46 minutes; ESI-MS(+)m / z [M+H] + : 982.4

[0265] Dde-Atriaz(PEG11-NH-Fmoc)-Cl-Trt [ka] Analysis conditions O: retention time = 1.46 minutes; ESI-MS(+)m / z [M+H] + : 1070.4

[0266] Dde-Atriaz[PEG11-NH-Asp(OtBu)-Fmoc]-Cl-Trt resin [ka] Analysis conditions O: retention time = 1.57 minutes; ESI-MS(+)m / z [M+H] + : 1241.6

[0267] Dde-Atriaz[PEG11-NH-Glu(OtBu)-Fmoc]-Cl-Trt(Resin A) [ka] Analysis conditions O: retention time = 1.60 minutes; ESI-MS(+)m / z [M+H] + : 1255.9

[0268] Preparation of (S)-40-amino-1-azido-37-oxo-3,6,9,12,15,18,21,24,27,30,33-undecaoxa-36-azahenetetracontan-41-oic acid: [ka]

[0269] Step 1: 1-(tert-butyl) 5-(2,5-dioxopyrrolidin-1-yl)(tert-butoxycarbonyl)-L-glutamate (2 g) and 35-azido-3,6,9,12,15,18,21,24,27,30,33-undecaoxapentatriacontan-1-amine (2.85 g) in THF (50 mL) were stirred at room temperature for 24 hours. After removing the solvent in vacuum, the resulting residue was used as it was. MS(M+H) + Theoretical value: 856.5; MS(M+H) + Observed value: 856.3

[0270] Step 2: tert-Butyl (S)-1-azido-40-((tert-butoxycarbonyl)amino)-37-oxo-3,6,9,12,15,18,21,24,27,30,33-undecaoxa-36-azahentetracontan-41-ate (400 mg) obtained in step 1 was added to 4N HCl / dioxane (10 mL) and stirred at room temperature for 24 hours. After removing the solvent in vacuum, benzene (10 mL) was added to the obtained residue and then concentrated. This procedure was repeated again to obtain a residue. This was dissolved in THF (20 mL) and this solution was used as is. MS (M+H) + Theoretical value: 700.4; MS(M+H) + Observed value: 700.3

[0271] General steps in the manufacture of the W3 structure: [ka] Step 1: A mixture of W1 (1 equiv.) and 2,2,2-trifluoroperfluorophenylacetate (1-1.5 equiv.) in a mixture of THF or dioxane or DME and iPr2NEt (volume ratio 3:1-1:1) was stirred at room temperature for 16-120 h, and the solution was used as is. Step 2: (S)-40-amino-1-azido-37-oxo-3,6,9,12,15,18,21,24,27,30,33-undecaoxa-36-azahentetracontan-41-oic acid (1 equivalent) was added to the solution obtained in step 1 (containing 1 equivalent of intermediate W2). The mixture was stirred at room temperature for 16-120 hours, and after removing the solvent in vacuo, the resulting residue was purified by preparative HPLC to give W3. [Table 12] [Table 13] [Table 14] [Table 15]

[0272] Production of W3-Ph-O10-002: [ka]

[0273] A solution of W3-Ph-O10-001 (80 mg) in CHCl (1.5 mL) was added to the mixture, which was stirred at room temperature for 4 hours and all the solvent was removed in vacuo to give (S)-1-azido-40-(10-(4-carboxyphenoxy)decanamido)-37-oxo-3,6,9,12,15,18,21,24,27,30,33-undecaoxa-36-azahentetracontan-41-oic acid (W3-Ph-O10-002) (60 mg). MS(M+H) + Theoretical value: 990.6; MS(M+H) + Observed value: 990.6

[0274] Production of W3-Ph-O12-002: [ka] W3-Ph-O12-002 was prepared by the same procedure as W3-Ph-O10-002, using W3-Ph-O12-001 as the starting material. MS (M+H) + Theoretical value: 1018.6; MS(M+H) + Observed value: 1018.3

[0275] Production of W3-Ph-O10-004: [ka] W3-Ph-O10-003 (20 mg) was dissolved in THF (2 mL) / water (1 mL) and sodium hydroxide (0.6 mL, 1N) was added to the solution. The mixture was stirred at room temperature for 16 hours and neutralized to pH 5 with 0.1N HCl. All solvents were removed in vacuo to give (S)-1-azido-40-(4-((9-carboxynonyl)oxy)benzamido)-37-oxo-3,6,9,12,15,18,21,24,27,30,33-undecaoxa-36-azahentetracontan-41-oic acid (W3-Ph-O10-004) (15 mg). MS(M+H) + Theoretical value: 990.6; MS(M+H) + Observed value: 990.5

[0276] General steps in the manufacture of the W3 structure: [ka] Step 1: A mixture of W1 (1 equiv.) and 2,2,2-trifluoroperfluorophenylacetate (1-1.5 equiv.) in a mixture of THF or dioxane or DME and iPr2NEt (volume ratio 3:1-1:1) was stirred at room temperature for 16-120 h, and the solution was used as is. Step 2: (S)-40-amino-1-azido-37-oxo-3,6,9,12,15,18,21,24,27,30,33-undecaoxa-36-azahentetracontan-41-oic acid (1 equivalent) was added to the solution obtained in step 1 (containing 1 equivalent of intermediate W2). The mixture was stirred at room temperature for 16-120 hours, and after removing the solvent in vacuo, the resulting residue was purified by preparative HPLC to give W3. [Table 16] [Table 17]

[0277] Synthesis of Alkyne Intermediates Below are detailed examples of the Pra intermediates used in the solution phase synthesis.

[0278] Manufacturing of INT-1001 [ka] INT-1001 was prepared according to the general synthetic procedure described for the preparation of Example 0001, which consisted of the following general steps: 2-chlorotrityl resin preloaded with Fmoc-Pra-OH was added in a 45 mL polypropylene solid phase reaction vessel in a 100 μmol scale, and the reaction vessel was placed in a peptide synthesizer (Symphony X). The following steps were carried out consecutively: Perform "Symphony X resin swelling procedure"; "Symphony X single coupling procedure" was performed with Fmoc-Cys(Trt)-OH; "Symphony X single coupling procedure" was performed with Fmoc-Leu-OH; "Symphony X single coupling procedure" was performed with Fmoc-N-Me-Nle-OH; "Symphony double coupling procedure" was performed with Fmoc-N-Me-Nle-OH; "Symphony double coupling procedure" was performed with Fmoc-Trp(1-CH2COOtBu)-OH; "Symphony X single coupling procedure" was performed with Fmoc-Dab(Boc)-OH; "Symphony X single coupling procedure" was performed with Fmoc-Trp(Boc)-OH; "Symphony X single coupling procedure" was performed with Fmoc-Hyp(OtBu)-OH; "Symphony X single coupling procedure" was performed with Fmoc-Leu-OH; "Symphony X single coupling procedure" was performed with Fmoc-Dap(Boc)-OH; "Symphony X single coupling procedure" was performed with Fmoc-Pro-OH; "Symphony double coupling procedure" was performed with Fmoc-Asn(Trt)-OH; "Symphony X single coupling procedure" was performed with Fmoc-N-Me-Ala-OH; "Symphony double coupling procedure" was performed with Fmoc-Tyr(OtBu)-OH; Perform "Symphony X chloroacetic anhydride coupling procedure"; Alternatively, perform "Symphony X single coupling (4 equivalents) procedure" or "Symphony X double coupling (4 equivalents) procedure" depending on the peptide elongation at each step; Alternatively, the linear peptides are prepared on a peptide synthesizer (Prelude) by a general procedure consisting of "Prelude resin swelling procedure", "Prelude single coupling procedure" or "Prelude double coupling procedure" (4-5 equivalents of amino acids and coupling time of each coupling reaction is 90-120 minutes), and "Prelude chloroacetic anhydride coupling procedure"; Carry out "Extensive Deprotection Method A"; "Cyclization Method A" was performed.

[0279] The crude material was purified by preparative LC / MS (Conditions: Column: XBridge C18, 200mm x 19mm, particle size: 5μm; Mobile phase A: 5:95 acetonitrile:water (containing 0.05% trifluoroacetic acid); Mobile phase B: 95:5 acetonitrile:water (containing 0.05% trifluoroacetic acid); Gradient: 20% B for 0 min, followed by 20-60% B over 25 min, then 100% B for 0 min; Flow rate: 20mL / min; Column temperature: 25°C). Fractions were collected as determined by MS signal. Fractions containing the desired product were combined and dried on a centrifugal evaporator, and the resulting material was further purified by preparative LC / MS (conditions: column: XBridge C18, 200mm x 30mm, particle size: 5μm; mobile phase A: 5:95 acetonitrile:water (containing ammonium acetate); mobile phase B: 95:5 acetonitrile:water (containing ammonium acetate); gradient: 17% B for 0 min, followed by 17-57% B over 20 min, then 100% B for 0 min; flow rate: 40mL / min; column temperature: 25°C), and fractions were collected as determined by MS signal. Fractions containing the desired product were combined and dried on a centrifugal evaporator. The product yield was 25.4mg, with an estimated purity of 100% by LCMS analysis. Analysis conditions A: retention time = 1.58 minutes; ESI-MS(+)m / z [M+H] 1+ : 1926.25 Analysis condition B: retention time = 1.69 minutes; ESI-MS(+)m / z [M+2H] 2+ : 963.98

[0280] The following alkyne compounds were synthesized following procedures similar to those described in INT-1001 and the general procedures described above.

[0281] Manufacturing of INT-1002 [ka] INT-1002 was prepared according to the general synthetic procedure described for the preparation of INT-1001 using chlorotrityl resin preloaded with Fmoc-Pra-OH on a 50 μmol scale. The crude material was purified by preparative LC / MS (conditions: column: XBridge C18, 200 mm x 30 mm, particle size: 5 μm; mobile phase A: 5:95 acetonitrile:water (containing 0.05% trifluoroacetic acid); mobile phase B: 95:5 acetonitrile:water (containing 0.05% trifluoroacetic acid); gradient: 14% B at 0 min, followed by 14-54% B over 20 min, then 100% B at 0 min; flow rate: 45 mL / min; column temperature: 25° C.) and fractions were collected as determined by MS signal. Fractions containing the desired product were combined and dried on a centrifugal evaporator, and the resulting material was further purified by preparative LC / MS (conditions: column: XBridge C18, 200mm x 30mm, particle size: 5μm; mobile phase A: 5:95 acetonitrile:water (containing ammonium acetate); mobile phase B: 95:5 acetonitrile:water (containing ammonium acetate); gradient: 16% B for 0 min, followed by 16-56% B over 20 min, then 100% B for 4 min; flow rate: 40mL / min; column temperature: 25°C). Fractions were collected as determined by MS signal. Fractions containing the desired product were combined and dried on a centrifugal evaporator. The product yield was 3.1mg, with an estimated purity of 100% by LCMS analysis. Analysis conditions A: retention time = 1.55 minutes; ESI-MS(+)m / z [M+2H] 2+ : 1021.2

[0282] Manufacturing of INT-1003 [ka] INT-1003 was prepared according to the general synthetic procedure described for the preparation of INT-1001 using chlorotrityl resin preloaded with Fmoc-Pra-OH on a 50 μmol scale. The crude material was purified by preparative LC / MS (conditions: column: XBridge C18, 200 mm x 30 mm, particle size: 5 μm; mobile phase A: 5:95 acetonitrile:water (containing ammonium acetate); mobile phase B: 95:5 acetonitrile:water (containing ammonium acetate); gradient: 25% B at 0 min, followed by 25-65% B over 20 min, then 100% B at 0 min; flow rate: 45 mL / min; column temperature: 25° C.) and fractions were collected as determined by MS signal. Fractions containing the desired product were combined and dried on a centrifugal evaporator, and the resulting material was further purified by preparative LC / MS (conditions: column: XBridge C18, 200mm x 30mm, particle size: 5μm; mobile phase A: 5:95 acetonitrile:water (containing 0.05% trifluoroacetic acid); mobile phase B: 95:5 acetonitrile:water (containing 0.05% trifluoroacetic acid); gradient: 30% B for 0 min, followed by 30-70% B over 20 min, then 100% B for 2 min; flow rate: 40mL / min; column temperature: 25°C). Fractions were collected as determined by MS signal. Fractions containing the desired product were combined and dried on a centrifugal evaporator. The product yield was 11.6mg, with an estimated purity of 97% by LCMS analysis. Analysis condition B: retention time = 1.99 minutes; ESI-MS(+)m / z [M+2H] 2+ : 1069.4

[0283] Manufacturing of INT-1004 [ka] INT-1004 was prepared following the general synthetic procedure described for the preparation of INT-1001 using chlorotrityl resin preloaded with Fmoc-Pra-OH on a 50 μmol scale. The crude material was purified by preparative LC / MS (conditions: column: XBridge C18, 200 mm x 19 mm, particle size: 5 μm; mobile phase A: 5:95 acetonitrile:water (containing ammonium acetate); mobile phase B: 95:5 acetonitrile:water (containing ammonium acetate); gradient: 26% B at 0 min, followed by 26-66% B over 25 min, then 100% B at 0 min; flow rate: 20 mL / min; column temperature: 25° C.) and fractions were collected as determined by MS signal. Fractions containing the desired product were combined and dried on a centrifugal evaporator. The product yield was 11.2 mg with an estimated purity of 92.8% by LCMS analysis. Analysis condition B: retention time = 1.81, 2.02 minutes; ESI-MS(+)m / z [M+2H] 2+ : 1077

[0284] Manufacturing of INT-1005 [ka] INT-1005 was prepared following the general synthetic procedure described for the preparation of INT-1001 using chlorotrityl resin preloaded with Fmoc-Pra-OH on a 50 μmol scale. The crude material was purified by preparative LC / MS (conditions: column: XBridge C18, 200 mm x 30 mm, particle size: 5 μm; mobile phase A: 5:95 acetonitrile:water (containing ammonium acetate); mobile phase B: 95:5 acetonitrile:water (containing ammonium acetate); gradient: 25% B at 0 min, followed by 25-65% B over 20 min, then 100% B at 0 min; flow rate: 45 mL / min; column temperature: 25° C.) and fractions were collected as determined by MS signal. Fractions containing the desired product were combined and dried on a centrifugal evaporator. The product yield was 22.4 mg with an estimated purity of 100% by LCMS analysis. Analysis conditions A: retention time = 1.87 minutes; ESI-MS(+)m / z [M+2H] 2+ : 1084.4

[0285] Manufacturing of INT-1006 [ka] INT-1006 was prepared following the general synthetic procedure described for the preparation of INT-1001 using chlorotrityl resin preloaded with Fmoc-Pra-OH on a 50 μmol scale. The crude material was purified by preparative LC / MS (conditions: column: XBridge C18, 200 mm x 30 mm, particle size: 5 μm; mobile phase A: 5:95 acetonitrile:water (containing 10 mM ammonium acetate); mobile phase B: 95:5 acetonitrile:water (containing 10 mM ammonium acetate); gradient: 25% B at 0 min, followed by 25-65% B over 20 min, then 100% B at 0 min; flow rate: 45 mL / min; column temperature: 25° C.) and fractions were collected as determined by MS signal. Fractions containing the desired product were combined and dried using a centrifugal evaporator. The product yield was 18.9 mg with an estimated purity of 100% by LCMS analysis. Analysis conditions A: retention time = 1.71 minutes; ESI-MS(+)m / z [M+2H] 2+ : 1084

[0286] Manufacturing of INT-1007 [ka] INT-1007 was prepared following the general synthetic procedure described for the preparation of INT-1001 using chlorotrityl resin preloaded with Fmoc-Pra-OH on a 50 μmol scale. The crude material was purified by preparative LC / MS (conditions: column: XBridge C18, 200 mm x 30 mm, particle size: 5 μm; mobile phase A: 5:95 acetonitrile:water (containing ammonium acetate); mobile phase B: 95:5 acetonitrile:water (containing ammonium acetate); gradient: 23% B at 0 min, followed by 23-63% B over 20 min, then 100% B at 0 min; flow rate: 45 mL / min; column temperature: 25° C.) and fractions were collected as determined by MS signal. Fractions containing the desired product were combined and dried on a centrifugal evaporator. The product yield was 26.8 mg with an estimated purity of 99% by LCMS analysis. Analysis condition B: retention time = 2.23 minutes; ESI-MS(+)m / z [M+2H] 2+ : 1077.2

[0287] Manufacturing of INT-1008 [ka] INT-1008 was prepared following the general synthetic procedure described for the preparation of INT-1001 using chlorotrityl resin preloaded with Fmoc-Pra-OH on a 50 μmol scale. The crude material was purified by preparative LC / MS (conditions: column: XBridge C18, 200 mm x 30 mm, particle size: 5 μm; mobile phase A: 5:95 acetonitrile:water (containing ammonium acetate); mobile phase B: 95:5 acetonitrile:water (containing ammonium acetate); gradient: 23% B at 0 min, followed by 23-63% B over 20 min, then 100% B at 0 min; flow rate: 45 mL / min; column temperature: 25° C.) and fractions were collected as determined by MS signal. Fractions containing the desired product were combined and dried on a centrifugal evaporator. The product yield was 24.9 mg with an estimated purity of 96.9% by LCMS analysis. Analysis condition B: retention time = 2.25 minutes; ESI-MS(+)m / z [M+2H] 2+ : 1077.4

[0288] Manufacturing of INT-1009 [ka] INT-1009 was prepared following the general synthetic procedure described for the preparation of INT-1001 using chlorotrityl resin preloaded with Fmoc-Pra-OH on a 50 μmol scale. The crude material was purified by preparative LC / MS (conditions: column: XBridge C18, 200 mm x 19 mm, particle size: 5 μm; mobile phase A: 5:95 acetonitrile:water (containing 0.05% trifluoroacetic acid); mobile phase B: 95:5 acetonitrile:water (containing 0.05% trifluoroacetic acid); gradient: 38% B at 0 min, 38-78% B over 20 min, then 100% B at 0 min; flow rate: 20 mL / min; column temperature: 25° C.) and fractions were collected as determined by MS signal. Fractions containing the desired product were combined and dried using a centrifugal evaporator. The product yield was 36.5 mg with an estimated purity of 100% by LCMS analysis. Analysis condition B: retention time = 2.21 minutes; ESI-MS(+)m / z [M+2H] 2+ : 1055.4

[0289] Manufacturing of INT-1010 [ka] INT-1010 was prepared following the general synthetic procedure described for the preparation of INT-1001 using chlorotrityl resin preloaded with Fmoc-Pra-OH on a 50 μmol scale. The crude material was purified by preparative LC / MS (conditions: column: XBridge C18, 200 mm x 30 mm, particle size: 5 μm; mobile phase A: 5:95 acetonitrile:water (containing ammonium acetate); mobile phase B: 95:5 acetonitrile:water (containing ammonium acetate); gradient: 26% B at 0 min, followed by 26-66% B over 20 min, then 100% B at 0 min; flow rate: 45 mL / min; column temperature: 25° C.) and fractions were collected as determined by MS signal. Fractions containing the desired product were combined and dried on a centrifugal evaporator. The product yield was 26.3 mg with an estimated purity of 100% by LCMS analysis. Analysis conditions A: retention time = 1.92 minutes; ESI-MS(+)m / z [M+2H] 2+ : 1055.3

[0290] Manufacturing of INT-1011 [ka] INT-1011 was prepared following the general synthetic procedure described for the preparation of INT-1001 using chlorotrityl resin preloaded with Fmoc-Pra-OH on a 50 μmol scale. The crude material was purified by preparative LC / MS (conditions: column: XBridge C18, 200 mm x 30 mm, particle size: 5 μm; mobile phase A: 5:95 acetonitrile:water (containing ammonium acetate); mobile phase B: 95:5 acetonitrile:water (containing ammonium acetate); gradient: 24% B at 0 min, followed by 24-64% B over 20 min, then 100% B at 0 min; flow rate: 45 mL / min; column temperature: 25° C.) and fractions were collected as determined by MS signal. Fractions containing the desired product were combined and dried using a centrifugal evaporator. The product yield was 17.7 mg with an estimated purity of 96.9% by LCMS analysis. Analysis condition B: retention time = 2.13 minutes; ESI-MS(+)m / z [M+2H] 2+ : 1055.8

[0291] Manufacturing of INT-1012 [ka] INT-1012 was prepared following the general synthetic procedure described for the preparation of INT-1001 using chlorotrityl resin preloaded with Fmoc-Pra-OH on a 50 μmol scale. The crude material was purified by preparative LC / MS (conditions: column: XBridge C18, 200 mm x 19 mm, particle size: 5 μm; mobile phase A: 5:95 acetonitrile:water (containing 0.05% trifluoroacetic acid); mobile phase B: 95:5 acetonitrile:water (containing 0.05% trifluoroacetic acid); gradient: 38% B at 0 min, 38-78% B over 25 min, then 100% B at 0 min; flow rate: 20 mL / min; column temperature: 25° C.) and fractions were collected as determined by MS signal. Fractions containing the desired product were combined and dried using a centrifugal evaporator. The product yield was 16.1 mg with an estimated purity of 98.9% by LCMS analysis. Analysis condition B: retention time = 2.18 minutes; ESI-MS(+)m / z [M+2H] 2+ : 1020.1

[0292] Manufacturing of INT-1013 [ka] INT-1013 was prepared following the general synthetic procedure described for the preparation of INT-1001 using chlorotrityl resin preloaded with Fmoc-Pra-OH on a 50 μmol scale. The crude material was purified by preparative LC / MS (conditions: column: XBridge C18, 200 mm x 30 mm, particle size: 5 μm; mobile phase A: 5:95 acetonitrile:water (containing 0.05% trifluoroacetic acid); mobile phase B: 95:5 acetonitrile:water (containing 0.05% trifluoroacetic acid); gradient: 19% B at 0 min, 19-59% B over 20 min, then 100% B at 0 min; flow rate: 45 mL / min; column temperature: 25° C.) and fractions were collected as determined by MS signal. Fractions containing the desired product were combined and dried using a centrifugal evaporator. The product yield was 20.2 mg with an estimated purity of 96.3% by LCMS analysis. Analysis conditions A: retention time = 1.53 minutes; ESI-MS(+)m / z [M+2H] 2+ : 1006.2

[0293] Manufacturing of INT-1014 [ka] INT-1014 was prepared according to the general synthetic procedure described for the preparation of INT-1001 using chlorotrityl resin preloaded with Fmoc-Pra-OH on a 50 μmol scale. The crude material was purified by preparative LC / MS (conditions: column: XBridge C18, 200 mm x 30 mm, particle size: 5 μm; mobile phase A: 5:95 acetonitrile:water (containing 0.05% trifluoroacetic acid); mobile phase B: 95:5 acetonitrile:water (containing 0.05% trifluoroacetic acid); gradient: 14% B at 0 min, followed by 14-54% B over 20 min, then 100% B at 0 min; flow rate: 45 mL / min; column temperature: 25° C.) and fractions were collected as determined by MS signal. Fractions containing the desired product were combined and dried on a centrifugal evaporator, and the resulting material was further purified by preparative LC / MS (conditions: column: XBridge C18, 200mm x 30mm, particle size: 5μm; mobile phase A: 5:95 acetonitrile:water (containing ammonium acetate); mobile phase B: 95:5 acetonitrile:water (containing ammonium acetate); gradient: 14% B for 0 min, followed by 14-54% B over 20 min, then 100% B for 2 min; flow rate: 40mL / min; column temperature: 25°C), and fractions were collected as determined by MS signal. Fractions containing the desired product were combined and dried on a centrifugal evaporator. The product yield was 10.7mg, with an estimated purity of 100% by LCMS analysis. Analysis conditions A: retention time = 1.5 minutes; ESI-MS(+)m / z [M+2H] 2+ : 1014

[0294] Manufacturing of INT-1015 [ka] INT-1015 was prepared according to the general synthetic procedure described for the preparation of INT-1001 using chlorotrityl resin preloaded with Fmoc-Pra-OH on a 50 μmol scale. The crude material was purified by preparative LC / MS (conditions: column: XBridge C18, 200 mm x 30 mm, particle size: 5 μm; mobile phase A: 5:95 acetonitrile:water (containing 0.05% trifluoroacetic acid); mobile phase B: 95:5 acetonitrile:water (containing 0.05% trifluoroacetic acid); gradient: 14% B at 0 min, followed by 14-54% B over 20 min, then 100% B at 0 min; flow rate: 45 mL / min; column temperature: 25° C.) and fractions were collected as determined by MS signal. Fractions containing the desired product were combined and dried on a centrifugal evaporator, and the resulting material was further purified by preparative LC / MS (conditions: column: XBridge C18, 200mm x 30mm, particle size: 5μm; mobile phase A: 5:95 acetonitrile:water (containing ammonium acetate); mobile phase B: 95:5 acetonitrile:water (containing ammonium acetate); gradient: 16% B for 0 min, followed by 16-56% B over 20 min, then 100% B for 2 min; flow rate: 35mL / min; column temperature: 25°C), and fractions were collected as determined by MS signal. Fractions containing the desired product were combined and dried on a centrifugal evaporator. The product yield was 9.1mg, with an estimated purity of 100% by LCMS analysis. Analysis conditions A: retention time = 1.55 minutes; ESI-MS(+)m / z [M+2H] 2+ : 1021.1

[0295] Manufacturing of INT-1016 [ka] INT-1016 was prepared following the general synthetic procedure described for the preparation of INT-1001 using chlorotrityl resin preloaded with Fmoc-Pra-OH on a 50 μmol scale. The crude material was purified by preparative LC / MS (conditions: column: XBridge C18, 200 mm x 30 mm, particle size: 5 μm; mobile phase A: 5:95 acetonitrile:water (containing 0.05% trifluoroacetic acid); mobile phase B: 95:5 acetonitrile:water (containing 0.05% trifluoroacetic acid); gradient: 19% B at 0 min, followed by 19-59% B over 20 min, then 100% B at 0 min; flow rate: 45 mL / min; column temperature: 25° C.) and fractions were collected as determined by MS signal. Fractions containing the desired product were combined and dried using a centrifugal evaporator. The yield of the product was 38.6 mg with an estimated purity of 93% by LCMS analysis. Analysis conditions A: retention time = 1.53 minutes; ESI-MS(+)m / z [M+2H] 2+ : 1028.4

[0296] Manufacturing of INT-1017 [ka] INT-1017 was prepared following the general synthetic procedure described for the preparation of INT-1001 using chlorotrityl resin preloaded with Fmoc-Pra-OH on a 50 μmol scale. The crude material was purified by preparative LC / MS (conditions: column: XBridge C18, 200 mm x 30 mm, particle size: 5 μm; mobile phase A: 5:95 acetonitrile:water (containing 0.05% trifluoroacetic acid); mobile phase B: 95:5 acetonitrile:water (containing 0.05% trifluoroacetic acid); gradient: 19% B at 0 min, 19-59% B over 20 min, then 100% B at 0 min; flow rate: 45 mL / min; column temperature: 25° C.) and fractions were collected as determined by MS signal. Fractions containing the desired product were combined and dried using a centrifugal evaporator. The yield of the product was 38.3 mg with an estimated purity of 90% by LCMS analysis. Analysis conditions A: retention time = 1.52 minutes; ESI-MS(+)m / z [M+2H] 2+ : 1028

[0297] Manufacturing of INT-1018 [ka] INT-1018 was prepared following the general synthetic procedure described for the preparation of INT-1001 using chlorotrityl resin preloaded with Fmoc-Pra-OH on a 50 μmol scale. The crude material was purified by preparative LC / MS (conditions: column: XBridge C18, 200 mm x 30 mm, particle size: 5 μm; mobile phase A: 5:95 acetonitrile:water (containing 0.05% trifluoroacetic acid); mobile phase B: 95:5 acetonitrile:water (containing 0.05% trifluoroacetic acid); gradient: 19% B at 0 min, followed by 19-59% B over 20 min, then 100% B at 0 min; flow rate: 45 mL / min; column temperature: 25° C.) and fractions were collected as determined by MS signal. Fractions containing the desired product were combined and dried using a centrifugal evaporator. The product yield was 22.7 mg with an estimated purity of 92.6% by LCMS analysis. Analysis conditions A: Retention time = 1.43 minutes; ESI-MS(+)m / z [M+2H] 2+ : 1021.4

[0298] Manufacturing of INT-1019 [ka] INT-1019 was prepared following the general synthetic procedure described for the preparation of INT-1001 using chlorotrityl resin preloaded with Fmoc-Pra-OH on a 50 μmol scale. The crude material was purified by preparative LC / MS (conditions: column: XBridge C18, 200 mm x 30 mm, particle size: 5 μm; mobile phase A: 5:95 acetonitrile:water (containing 0.05% trifluoroacetic acid); mobile phase B: 95:5 acetonitrile:water (containing 0.05% trifluoroacetic acid); gradient: 20% B at 0 min, followed by 20-60% B over 20 min, then 100% B at 0 min; flow rate: 45 mL / min; column temperature: 25° C.) and fractions were collected as determined by MS signal. Fractions containing the desired product were combined and dried using a centrifugal evaporator. The product yield was 23.6 mg with an estimated purity of 91.2% by LCMS analysis. Analysis condition B: retention time = 1.59 minutes; ESI-MS(+)m / z [M+3H] 3+ : 681

[0299] Manufacturing of INT-1020 [ka] INT-1020 was prepared following the general synthetic procedure described for the preparation of INT-1001 using chlorotrityl resin preloaded with Fmoc-Pra-OH on a 50 μmol scale. The crude material was purified by preparative LC / MS (conditions: column: XBridge C18, 200 mm x 30 mm, particle size: 5 μm; mobile phase A: 5:95 acetonitrile:water (containing 0.05% trifluoroacetic acid); mobile phase B: 95:5 acetonitrile:water (containing 0.05% trifluoroacetic acid); gradient: 21% B at 0 min, followed by 21-61% B over 20 min, then 100% B at 0 min; flow rate: 45 mL / min; column temperature: 25° C.) and fractions were collected as determined by MS signal. Fractions containing the desired product were combined and dried using a centrifugal evaporator. The product yield was 31.1 mg with an estimated purity of 98.1% by LCMS analysis. Analysis condition B: retention time = 1.63 minutes; ESI-MS(+)m / z [M+H] + : 1997.3

[0300] Manufacturing of INT-1021 [ka] INT-1021 was prepared according to the general synthetic procedure described for the preparation of INT-1001 using chlorotrityl resin preloaded with Fmoc-Pra-OH on a 50 μmol scale. The crude material was purified by preparative LC / MS (conditions: column: XBridge C18, 200 mm x 30 mm, particle size: 5 μm; mobile phase A: 5:95 acetonitrile:water (containing 0.05% trifluoroacetic acid); mobile phase B: 95:5 acetonitrile:water (containing 0.05% trifluoroacetic acid); gradient: 20% B for 0 min, followed by 20-60% B over 20 min, then 100% B for 0 min; flow rate: 45 mL / min; column temperature: 25° C.) and fractions were collected as determined by MS signal. Fractions containing the desired product were combined and dried on a centrifugal evaporator, and the resulting material was further purified by preparative LC / MS (conditions: column: XBridge C18, 200mm x 30mm, particle size: 5μm; mobile phase A: 5:95 acetonitrile:water (containing ammonium acetate); mobile phase B: 95:5 acetonitrile:water (containing ammonium acetate); gradient: 15% B for 0 min, followed by 15-55% B over 20 min, then 100% B for 2 min; flow rate: 40mL / min; column temperature: 25°C), and fractions were collected as determined by MS signal. Fractions containing the desired product were combined and dried on a centrifugal evaporator. The product yield was 12mg, with an estimated purity of 100% by LCMS analysis. Analysis condition B: retention time = 1.62 minutes; ESI-MS(+)m / z [M+2H] 2+ : 999.3

[0301] Manufacturing of INT-1022 [ka] INT-1022 was prepared according to the general synthetic procedure described for the preparation of INT-1001 using chlorotrityl resin preloaded with Fmoc-Pra-OH on a 50 μmol scale. The crude material was purified by preparative LC / MS (conditions: column: XBridge C18, 200 mm x 30 mm, particle size: 5 μm; mobile phase A: 5:95 acetonitrile:water (containing 0.05% trifluoroacetic acid); mobile phase B: 95:5 acetonitrile:water (containing 0.05% trifluoroacetic acid); gradient: 21% B at 0 min, followed by 21-61% B over 20 min, then 100% B at 0 min; flow rate: 45 mL / min; column temperature: 25° C.) and fractions were collected as determined by MS signal. Fractions containing the desired product were combined and dried on a centrifugal evaporator, and the resulting material was further purified by preparative LC / MS (conditions: column: XBridge C18, 200mm x 30mm, particle size: 5μm; mobile phase A: 5:95 acetonitrile:water (containing ammonium acetate); mobile phase B: 95:5 acetonitrile:water (containing ammonium acetate); gradient: 18% B for 0 min, followed by 18-58% B over 20 min, then 100% B for 2 min; flow rate: 40mL / min; column temperature: 25°C), and fractions were collected as determined by MS signal. Fractions containing the desired product were combined and dried on a centrifugal evaporator. The product yield was 11mg, with an estimated purity of 98.3% by LCMS analysis. Analysis conditions A: retention time = 1.59 minutes; ESI-MS(+)m / z [M+H] + : 1996.9

[0302] Manufacturing of INT-1023 [ka] Linear INT-1023 was prepared according to the synthetic procedure described above (see Scheme 1) using chlorotrityl resin preloaded with Fmoc-Pra-OH. The linear compound (Resin A in Scheme 1) was cleaved and extensively deprotected using "Extensive Deprotection Method A" and then cyclized using "Cyclization Method A". The resulting crude was purified by reversed-phase HPLC. The product yield was 30.4 mg with an estimated purity of 95.1% by LCMS analysis. Analysis conditions A: retention time = 1.53 minutes; ESI-MS(+)m / z [M+H] + :1983.8

[0303] Synthesis of the final compound Below are detailed examples of final compounds synthesized by solution-phase click reaction.

[0304] Example 1001 [ka] The compound was synthesized according to the general "Solution-Phase Click Reaction Method A" procedure: (S)-2-(2-((6S,9S,12S,18R,21S,24S,27S,30S,33S,36S,38aS,40R,44S,47S,49aS)-36-((1H-indol-3-yl)methyl)-6-(2-amino-2-oxoethyl)-33-(2-aminoethyl)-47-(aminomethyl)-24,27-dibutyl-30-((1-(carboxymethyl)-1H-indol- 3-yl)methyl)-40-hydroxy-12-(4-hydroxybenzyl)-21,44-diisobutyl-9,10,25,28-tetramethyl-5,8,11,14,20,23,26,29,32,35,38,43,46,49-tetradecaoxohexatetracontahydro-1H,5H-dipyrrolo[2,1-g1:2',1'-x][1]thia[4,7,10,13,16,19,22,2 5,28,31,34,37,40,43]tetradecaazacyclopentatetracontin-18-carboxamido)acetamido)pent-4-ynoic acid (INT-1023, 15 mg, 7.56 μmol) and (S)-1-azido-40-(10-(4-carboxyphenoxy)decanamido)-37-oxo-3,6,9,12,15,18,21,24,27,30,33-undecaoxa- To a solution of 36-azahentetracontan-41-oic acid (11.23 mg, 0.011 mmol) in DMF (1 mL) was added sodium (R)-5-((S)-1,2-dihydroxyethyl)-4-hydroxy-2-oxo-2,5-dihydrofuran-3-olate (3.00 mg, 0.015 mmol) and copper(II) sulfate pentahydrate (2.83 mg, 0.011 mmol) in water (0.2 mL). The mixture was stirred at room temperature for 2 h and purified to obtain a single compound. The crude material was purified by preparative LC / MS (conditions: column: XBridge C18, 200mm x 19mm, particle size: 5μm; mobile phase A: 5:95 acetonitrile:water (containing 0.1% trifluoroacetic acid); mobile phase B: 95:5 acetonitrile:water (containing 0.1% trifluoroacetic acid); gradient: 23% B at 0 min, followed by 23-53% B over 30 min, then 100% B at 0 min; flow rate: 20mL / min; column temperature: 25°C) and fractions were collected as determined by MS signal. Fractions containing the desired product were combined and dried in a centrifugal evaporator. The product yield was 3.1mg with an estimated purity of 95% by LCMS analysis. Analysis conditions A: retention time = 1.56 minutes; ESI-MS(+)m / z [M+3H] 3+ : 991.60 Analysis condition B: retention time = 1.73 minutes; ESI-MS(+)m / z [M+3H] 3+ : 991.80

[0305] Preparation of Example 1002 [ka] Example 1002 was prepared on a 42 μmol scale from linear INT-1023 and (S)-4-azido-2-(14-sulfotetradecanamido)butanoic acid using "On-resin click reaction method A", followed by "Extensive deprotection method A" and "Cyclization method A". Click reaction on Resin A with protected linear peptide attached (0.042 mmol scale): Resin A in a tube (Bio Rad) was washed with DCM (3x5mL) and then with DMF (4x5mL).To the resin was added a solution of bis(2,2,6,6-tetramethyl-3,5-heptanedionato)copper(II) (9.12mg, 0.021mmol), vitamin C (0.022g, 0.127mmol), (0.049mL, 0.424mmol), DIEA (0.074mL, 0.424mmol), THF (1.5mL) and DMF (1.5mL). The above solution was added to a weighed vial of (S)-1-azido-25-(10-(4-(tert-butoxycarbonyl)phenoxy)decanamido)-22-oxo-3,6,9,12,15,18-hexaoxa-21-azahexacosane-26-oic acid (0.035 g, 0.042 mmol) and this was added to the resin. The tube was capped and shaken overnight on a rocking platform. The solution was drained and the resin washed with DMF (6x5 mL) followed by DCM (3x5 mL). The resin was treated with 95% TFA + 2.5% TIS + 2.5% DTT (5 mL) and shaken at room temperature for 1 h. The solution was drained into a conical tube (50 mL, Falcon) containing cold Et2O (35 mL). The resulting white precipitate was collected by centrifugation (3x4 min x 300 RPM) and the ether layer was discarded. The resulting pellet was air-dried at room temperature for 1 hour, dissolved in DMF (30 mL) and DIEA (1 mL) was added. The reaction mixture was shaken at room temperature for 6 hours and concentrated in a centrifugal evaporator (Genevac). The resulting sample was dissolved in DMF (2 mL) and purified. The crude material was purified by preparative LC / MS (conditions: column: XBridge C18, 200mm x 19mm, particle size: 5μm; mobile phase A: 5:95 acetonitrile:water (containing 0.05% trifluoroacetic acid); mobile phase B: 95:5 acetonitrile:water (containing 0.05% trifluoroacetic acid); gradient: 15% B for 0 min, followed by 15-55% B over 20 min, then 100% B for 0 min; flow rate: 20mL / min; column temperature: 25°C) and fractions were collected as determined by MS signal. Fractions containing the desired product were combined and dried on a centrifugal evaporator, and the resulting material was further purified by preparative LC / MS (conditions: column: XBridge C18, 200mm x 19mm, particle size: 5μm; mobile phase A: 5:95 acetonitrile:water (containing ammonium acetate); mobile phase B: 95:5 acetonitrile:water (containing ammonium acetate); gradient: 15% B for 0 min, followed by 15-55% B over 20 min, then 100% B for 0 min; flow rate: 20mL / min; column temperature: 25°C), and fractions were collected as determined by MS signal. Fractions containing the desired product were combined and dried on a centrifugal evaporator. The product yield was 2.9mg, with an estimated purity of 100% by LCMS analysis. Analysis conditions A: retention time = 1.53 minutes; ESI-MS(+)m / z [M+3H] 3+ : 918.30 Analysis condition B: retention time = 1.81 minutes; ESI-MS(+)m / z [M+3H] 3+ : 918.20

[0306] Preparation of Example 1003 [ka] Example 1003 was prepared on a 51 μmol scale by reacting linear INT-1023 (Resin A) with N3-Peg11-γGlu-C12-Op-phenyl-COOtBu using "Click reaction on resin method A" according to the procedure of Example 1002. The crude material was purified by preparative LC / MS (conditions: column: XBridge C18, 200mm x 19mm, particle size: 5μm; mobile phase A: 5:95 acetonitrile:water (containing 0.05% trifluoroacetic acid); mobile phase B: 95:5 acetonitrile:water (containing 0.05% trifluoroacetic acid); gradient: 18% B for 0 min, followed by 18-58% B over 20 min, then 100% B for 0 min; flow rate: 20mL / min; column temperature: 25°C) and fractions were collected as determined by MS signal. Fractions containing the desired product were combined and dried on a centrifugal evaporator, and the resulting material was further purified by preparative LC / MS (conditions: column: XBridge C18, 200mm x 19mm, particle size: 5μm; mobile phase A: 5:95 acetonitrile:water (containing ammonium acetate); mobile phase B: 95:5 acetonitrile:water (containing ammonium acetate); gradient: 18% B for 0 min, followed by 18-58% B over 20 min, then 100% B for 0 min; flow rate: 20mL / min; column temperature: 25°C), and fractions were collected as determined by MS signal. Fractions containing the desired product were combined and dried on a centrifugal evaporator. The product yield was 1.7mg, with an estimated purity of 100% by LCMS analysis. Analysis conditions A: retention time = 1.62 minutes; ESI-MS(+)m / z [M+3H] 3+ : 1001.20 Analysis condition B: retention time = 1.93 minutes; ESI-MS(+)m / z [M+3H] 3+ : 1001.20

[0307] Following a similar procedure to Example 1001, Examples 1004-1006 were obtained.

[0308] Preparation of Example 1004 [ka] The crude material was purified by preparative LC / MS (conditions: column: XBridge C18, 200mm x 19mm, particle size: 5μm; mobile phase A: 5:95 acetonitrile:water (containing 0.1% trifluoroacetic acid); mobile phase B: 95:5 acetonitrile:water (containing 0.1% trifluoroacetic acid); gradient: 20% B at 0 min, 20-50% B over 20 min, then 100% B at 0 min; flow rate: 20mL / min; column temperature: 25°C) and fractions were collected as determined by MS and UV signals. Fractions containing the desired product were combined and dried in a centrifugal evaporator. The product yield was 1.1 mg with an estimated purity of 82% by LCMS analysis. Analytical LC / MS was used to determine the final purity. Analysis conditions A: retention time = 1.55 minutes; ESI-MS(+)m / z [M+3H] 3+ : 1009.10 Analysis condition B: retention time = 1.63 minutes; ESI-MS(+)m / z [M+3H] 3+ : 1009.10

[0309] Preparation of Example 1005 [ka] The crude material was purified by preparative LC / MS (conditions: column: XBridge C18, 200mm x 19mm, particle size: 5μm; mobile phase A: 5:95 acetonitrile:water (containing 0.1% trifluoroacetic acid); mobile phase B: 95:5 acetonitrile:water (containing 0.1% trifluoroacetic acid); gradient: 29% B for 0 min, followed by 29-59% B over 30 min, then 100% B for 5 min; flow rate: 20mL / min; column temperature: 25°C) and fractions were collected as determined by MS and UV signals. Fractions containing the desired product were combined and dried in a centrifugal evaporator. The product yield was 1.2mg with an estimated purity of 95% by LCMS analysis. Analysis conditions A: Retention time = 1.65 minutes; ESI-MS(+)m / z [M+3H] 3+: 1005.60 Analysis condition B: retention time = 1.9 minutes; ESI-MS(+)m / z [M+3H] 3+ : 1005.30

[0310] Preparation of Example 1006 [ka] The crude material was purified by preparative LC / MS (conditions: column: XBridge C18, 200mm x 19mm, particle size: 5μm; mobile phase A: 5:95 acetonitrile:water (containing 10mM ammonium acetate); mobile phase B: 95:5 acetonitrile:water (containing 10mM ammonium acetate); gradient: 15% B for 0 min, followed by 15-45% B over 30 min, then 100% B for 5 min; flow rate: 20mL / min; column temperature: 25°C) and fractions were collected as determined by MS and UV signals. Fractions containing the desired product were combined and dried in a centrifugal evaporator. The product yield was 2.7mg with an estimated purity of 95% by LCMS analysis. Analysis conditions A: retention time = 1.6 minutes; ESI-MS(+)m / z [M+3H] 3+ : 1006.40 Analysis condition B: retention time = 1.84 minutes; ESI-MS(+)m / z [M+3H] 3+ : 1006.40

[0311] 293T-hPD-L1 cell binding high concentration screening assay (CBA) Phycoerythrin (PE) was covalently conjugated to the Ig epitope tag of human PD-1-Ig, and this fluorescently labeled PD-1-Ig was used in a binding assay with a human embryonic kidney cell line (293T) stably overexpressing human PD-L1 (293T-hPD-L1). 320μL of 293T-hPD-L1 cells / DMEM (containing 10% fetal bovine serum) were seeded into 384-well plates and cultured overnight. Compounds (125nL) were added to the cells, followed by 5μL of PE-labeled PD-1-Ig (final 0.5nM) diluted in DMEM (containing 10% fetal bovine serum), followed by incubation at 37℃ for 1h. Cells were washed with dPBS (3x100μL) and then fixed with 30μL of 4% paraformaldehyde / dPBS (containing 10μg / mL Hoechst 33342) for 30min at room temperature. Cells were washed with dPBS (3x100μL) followed by a final addition of 15μL of dPBS. Data were collected and processed using a Cell Insight NXT High Content Imager and associated software.

[0312] Table 1 shows the IC of representative examples of the present disclosure measured in the 293T-hPD-L1 cell binding high concentration screening assay described above. 50 The values ​​are listed. [Table 18]

[0313] It will be apparent to those skilled in the art that the present disclosure is not limited to the above-described examples, and that it may be embodied in other specific forms without departing from the essential characteristics of the present disclosure. The examples are therefore to be considered in all respects as illustrative and not restrictive, with reference to the claims rather than to the above-described examples, and therefore all changes which come within the meaning and range of equivalency of the claims are intended to be embraced in the present disclosure.

[0314] The compounds of formula (I) have activity as inhibitors of PD-1 / PD-L1 interaction, and therefore can be used to treat diseases or deficiencies associated with PD-1 / PD-L1 interaction. Through inhibition of PD-1 / PD-L1 interaction, the compounds of the present disclosure can be used to treat infectious diseases (e.g., HIV, septic shock, hepatitis A, hepatitis B, hepatitis C, or hepatitis D) and cancer.

[0315] It should be understood that the claims are intended to be interpreted using the description in the "Description of the Preferred Embodiments" rather than the description in the "Summary of the Invention" and Abstract. The descriptions in the "Summary of the Invention" and Abstract may show one or more examples of the embodiments of the present disclosure as contemplated by the inventors, but may not show all examples, and are in no way intended to limit the present invention and the claims.

[0316] The present disclosure has been described above using functional group components, illustrating the operation of certain functional groups and their interactions. The boundaries of these functional group components are arbitrarily defined herein for convenience of description. Other boundaries may be defined as long as the certain functional groups and their interactions function properly.

[0317] The description of the specific embodiments above fully discloses the general nature of the present disclosure, so that those other than the inventors can easily modify and / or adapt the specific embodiments described above for various applications by applying the knowledge of those skilled in the art without undue experimentation and without departing from the basic concept of the present disclosure. Therefore, such modifications and adaptations are intended to be within the meaning and scope equivalent to the embodiments of the present disclosure based on the content and guidance described herein. It should be understood that the expressions or terminology used in this specification are for explanatory purposes and are not limited to the expressions or terminology used in this specification that would be interpreted by a person skilled in the art in light of the content and guidance.

[0318] The scope of the present disclosure should not be limited by any of the above-described exemplary embodiments, but should be defined only in accordance with the following claims and their equivalents.

Claims

1. Formula (I) 【Chemistry 1】 [In the formula, A is, 【Chemistry 2】 is selected from; where 【Chemistry 3】 is the moiety that binds to the carbonyl group, 【Chemistry 4】 represents a moiety attached to a nitrogen atom; n is 0 or 1; m is 1 or 2; u is 0 or 1; w is 0, 1, or 2; R x is selected from hydrogen, amino, hydroxy, and methyl; R 14 and R 15 is independently selected from hydrogen and methyl; R 16a is hydrogen and C 1 -C 6 alkyl; R 16 is -(C(R 17a ) 2 ) 2 -XR 30 , -(C(R 17a R 17 )) 0-2 -X'-R 30 , -(C(R 17a R 17 ) 1-2 C(O)NR 16a ) m' -X'-R 30 , -C(R 17a ) 2 C(O)N(R 16a )C(R 17a ) 2 -X'-R 31 , -(C(R 17a R 17 )) 1-2 C(O)N(R 16a )C(R 17a ) 2 -X'-R 31 , -C(R 17a ) 2 [C(O)N(R 16a )C(R 17a ) 2 ] w' -XR 31 , -C(R 17a R 17 ) 1-2 [C(O)N(R 16a )C(R 17a R 17 ) 1-2 ] w' X'-R 31 , -(C(R 17a )(R 17 )C(O)NR 16a ) n' -H, and -(C(R 17a )(R 17 )C(O)NR 16a ) m' -C(R 17a )(R 17 )-CO 2 Selected from H; Here, the spacer PEG q' R 16 (q' is -(CH 2 CH 2 (O)- is the number of units); where w' is 2 or 3; n' is 1 to 6; m' is 0 to 5; q' is from 1 to 20; X is a chain of 1 to 172 atoms, the atoms being selected from nitrogen, carbon and oxygen, the chain may contain 1, 2, 3 or 4 groups selected from -NHC(O)-, -NHC(O)NH-, and -C(O)NH-, as incorporated herein; the chain may contain -CO 2 H, -C(O)NH 2 , -CH 2 C(O)NH 2 , and -(CH 2 ) 1-2 CO 2 H; X' is a chain of 1 to 172 atoms, the atoms being selected from carbon and oxygen, the chain may contain 1, 2, 3, or 4 groups selected from -NHC(O)-, -NHC(O)NH-, and -C(O)NH-, as incorporated herein; the chain may contain -CO 2 H, -C(O)NH 2 , and -(CH 2 ) 1-2 CO 2 H, where X' is other than unsubstituted PEG; R 30 -YB-COOH, -YB-SO 3 H, -YBS(O)OH and -YBP(O)(OH) 2 Selected from; R 31 -YB-COOH, -YB-SO 3 H, -YBS(O)OH and -YBP(O)(OH) 2 Selected from; Each R 17a are independently hydrogen, C 1 -C 6 Alkyl, -CH 2 OH, -CH 2 CO 2 H, -(CH 2 ) 2 CO 2 Selected from H; Each R 17 are independently hydrogen, -CH 3 , (CH 2 ) z N 3 , -(CH 2 ) z NH 2 , -XR 31 , -(CH 2 ) z CO 2 H, -CH 2 OH, CH 2 C≡CH, and -(CH 2 ) z -Triazolyl-XR 35 is selected from; where z is 1 to 6; R 35 -YB-COOH, -YB-SO 3 H, -YBS(O)OH and -YBP(O)(OH) 2 Selected from; B is a 5-6 membered aryl or heteroaryl group, said heteroaryl group containing 1-3 heteroatoms selected from -O-, -S-, and -N-; Y is a bond, O, S, or S(O) 1-2 Selected from; R a , R e , R j , and R k are each independently selected from hydrogen and methyl; R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , and R 13 are independently selected from the side chains of natural amino acids and the side chains of unnatural amino acids, or form a ring with the adjacent corresponding R groups described below; R b is methyl, or R b and R 2 together with the atoms to which they are attached form a ring selected from azetidine, pyrrolidine, morpholine, piperidine, piperazine, and tetrahydrothiazole; wherein each ring is optionally substituted with 1 to 4 groups independently selected from amino, cyano, methyl, halogen, and hydroxy; R d is hydrogen or methyl, or R d and R 4 together with the atoms to which they are attached form a ring selected from azetidine, pyrrolidine, morpholine, piperidine, piperazine, and tetrahydrothiazole; wherein each ring is optionally substituted with 1 to 4 groups independently selected from amino, cyano, methyl, halogen, hydroxy, and phenyl; R g is hydrogen or methyl, or R g and R 7 together with the atoms to which they are attached form a ring selected from azetidine, pyrrolidine, morpholine, piperidine, piperazine, and tetrahydrothiazole; wherein each ring is optionally substituted with 1 to 4 groups independently selected from amino, benzyl optionally substituted with halogen, benzyloxy, cyano, cyclohexyl, methyl, halogen, hydroxy, isoquinolinyloxy optionally substituted with methoxy groups, quinolinyloxy optionally substituted with halogen, and tetrazolyl; said pyrrolidine and piperidine rings are optionally fused to a cyclohexyl, phenyl, or indole group; and R l is methyl, or R l and R 12 together with the atoms to which they are attached form a ring selected from azetidine and pyrrolidine, wherein each ring is optionally substituted with 1 to 4 groups independently selected from amino, cyano, methyl, halogen, and hydroxy. or a pharma- ceutically acceptable salt thereof.

2. In the formula, A is 【Chemistry 5】 and; m is 1; w is 0; and R 14 , R 15 , and R 16a are hydrogen, 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof.

3. During the ceremony, R 16 But -(C(R 17a ) 2 ) 2 -XR 30 , -(C(R 17a R 17 )) 0-2 -X'-R 30 and -(C(R 17a R 17 ) 1-2 C(O)NR 16a ) m' -X'-R 30 Selected from; Each R 17a But hydrogen, -CO 2 H, and -CH 2 CO 2 Selected from H; X is a chain of 8 to 46 atoms, the atoms being selected from carbon and oxygen, the chain may contain one, two or three -NHC(O)-, C(O)NH groups incorporated herein; the chain may be -CO 2 H, -C(O)NH 2 , -CH 2 C(O)NH 2 , and -CH 2 CO 2 H; and R 30 but, 【Chemistry 6】 Selected from; Y is selected from a bond, O or S; 3. The compound of claim 2, or a pharma- ceutically acceptable salt thereof.

4. In the formula, A is 【change】 and; m is 1; w is 0; R 14 , R 15 , and R 16a are hydrogen; R 16 But -C(R 17a ) 2 C(O)N(R 16a )C(R 17a ) 2 -X'-R 31 and -(C(R 17a R 17 )) 1-2 C(O)N(R 16a )C(R 17a ) 2 -X'-R 31 Selected from; Each R 17a But hydrogen, -CO 2 H, and -CH 2 CO 2 Selected from H; X' is a chain of 8 to 48 atoms, the atoms being selected from carbon and oxygen, the chain optionally containing one, two or three -NHC(O)- or -C(O)NH- groups as incorporated herein; the chain optionally containing one, two or three -CO 2 H, -C(O)NH 2 , -CH 2 C(O)NH 2 , and -CH 2 CO 2 H, where X′ is other than unsubstituted PEG; and R 30 but, 【Chemistry 7】 Selected from; Y is selected from a bond, O or S; 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof.

5. In the formula, A is 【Chemistry 8】 and; m is 1; w is 0; R 14 , R 15 , and R 16a are hydrogen; R 16 But -C(R 17a ) 2 [C(O)N(R 16a )C(R 17a ) 2 ] w' -XR 31 and -C(R 17a R 17 ) 1-2 [C(O)N(R 16a )C(R 17a R 17 ) 1-2 ] w' -X'-R 31 Selected from; Each R 17 But hydrogen, -CO 2 H, and -CH 2 CO 2 Selected from H; X is a chain of 8 to 48 atoms, the atoms being selected from carbon and oxygen, the chain optionally containing 1, 2, or 3 -NHC(O)- or -C(O)NH- groups as incorporated herein; the chain optionally containing -CO 2 H, -C(O)NH 2 , -CH 2 C(O)NH 2 , and -CH 2 CO 2 H; and R 31 but, 【Chemistry 9】 Selected from; Y is selected from a bond, O or S; 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof.

6. In the formula, A is 【Chemistry 10】 and; m is 1; w is 0; R 14 , R 15 , and R 16a are each hydrogen; and R 16 But -(C(R 17a )(R 17 )C(O)NR 16a ) n' -H; Each R 17a is hydrogen; and Each R 17 is hydrogen, -CH 3 , (CH 2 ) z N 3 , -(CH 2 ) z NH 2 , -XR 31 , -(CH 2 ) z CO 2 H, -CH 2 OH, CH 2 C≡CH, and -(CH 2 ) z -Triazolyl-XR 35 , where at least one R 17 is hydrogen, -CH 3 , or -CH 2 is other than OH; z is 1 to 4; R 31 but, 【Chemistry 11】 Selected from; X is a chain of 7 to 155 atoms, the atoms being selected from carbon and oxygen, the chain optionally containing one, two or three -NHC(O)- or -C(O)NH- groups incorporated herein; the chain optionally containing one, two or three -CO 2 H, -C(O)NH 2 , -CH 2 C(O)NH 2 , and -CH 2 CO 2 H; and R 35 but, 【Chemistry 12】 Selected from; Y is selected from a bond, O or S; 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof.

7. In the formula, A is 【Chemistry 13】 and; m is 1; w is 0; R 14 , R 15 , and R 16a are hydrogen; R 16 But -(CR 17a )(R 17 )C(O)NR 16a ) m' -C(R 17a )(R 17 )-CO 2 H; m' is 1 to 3; Each R 17a is hydrogen; Each R 17 is hydrogen, -CH 3 , (CH 2 ) z N 3 , -(CH 2 ) z NH 2 , -XR 31 , -(CH 2 ) z CO 2 H, -CH 2 OH, CH 2 C≡CH, -(CH 2 ) z -Triazolyl-XR 35 and 【Chemistry 14】 , where at least one R 17 is hydrogen, -CH 3 , or -CH 2 is other than OH; z is 1 to 4; R 31 but, 【Chemistry 15】 Selected from; Y is selected from a bond, O, or S; X is a chain of 20 to 60 atoms, the atoms being selected from carbon and oxygen, the chain may contain 1, 2 or 3 -NHC(O)-, -C(O)NH- groups incorporated herein; the chain may be -CO 2 H, -C(O)NH 2 , -CH 2 C(O)NH 2 , and -CH 2 CO 2 H; and R 35 but, 【Chemistry 16】 Selected from; Y is selected from a bond, O or S; 13. A compound according to claim 12, or a pharma- ceutically acceptable salt thereof.

8. During the ceremony, R 1 But phenyl C 1 -C 3 alkyl, where the phenyl moieties may be optionally substituted with hydroxyl, halogen, or methoxy; R 2 But, C 1 -C 7 alkyl or R 2 and R b form a piperidine ring together with the atoms to which they are attached; R 3 But NR x R y (C 1 -C 7 alkyl), NR u R v Carbonyl C 1 -C 3 Alkyl or CarboxyC 1 -C 3 is alkyl; R 4 and R d form a pyrrolidine ring together with the atoms to which they are attached; R 5 But hydroxy C 1 -C 3 Alkyl, imidazolyl C 1 -C 3 Alkyl, or NR x R y (C 1 -C 7 alkyl); R 6 But Carboxy C 1 -C 3 Alkyl, NR u R v Carbonyl C 1 -C 3 Alkyl, NR x R y (C 1 -C 7 alkyl), or C 1 -C 7 is alkyl; R 7 and R g together with the atoms to which they are attached form a pyrrolidine ring which may be optionally substituted with hydroxy; R 8 and R 10 but benzothienyl or carboxy C 1 -C 3 Indolyl C optionally substituted with alkyl 1 -C 3 is alkyl; R 9 But hydroxy C 1 -C 3 Alkyl, Amino C 1 -C 4 Alkyl, or C 1 -C 7 is alkyl; R 11 But, C 1 -C 3 Alkoxy C 1 -C 3 Alkyl or C 1 -C 7 is alkyl; R 12 But, C 1 -C 7 Alkyl or Hydroxy C 1 -C 3 is alkyl; and R 13 But, C 1 -C 7 Alkyl, Carboxy C 1 -C 3 Alkyl, or -(CH 2 ) 3 NHC(NH)NH 2 That is, 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof.

9. In the formula, A is 【Chemistry 17】 and; m is 1; w is 0; R 14 and R 15 are hydrogen; R 16a is hydrogen or methyl; R d is methyl or R d and R 4 together with the atoms to which they are attached form a ring selected from azetidine, pyrrolidine, morpholine, piperidine, piperazine, and tetrahydrothiazole; wherein each ring is optionally substituted with one or two groups independently selected from amino, cyano, methyl, halogen, hydroxy, and phenyl; R g is methyl or R g and R 7 together with the atoms to which they are attached form a ring selected from azetidine, pyrrolidine, morpholine, piperidine, piperazine, and tetrahydrothiazole; wherein each ring is optionally substituted with one or two groups independently selected from amino, benzyl optionally substituted with halogen, benzyloxy, cyano, cyclohexyl, methyl, halogen, hydroxy, isoquinolinyloxy optionally substituted with methoxy groups, quinolinyloxy optionally substituted with halogen, and tetrazolyl; said pyrrolidine and piperidine rings are optionally fused to a cyclohexyl, phenyl, or indole group; and R l is methyl or R l and R 12 together with the atoms to which they are attached form a ring selected from azetidine, pyrrolidine, morpholine, piperidine, piperazine, and tetrahydrothiazole; wherein each ring is optionally substituted with one or two groups independently selected from amino, cyano, methyl, halogen, and hydroxy; 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof.

10. the below described, 【Chemistry 18】 【Chemistry 19】 【Chemistry 20】 【Chemistry 21】 【Chemical 22】 and 【Chemistry 23】 or a pharma- ceutically acceptable salt thereof.

11. A pharmaceutical composition comprising a compound according to any one of claims 1 to 10, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable carrier.

12. 11. A pharmaceutical composition comprising a compound of claim 10, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable carrier.

13. A method for enhancing, stimulating, and / or enhancing an immune response in a patient in need of treatment, comprising administering to the subject a therapeutically effective amount of a compound of claim 1 or a pharma- ceutical acceptable salt thereof.

14. A method for inhibiting the growth, proliferation, or metastasis of cancer cells in a patient in need of treatment, comprising administering to the subject a therapeutically effective amount of a compound of claim 1 or a pharma- ceutical acceptable salt thereof.

15. 15. The method of claim 14, wherein the cancer is selected from melanoma, renal cell carcinoma, squamous non-small cell lung cancer (NSCLC), non-squamous NSCLC, colorectal cancer, castration-resistant prostate cancer, ovarian cancer, gastric cancer, hepatocellular carcinoma, pancreatic cancer, squamous cell carcinoma of the head and neck, esophageal, gastrointestinal and breast cancer, and hematopoietic tumors.

16. 13. A method for treating an infectious disease in a patient in need of such treatment, comprising administering to the subject a therapeutically effective amount of a compound of claim 1, or a pharma- ceutically acceptable salt thereof.

17. 17. The method of claim 16, wherein the infectious disease is caused by a virus.

18. 13. A method for treating septic shock in a patient in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of claim 1, or a pharma- ceutical acceptable salt thereof.

19. A method for inhibiting interaction of PD-L1 with PD-1 and / or CD80 in a subject, comprising administering to the subject a therapeutically effective amount of a compound of claim 1 or a pharma- ceutical acceptable salt thereof.